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BCoAT  butyryl-CoA acetate CoA-transferase 
BCS   body condition score 
BK   butyrate kinase 
BMI   body mass index 
BW   body weight 
C0   carnitine  
C2   acetylcarnitine 
C3   propionylcarnitine  
C3DC   malonylcarnitine 
C4   isobutyrylcarnitine  
C4DC   methylmalonylcarnitine 
C5   isovalerylcarnitine and methylbutyrylcarnitine 
CAT   catalase 
CCECAI  canine chronic enteropathy clinical activity index 
CD   Crohn’s disease 
CF   crude fibre 
CFU   colony forming units 
CIBDAI  canine inflammatory bowel disease activity index 
CoA   co-enzyme A 
CP   crude protein  
CRP   C-reactive protein 
DC   dry control 
DGGE   denaturing gradient gel electrophoresis 
DGLA   dihomo-gamma-linolenic acid 
DHA   docosahexaenoic acid 
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PRRs   pattern recognition receptors 
PUFA   polyunsaturated fatty acid 
qPCR   quantitative real-time polymerase chain reaction 
RBC   red blood cell 
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1.1 GASTROINTESTINAL MICROBIOTA IN CANINE HEALTH: CURRENT KNOWLEDGE  
Endogenous gastrointestinal (GI) microbiota have long been recognized to play an 
essential role in host health and disease (Sekirov et al., 2010). The main functions of the gut 
microbiota include providing nutrients and energy to the host (Flint et al., 2012), shaping 
intestinal immune responses (Round and Mazmanian, 2009), and fortifying the gut mucosal 
barrier (Hooper et al., 2001). With a rapid development and application of molecular 
sequencing technologies, the true diversity, ubiquity and functional capacity of the gut 
microbiota is being explored.  
The knowledge of canine gut microbiota, especially the metabolic capacity, is much 
less complete than that of human. However, there are many similarities of GI physiology, 
dietary patterns, metabolic processes and intestinal disease aetiology between dogs and 
humans (Swanson and Schook, 2006). Importantly, phlyogenetic and metabolic similarity 
between dogs, humans and mice has been demonstrated by using hierarchical clustering of 
several GI metagenomes (Swanson et al., 2011). Thus, the knowledge from human gut 
microbiota could provide a good foundation for research in dogs. Nevertheless, extrapolation 
of human microbiome data to dog microbiome data should be done with caution as species 
differences may also occur. 
1.1.1 OVERVIEW OF CANINE GUT MICROBIOTA  
Gut microbiota are composed of a diverse microbial community which includes 
bacteria, archaea, viruses, fungi and protozoa. As bacteria are the most predominant microbes 
in the gut and as less is known about the other domains of prokaryotic life, this review will 
focus on bacteria.  
1.1.1.1 Composition of canine gut microbiota 
Each dog harbours a very unique and individual microbial profile (Simpson et al., 
2002). A summary of the phylogenetic distribution of canine gut microbiota is shown in Table 
1.1. Generally, based on different sampling locations and technologies that have been applied, 
the characterization of canine gut microbiota yields different results (Figure 1.1). In addition, 
many other factors may influence the gut microbiota such as diet, breed, age and other 
environmental factors. Nevertheless, it can still be concluded from different studies that the 
phyla Firmicutes, Proteobacteria, Bacteroidetes, Fusobacteria and Actinobacteria constitute 
the vast majority of all gut bacteria in dogs (Figure 1.1). The minority gut bacterial groups are 
represented by the phyla Tenericutes, Verrucomicrobia, Spirochaetes, Cyanobacteria, 
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Planctomycetes, Choriobi, Deferibacteria, Thermotogae, Synergistetes and Chloroflexi in 
dogs (Figure 1.1). 
Table 1.1 The phylogenetic distribution of canine gut microbiota
1
  
Phylum Class Order Family Genus 
Actinobacteria Actinobacteria Actinomycetales Actinomycineae Actinomyces 
   
Dietziaceae Dietzia 
   
Microbacteriaceae Zimmermannella 
    
Cellulomonas 
   
Micrococcineae Curtobacterium 
    
Microbacterium 
   
Propionibacterineae Brooklawnia 
  
Bifidobacteriales Bifidobacteriaceae Bifidobacterium 
  
Coriobacteriales Coriobacteriaceae Collinsella 
    
Slackia 
    
Eggerthella 
    
Atopobium 
    
Gordonibacter  
  
Propionibacteriales Propionibacteriaceae Propionibacterium 
Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
   
Porphyromonadaceae Parabacteroides 
   
Prevotellaceae Prevotella 
   
Rikenellaceae Alistipes 
 
Flavobacteriia Flavobacteriales Flavobacteriaceae Bergeyella 
    
Capnocytophaga 
    
Chryseobacterium 
    
Empedobacter 
 
Sphingobacteriia Sphingobacteriales Sphingobacteriaceae Sphingobacterium 
Firmicutes Bacilli Bacillales Bacillaceae Bacillus 
   
Paenibacillaceae Paenibacillus 
   
Staphylococcaceae Jeotgalicoccus 
  
Lactobacillales Aerococcaceae Facklamia 
    
Abiotrophia 
   
Carnobacteriaceae Dolosigranulum 
   
Enterococcaceae Enterococcus 
   
Lactobacillaceae Lactobacillus 
   
Streptococcaceae Lactococcus 
    
Streptococcus 
    
Staphylococcus 
 
Clostridia Clostridiales Clostridiaceae Clostridium 
   
Eubacteriaceae Eubacterium 
   
Lachnospiraceae Blautia 
    
Dorea 
    
Lachnospira 
    
Lactonifactor 
    
Roseburia 
   
Rumninococcaceae Anaerofilum 
    
Anaerotruncus 
    
Faecalibacterium 
    
Oscillospira 
    
Ruminococcus 
        Subdoligranulum 
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Table 1.1 The phylogenetic distribution of canine gut microbiota (continued) 
Phylum Class Order Family Genus 
Firmicutes Clostridia Clostridiales Peptococcaceae Peptococcus 
    
Desulfotomaculum 
   
Peptostreptococcaceae Anaerococcus 
 
Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Allobaculum 
    
Bulleidia 
    
Catenibacterium 
    
Coprobacillus 
    
Holdemania 
    
Turicibacter 
 
Negativicutes Selenomonadales Acidaminococcaceae Acidaminococcus  
    
Phascolarctobacterium 
    
Succiniclasticum 
    
Succinispira 
   
Veillonellaceae Dialister 
    
Megamonas 
    
Megasphaera 
    
Veillonella 
Fusobacteria Fusobacteriia Fusobacteriales Fusobacteriaceae Cetobacterium 
    
Fusobacterium 
    
Ilyobacter 
    
Propionigenium 
Proteobacteria Alphaproteobacteria Caulobacterales Caulobacteraceae Brevundimonas 
  
Rhizobiales Bradyrhizobiaceae Bradyrhizobium 
   
Brucellaceae Brucella 
    
Ochrobactrum 
  
Sphingomonadales Sphingomonadaceae Sphingomonas 
    
Sphingopyxis 
 
Betaproteobacteria Burkholderiales Alcaligenaceae Achromobacter 
   
Comamonadaceae Delftia 
    
Diaphorobacter 
   
Sutterellaceae Sutterella 
  
Neisseriales Neisseriaceae Conchiformibius 
    
Neisseria 
 
Epsilonproteobacteria Campylobactreales Helicobacteraceae Helicobacter 
 
Gammaproteobacteria Aeromonadales Succinivibrionaceae Anaerobiospirillum 
    
Succinivibrio 
  
Enterobacteriales Enterobacteriaceae Citrobacter 
    
Escherichia 
    
Salmonella 
    
Shigella 
  
Pasteurellaceae Pasteurellaceae Actinobacillus 
    
Haemophilus 
    
Pasteurella 
  
Pseudomonadales Moraxellaceae Acinetobacter 
    
Branhamella 
    
Moraxella 
   
Pseudomonadaceae Pseudomonas 
    Xanthomonadales Xanthomonadaceae Stenotrophomonas 
1
Reference: Panasevich et al., 2014; Kerr et al., 2013; Suchodoski et al., 2012a; 2010 and 
Handl et al., 2011.  
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Gut microbiota differ between the anatomical regions in dogs (Suchodolski et al., 2008; 
2005). The small intestine has a fairly short transit time (approximately 2h for dogs) and high 
bile acid concentrations, making it challenging for bacteria to colonize (Zoetendal et al., 2012; 
Dressman, 1986). In contrast, the large intestine provides a better environment (longer transit 
time, less bile acid concentration, a more favourable pH and larger volume) for bacterial 
growth and thus harbours the densest microbial community in the body. It has been reported 
that the numbers of total bacterial cells present in the canine GI tract shows a continuum that 
goes from 10
1
~10
6
 colony forming units (CFU)/g in the stomach, duodenum and jejunum, 
progressing to 10
7
~10
8
 CFU/g in the ileum and cecum and culminating in 10
10
~10
11 
CFU/g in 
the colon and rectum (Benno et al., 1992). Enterobacteriaceae, Streptococci and Staphylococci 
are the predominant aerobic/facultative anaerobic bacteria, while Eubacteria, Clostridium, 
Bacteroides, Lactobacillus, Bifidobacterium are the predominant anaerobic bacteria that have 
been cultured from the canine GI tract (Benno et al., 1992). Generally, aerobic bacteria exist 
in a higher abundance in the small intestine while anaerobic bacteria are predominant in the 
large intestine (Mentula et al., 2005). This is supported by culture-independent techniques, 
where anaerobic Fusobacteriales and Bacteroidales were only sporadically found in the 
proximal small intestine but increased in their abundance in the ileum and colon of dogs 
(Suchodolski et al., 2008). In the same study, facultative anaerobic Proteobacteria were shown 
to have a higher abundance in the duodenum and a lower abundance in the colon whereas 
Lactobacillales occurred commonly in all compartments of the intestine. 
1.1.1.2 Techniques to study gut microbiota 
A variety of techniques are available to study gut microbial communities, the target, 
advantages and disadvantages of each technique are summarised in Table 1.2. Traditional 
cultivations are classical methods for the detection of specific intestinal pathogens, and for 
testing antibiotic susceptibility and genotyping of cultured isolates. However, it only provides 
a limited view of the diversity of the gut microbiota because more than 80% of gut microbiota 
have not been cultured to date (Le Chatelier et al., 2013; Qin et al., 2010; Eckburg et al., 
2005). This has led to an extensive development and application of molecular-based 
techniques to study complex microbial ecosystems. Most (but not all) contemporary culture-
independent techniques use the bacterial 16S ribosomal RNA (rRNA) gene as a marker of 
genetic diversity. 16S rRNA has relatively small size (~1.5 kb) and an appropriate balance of 
conservation and variability to distinguish between different species and strains (Olsen et al., 
1986). The 16S rRNA techniques greatly advanced our understanding of the composition of 
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the gut microbiota. However, these techniques could not give an answer on the biological 
significance of the association between a microbial pattern and host status (e.g. in diseases). 
Thus, the “meta” family has been developed to provide a description of functional 
contributions of gut microbial communities to their host, for instance, metagenomics and 
metabolomics (Table 1.2). 
When choosing which technique to use for a study to determine the gut microbiota, the 
cost and the depth of analysis must be considered. DGGE is a useful technique for rapid 
assessment of the composition of the gut microbiota and is particularly suitable for a first-pass 
comparison of multiple samples (Fraher et al., 2012). qPCR can be challenging if new assays 
are to be designed for poorly characterized bacterial species, but many validated assays are 
available in the literature (Fraher et al., 2012). Next-generation sequencing techniques can 
provide in-depth information but they remain somewhat expensive, however, the cost has 
been dramatically reduced in recent years. 
1.1.2 THE METABOLIC ACTIVITIES OF GUT MICROBIOTA AND THEIR INTERACTION WITH 
THE HOST 
The complexity of the gut microbial community is becoming clearer, however, the 
functional relationships between microbes and the host are less well understood in both 
human and animals. In general however, gut microbiota are responsible for the fermentation 
of the non-digestible dietary residue and endogenous mucus produced by epithelia (Guarner 
and Malagelada, 2003). These dietary residues normally consist of dietary carbohydrates, 
protein and fat. The impact of these major components on gut microbiota will be discussed 
later in section 1.2. In addition, gut microbiota play a crucial role in the maintenance of 
epithelial barrier function and in the modulation of the immune system as has been expertly 
reviewed by Kamada et al. (2013) and Round and Mazmanian (2009).  
In this section, the focus will be on the products of microbial fermentation and their 
role as signalling molecules and their influence on host metabolism. The major fermentation 
end products are short-chain fatty acids (SCFA, mainly acetate, propionate and butyrate), 
phenolic and indolic compounds, ammonia, amines, and gases (hydrogen, carbon dioxide, 
methane and hydrogen sulphide). Some of the main fermentation metabolites that regulate 
host-microbiota interactions are listed in Table 1.3. Many different microbial genera and 
species are contributing to metabolite formation (Figure 1.2); however, our knowledge of the 
relationship between the specific bacteria and their metabolic compound is currently limited. 
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1.1.2.1 Saccharolytic fermentation end products 
Generally, SCFA are main products from carbohydrate fermentation. Acetate is 
produced by most enteric bacteria as a fermentation product, but it is also generated by 
acetogenic bacteria, such as Blautia hydrogenotrophica, from H2 and CO2 or from formate via 
the Wood-Ljungdahl pathway (Louis et al., 2014; Rey et al., 2010) (Figure 1.2). Propionate is 
mainly produced via the succinate pathway by Bacteroidetes and by some Firmicutes that 
belong to the Negativicutes class (such as Phascolarctobacterium succinatutens, Dialister 
spp. and Veillonella spp.) in the human gut (Louis et al., 2014; Reichardt et al., 2014) (Figure 
1.2). Although the succinate pathway is well described for some of the most prevalent 
bacteria in the human gut, the acrylate pathway and the propanediol pathway also contributes 
to the formation of propionate (Reichardt et al., 2014; Hosseini et al., 2011). Butyrate-
producing bacteria are mainly belonging to clostridial clusters IV and XIVa (including species 
of Clostridium, Eubacterium, Roseburia, Faecalibacterium, and Coprococcus) (Pryde et al., 
2002). Two biosynthetic pathways were identified for butyrate formation, the butyrate kinase 
pathway and the butyryl-CoA acetate CoA-transferase (BCoAT) pathway (Figure 1.2). The 
former pathway was only found in few strains from the human gut, while the latter pathway is 
used in the majority of human colonic isolates (Duncan et al., 2004). More recently a study 
found the BCoAT pathway to be enriched in omnivores and herbivores whereas the butyrate 
kinase pathway was more abundant in carnivores (Vital et al., 2015). Therefore, investigating 
the distribution of butyrate producing pathways will provide new insights for buyrate 
production in dogs. 
The SCFA are absorbed by the host and used as an energy source, e.g. butyrate 
provides approximately 2/3 of the energy supply for colonic epithelium in vitro (Scheppach, 
1994). The colonocytes of patients with ulcerative colitis (UC, one of two major types of 
inflammatory bowel disease in humans) exhibited impaired ability to metabolize butyrate 
(Roediger, 1980). Butyrate also exerts anti-inflammatory and anti-apoptotic properties that 
may be important for the prevention of inflammatory bowel disease (IBD) and colorectal 
cancer in humans (Hamer et al., 2008; Segain et al., 2000). In addition, SCFA may influence 
the regulation of lipogenesis, whereas the interactions between SCFA and host receptors (free 
fatty acid receptor 2 and 3) have been involved in controlling anorectic hormones in mice 
(Tolhurst et al., 2012; Sleeth et al., 2010). Furthermore, SCFA play an important role in 
determining the gut environment, influencing pH, and gut transit time (Flint et al., 2015). 
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After being rapidly absorbed from the gut lumen, the SCFA concentrations in the 
systemic circulation are different. The butyrate concentration in the systemic circulation is 
low, propionate is mostly metabolized in the liver, and only acetate achieves relatively high 
concentrations in peripheral blood in humans and some other animal species (i.e. sheep, rabbit 
and pig) (Bergman, 1990). Based on the concentrations in peripheral and portal blood, about 
75% of acetate, 90% of propionate and 95% of butyrate are taken up during a single pass of 
blood through the human liver (Cummings et al., 1987). The metabolism of SCFA requires 
activation with coenzyme (Co) A (Bremer, 1983). Intracellular CoA bound acylgroups are 
then transported from the cytoplasm to the mitochondria by means of carnitine groups. 
Therefore, acetylcarnitine, propionylcarnitine and butyrylcarnitines are a measure of the 
respective SCFA-CoA and reflect the major means by which SCFA influence cellular 
metabolism (Aas and Bremer, 1968) (Figure 1.3). 
Lactate, succinate and formate are acids that are produced during fermentation and 
normally serve as intermediates in microbial metabolism in the human gut because of further 
conversion to other SCFA (Flint et al., 2012). In addition, Eubacterium hallii and 
Anaerostipes caccae isolate from human faeces are able to utilize lactate to produce butyrate 
(Duncan et al., 2004). Some members of the clostridial cluster IX from human faecal isolates 
are able to convert lactate to propionate (Louis et al., 2007). All these activities of the lactate 
utilising bacteria contribute to the low lactate level seen in the gut in healthy conditions, 
which is vital to for maintaining homeostasis within the gut microbial community. When 
disease occurs, lactate might accumulate in the gut, decreasing pH and disturbing the gut 
microbiota activity. Indeed, a low pH value and high colonic lactate concentration have been 
shown to be associated with human with UC (Fallingborg et al., 1993). 
1.1.2.2 Proteolytic fermentation end products 
Anaerobic degradation of peptides and proteins in the colon by the resident microbiota, 
a process called putrefaction, also produces SCFA, including branched-chain fatty acids 
(BCFA), but in the meantime, generates a series of other substances like ammonia, amines, 
phenols and indols (Table 1.3). In humans, many of those metabolites (e.g. ammonia, phenol 
and indol) are considered to be potentially toxic (Windey et al., 2012). However, the impact 
of protein fermentation end products on health and well-being in dogs are largely unknown. A 
subset of bacteria, including several Bacteroides spp. and some Firmicutes (Eubacterium 
hallii and Clostridium bartlettii), can ferment aromatic amino acids to produce potentially 
bioactive products, such as phenylacetic acid, phenol, and indole (Russell et al., 2013). The  
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genera Clostridium, Bifidobacterium and Bacteroides have been shown to produce amines 
(Smith and Macfarlane, 1996). 
Most of the ammonia produced is rapidly absorbed, metabolised into urea by the liver 
and excreted in urine. When not enough nitrogen is available in the gut, ammonia from the 
host can be absorbed in the gut and used as a nitrogen source for bacterial growth. Indole can 
be metabolized to indoxyl sulphate by the liver in both animals and humans (Wikoff et al., 
2009), and the latter has been associated with inflammation of the kidney and the progress of 
chronic renal failure in humans (Miyazaki et al., 1997; Niwa et al., 1997) and chronic kidney 
diseases in dogs (Cheng et al., 2015). Phenols are rapidly absorbed in the colon, metabolised 
in the liver and excreted principally as p-cresol (Tamm and Villako, 1971). In addition, some 
plasma acylcarnitines also represent metabolites of the protein catabolic pathways (Figure 
1.2). For example, isobutyrylcarnitine (C4) and isovalerylcarnitine (C5) represent metabolites 
from valine and isoleucine, respectively. However, these carnitines can originate from both 
host and microbial metabolism (Michal, 1999), making the data interpretation of these 
carnitines difficult. 
1.1.2.3 Gases and vitamins 
H2 is also an intermediate that plays a key role in the gut microbial ecosystem 
(Macfarlane and Macfarlane, 2003). A broad variety of hydrogenotrophic microbial activities 
have been involved in H2 consumption, including methanogensis, dissimilatory sulphate 
reduction, and acetogenesis (Macfarlane and Macfarlane, 2012). A slower transit time will be 
associated with increased methanogenesis, as methanogenic archaea will use H2 and CO2, or 
formate to generate methane (El Oufir et al., 1996). H2S generated by sulphate-reducing 
bacteria (SRB) is generally regarded as a toxic product for humans. More recently, H2S has 
been proposed as a gaseous signal molecule that regulates mucosal homeostasis and promotes 
resolution of colonic inflammation through restoring the microbiota biofilm and increasing 
the production of mucus granules (Motta et al., 2015; Linden, 2014).  
Colonic bacteria also play a role in vitamin synthesis, particularly those of the B group, 
vitamin B9 (folate) and B12 (cobalamin) (Hill, 1997). Folate is involved in various essential 
metabolic functions such as DNA replication, repair and methylation, and synthesis of 
nucleotides, vitamins and certain amino acids (Choi and Mason, 2002). Folate can be produce 
by Bifidobacterium and a variety of lactic acid bacteria, such as Lactococcus lactis, 
Streptococcus thermophilus, and Leuconostoc spp. (Sybesma et al., 2003). Cobalamin is the 
only vitamin that is exclusively produced by microbes (e.g. Bacillus, Propionibacterium, and  
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Clostridium) because animals, plants, and fungi are incapable of cobalamin production 
(Rodionov et al., 2003). Low serum cobalamin concentrations in dogs have beenassociated 
with exocrine pancreatic insufficiency, severe intestinal disease, and putatively small 
intestinal bacterial overgrowth (Simpson et al., 2001). 
 
1.2 DIETARY MANIPULATION OF GUT MICROBIOTA 
Diet has a strong impact on health and well-being in humans and animals. This could 
be due to its effects on modulating the composition of gut microbiota. Among other factors 
that may influence gut microbiota, including age, genetics, environmental factors, diseases, 
diet is the easiest to modify and therefore presents the simplest route for therapeutic 
intervention of gut microbiota associated diseases (Wu et al., 2011). The gut microbial 
ecosystem harbours a considerable amount of nutritional patterns. Different nutritional types 
of bacteria include saccharolytic species, nitrogen utilisers and bacteria that metabolize gases 
(Gibson and Roberfroid, 1995).  
It has been shown that changes in dietary macronutrients (i.e. carbohydrates, protein 
and fat) can alter the gut microbiome within 24 hours in humans (David et al., 2014; Wu et 
al., 2011). Recently, human gut microbial enterotypes, that are independent of nationality, 
gender, age, or body mass index (BMI), and dominated by Bacteroides, Prevotella or 
Ruminococcus, were proposed (Arumugam et al., 2011). Long-term diets are strongly 
associated with enterotypes. Particularly the Bacteroides enterotype is strongly correlated 
with dietary animal protein and Prevotella is correlated with dietary carbohydrates (Wu et al., 
2011). Next, a study found that the genus Prevotella could be reduced in vegetarian subjects 
upon consumption of an animal-based diet (David et al., 2014). In the same study, the animal-
based diet increased the abundance of bile-tolerant microbiota (Alistipes, Bilophila and 
Bacteroides) and decreased the levels of Firmicutes that metabolize dietary plant 
polysaccharides (Roseburia, Eubacterium rectal and Ruminococcus bromii) (David et al., 
2014). These results imply that the modulation of gut microbiota is possible through dietary 
changes and that these changes can be reversible. 
Dogs are not obligatory carnivores, as modern evidence has proven that compared to 
wolves, the dog’s genome has adapted to a starch-rich diet facilitating starch digestion and 
further absorption (Axelsson et al., 2013). Traditional commercial dog foods (i.e. canned and 
dry diets) vary widely in macronutrients distribution (Hill et al., 2009). However, the 
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knowledge on the existence of enterotypes, in similarity to humans, or on the reversibility of 
gut microbial changes is not well understood/known in dogs. Therefore, it is important to 
understand the impact of macronutrients on the composition and functionality of canine gut 
microbiota to provide adequate nutritional advices.  
1.2.1 NON-DIGESTIBLE DIETARY CARBOHYDRATES  
Non-digestible carbohydrates reaching the large intestine are plant cell wall 
polysaccharides (such as cellulose, arabinoxylan, xyloglucan, β-glucan, mannan, pectins and 
lignin), resistant starch, inulin and fructo-oligosaccharides (FOS), unabsorbed sugars and 
sugar derivatives (Louis et al., 2007). One of the best-studied areas of dietary changes 
influencing the gut microbiota has been on dietary fibre, non-digestible carbohydrates and 
prebiotics (Deng and Swanson, 2014). Dietary fibre and other non-digestible carbohydrates 
are the main growth substrates of gut microorganism. According to Codex Alimentarius 
Commission (2009), dietary fibre is defined as carbohydrate polymers with ten or more 
monomeric units, which are not hydrolyzed by endogenous enzymes in small intestine of 
human beings. It includes resistant oligosaccharides, resistant starch and resistant 
maltodextrins (Jones, 2014). Prebiotics are non-digestible carbohydrates that beneficially 
affect the host by selectively stimulating the growth and/or activity of one or a limited number 
of microorganisms (Gibson and Roberfroid, 1995). For example, FOS, galacto-
oligosaccharides and lactulose have been defined as prebiotics for humans (Gibson et al., 
2004).  
The effects of non-digestible carbohydrates on the composition and activity of 
gut/faecal microbiota are summarized in Table 1.4. Traditionally, lactate-producing bacteria 
such as Lactobacillus and Bifidobacterium are considered beneficial members of the colonic 
microbiota. Although Clostridium spp. and E.coli are part of the commensal bacteria and may 
reside in healthy animals without causing disease for years, they are considered to be potential 
pathogens and often are viewed as examples of detrimental bacteria (Swanson and Fahey, 
2006). Therefore, these bacteria were chosen to be analyzed in the past using cultivation or 
qPCR. Approximately 50% of the studies demonstrated increased faecal Bifidobacteria and/or 
decreased faecal Clostridia concentrations in dogs consuming fibres (Table 1.4).  
The most recent studies have investigated the effects of dietary fibre on canine faecal 
microbiota using high-throughput sequencing methods as summarized in Table 1.4. Dietary 
fibres inclusion (i.e. potato fibre, cooked navy beans, and beet pulp) significantly increased  
 28 Chapter 1 
General introduction 
 
 
T
a
b
le
 1
.4
 T
h
e 
ef
fe
ct
 o
f 
fi
b
re
s 
in
cl
u
si
o
n
 o
n
 f
ae
ca
l 
fe
rm
en
ta
ti
o
n
 e
n
d
 m
et
ab
o
li
te
s 
an
d
 f
ae
ca
l 
m
ic
ro
b
io
ta
 c
o
m
p
o
si
ti
o
n
 i
n
 d
o
g
s 
1
 
Chapter 1 
General introduction 
29 
 
 
  
T
a
b
le
 1
.4
 T
h
e 
ef
fe
ct
 o
f 
fi
b
re
s 
in
cl
u
si
o
n
 o
n
 f
ae
ca
l 
fe
rm
en
ta
ti
o
n
 e
n
d
 m
et
ab
o
li
te
s 
an
d
 f
ae
ca
l 
m
ic
ro
b
io
ta
 c
o
m
p
o
si
ti
o
n
 i
n
 d
o
g
s 
(c
o
n
ti
n
u
ed
) 
1
 
1
 I
f 
n
o
t 
sp
ec
if
ic
al
ly
 m
en
ti
o
n
ed
, 
th
e 
b
ac
te
ri
al
 g
ro
u
p
s 
an
d
 f
er
m
en
ta
ti
o
n
 m
et
ab
o
li
te
s 
w
er
e 
m
ea
su
re
d
 i
n
 f
ae
ce
s.
 B
P
: 
b
ee
t 
p
u
lp
; 
C
: 
ce
ll
u
lo
se
; 
cf
u
: 
co
lo
n
y
 f
o
rm
in
g
 
u
n
it
s;
 C
P
: 
cr
u
d
e 
p
ro
te
in
, 
u
n
it
 (
g
/1
0
0
g
D
M
);
 F
O
S
: 
fr
u
ct
o
-o
li
g
o
sa
cc
h
ar
id
es
; 
G
G
M
O
: 
g
al
ac
to
g
lu
co
m
an
n
an
 o
li
g
o
sa
cc
h
ar
id
e;
 L
A
C
: 
L
a
ct
o
b
a
ci
ll
u
s 
a
ci
d
o
p
h
il
u
s;
 
M
O
S
: 
m
an
n
an
o
li
g
o
sa
cc
h
ar
id
es
; 
N
B
: 
co
o
k
ed
 n
av
y
 b
ea
n
; 
S
C
F
A
: 
sh
o
rt
-c
h
ai
n
 f
at
ty
 a
ci
d
s;
 P
F
: 
p
o
ta
to
 f
ib
re
; 
Y
C
W
: 
y
ea
st
 c
el
l 
w
al
l 
ex
tr
ac
t;
 N
/A
: 
n
o
t 
ap
p
li
ca
b
le
; 
(+
) 
p
o
si
ti
v
e 
co
rr
el
at
io
n
 
 30 Chapter 1 
General introduction 
 
Firmicutes and decreased Fusobacteria in all the studies (Panasevich et al., 2014; Kerr et al., 
2013; Swanson et al., 2011; Middelbos et al., 2010). Decreased Actinobacteria has also been 
observed occasionally (Kerr et al., 2013; Middelbos et al., 2010). In addition, bacterial 
fermentation end products were measured in many studies. Most studies showed 
increased faecal total SCFA, and lactate concentrations and decreased putrefactive 
substances (e.g. ammonia, phenol and indole) in dogs consuming prebiotics and dietary 
fibres (Faber et al., 2011; Middelbos et al., 2007b; Swanson et al., 2002a; Flickinger et 
al., 2000). However, none of these studies was able to identify the underlying 
mechanisms behind these changes or what the impact of these changes could have for the 
host metabolism. Hence, more research is needed to fully elucidate the underlying 
mechanism behind gut microbial profile changes. 
1.2.2 DIETARY PROTEINS  
Available proteins for fermentation come from elastin and collagen in the diet, 
endogenous enzymes, sloughed epithelial cells and lysed bacteria as well as dietary protein 
escaped the digestion or absorption from the small intestine (Salminen et al., 1998). In 
contrast to dietary carbohydrates, microbial degradation of protein results in the production of 
numerous putrefactive catabolites, such as ammonia and phenol. In addition, it produces 
sulphate-containing substrates that have been implicated to be detrimental for host health 
(Windey et al., 2012). A high protein intake is associated with an increased incidence of IBD 
in humans (Jantchou et al., 2010). Moreover, decreased faecal concentrations of butyrate and 
butyrate-producing bacteria were observed in obese human subjects consuming a high 
protein, low carbohydrate diet (Duncan et al., 2007). 
As being carnivore is associated with high protein intake (WHO, 2007; NRC 2006), 
dogs and cats might have adapted to cope with the negative effects of protein fermentation. 
Indeed, Novosphingobium sp. and Haliangium ochraceum, which are capable of breaking 
down the aromatic putrefactive substances has been found to be increased when cats were fed 
a high protein diet vs. moderate protein diet (Lubbs et al., 2009). In addition, the gut 
microbiota were more stable and diverse in cats fed high vs. moderate protein diet, and the 
diet-related differences were mostly related to amino acid metabolism in the faecal 
microbiome (Deusch et al., 2014). Of interest, Faecalibacterium, Ruminococcus, Blautia and 
Eubacterium, all belonging to butyrate-producing bacteria, were higher in cats fed high vs. 
moderate protein diet (Hooda et al., 2013). Interestingly, these results are opposite to the 
observations from human studies (Duncan et al., 2007). Therefore, species differences in 
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terms of the impact of dietary habits on gut microbiota do exist and need to be further 
investigated. 
A summary of canine studies that investigated the impact of dietary protein on faecal 
microbiota is shown in Table 1.5. Increased dietary protein may lead to greater abundance of 
faecal C. perfringens in dogs (Zentek et al., 2004; 2003). A more in-depth view of gut 
microbiota alteration during dietary changes is provided with the incorporation of culture 
independent molecular technology. High dietary protein content reduced levels of 
representatives of the family Lachnospiraceae, specifically clostridial cluster XIVa and 
favoured representatives of the order Fusobacteriales in dog faecal samples (Hang et al., 
2012). These results are inconsistent with the findings from the previously mentioned cat 
study (Hooda et al., 2013), thus more research is warranted in dogs to assess the impact of 
dietary protein on gut microbiota, especially for butyrate-producing bacteria, and their 
fermentation products. 
1.2.3 DIETARY FAT 
Dietary fat is mostly absorbed in the small intestine. Indeed, only 7% of 
13
C labelled 
fatty acids have been found to be excreted in human stool after digestion of a fat-rich meal 
(Gabert et al., 2011). However, consumption of a high fat diet compared to a low fat diet 
significantly reduced faecal SCFA concentrations, including butyrate concentrations and 
bifidobacteria counts in humans (Brinkworth et al., 2009). The adverse effect of dietary fat on 
total SCFA production might be explained by the toxicity of unsaturated fatty acids to the gut 
microbiota (destabilization of bacterial wall fluidity and stability), similarly to what has been 
reported for rumen bacteria (Doreau and Chilliard, 1997), explaining the need for 
biohydrogenation (or saturation) of the dietary fat (Hess et al., 2008). In addition, consuming 
an animal-based high fat diet increased the faecal abundance of bile resistant bacteria 
including Bilophila wadsworthia, Alistipes putredinis, and Bacteriodes spp. in humans (David 
et al., 2014). However, the composition of other marconutrients (i.e. protein or carbohydrate) 
was also different between the diets in the studies of David et al. (2014) and of Brinkworth et 
al. (2009). Therefore, it is not clear whether the crucial dietary factor affecting microbiota 
composition and metabolism is the elevated fat or other nutrients. To our knowledge, neither 
studies have investigated the effect of dietary fat on gut microbiota and fermentation end 
products in dogs, nor its interaction with increased protein or carbohydrates in the diet. 
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1.2.4 OTHER FACTORS 
Many studies also investigated the combined effect of fibre inclusion in high protein 
diets, which resulted in reduced protein fermentation metabolites and altered faecal 
microbiota, e.g. increase in Bifidobacterium and decrease in C. perfringens numbers (Table 
1.4). Besides dietary non-digestible carbohydrates, and protein, the effects of probiotics and 
synbiotics on canine gut microbiota are also of interest.  
Probiotics have been defined as living microorganisms, which upon ingestion at 
sufficiently high numbers, exert health benefits beyond inherent basic nutrition (Guarner and 
Schaafsma, 1998). The typical microorganisms used as probiotics are lactate-producing 
bacteria. Lactobacillus spp., Bifidobacterium, and Enterococcus spp. have been evaluated to 
be used as probiotics in healthy dogs and/or dogs with GI disease, and beneficial effects on 
gut intestinal health, such as reduced incidence of diarrhoea, and improved immune function 
were observed (Bybee et al., 2011; Baillon et al., 2004; Kelley et al., 2010; Kelley et al., 
2009; Simpson et al., 2009).  
Synbiotic is a combination of a probiotic(s) and prebiotic(s). A study recently 
evaluated a synbiotic (a mixture of Enterococcus faecium SF68, Bacillus coagulans, 
Lactobacillus acidophilus, fructooligosaccharides, mannanoligosaccharides, vitamins, 
brewer’s yeast, soy lecithin, magnesium stearate, microcrystalline cellulose, mono- and 
diglyceraldehyde, and silica dioxide) in training sled dogs (Gagne et al., 2013). The use of 
this synbiotic resulted in an increase of presumed beneficial bacteria (Lactobacillus and 
Bifidobacterium) of the dog colon which was associated with a decrease in the prevalence of 
diarrhoea (Gagne et al., 2013). However, probiotics can result in opportunistic (beneficial or 
detrimental) performance in the host (Didari et al., 2014). In dogs, Enterococcus faecium 
enhanced the adhesion and colonization of Campylobacter jejuni in the intestine, which could 
be a potential risk factor for the dog health (Rinkinen et al., 2003). Thus, more research 
emphasizing the mechanisms of action for probiotic function are greatly needed to better 
understand if such changes have a substantive impact on host health. 
 
1.3 GUT MICROBIOTA RELATED PROBLEMS: FOCUS ON IBD AND OBEISTY 
Gut microbial dysbiosis occur with many types of diseases, including inflammatory 
bowel diseases (Minamoto et al., 2015) and obesity in dogs (Park et al., 2015). Since IBD and 
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obesity are two of the most important gut microbiota related diseases in both humans and 
animals, the focus in this chapter will be on the possible role of gut microbiota in the 
ethiology of IBD and obesity. 
1.3.1 INFLAMMATORY BOWEL DISEASE 
Canine idiopathic IBD is a group of disorders characterized by persistent or recurrent 
clinical signs (e.g. vomiting and diarrhoea) of GI disease of undetermined cause associated 
with histologic evidence of inflammation in the GI mucosa (German et al., 2003). A study has 
reported the incidence rate of lymphocytic-plasmacytic enteritis (PLE) in dogs to be 1.38% at 
the Veterinary Medical Center of Tokyo (Ohno et al., 2006). The major forms of canine IBD 
in the small intestine are lymphocytic-plasmacytic enteritis and esinophilic enteritis 
(Cerquetella et al., 2010). Four main conditions are recognized as canine IBD in the large 
intestine, namely lymphocytic-plasmacytic colitis, eosinophilic colitis, histiocytic ulcerative 
colitis, and regional granulomatous colitis (Cerquetella et al., 2010). However, it has to be 
taken into account that often both the small and the large intestine, or even stomach are 
involved, e.g. lymphocytic-plasmacytic enterocolitis, eosinophilic enterocolitis or 
gastroenterocolitis (Cerquetella et al., 2010). It is thus quite difficult to associate the type of 
IBD with a particular ethiology or gut microbial changes due to a diverse array of clinical and 
histological presentations of this disease. Hence, comparing the finding from different studies 
in canine IBD might be difficult.  
Advances in the understanding of the molecular pathogenesis of human IBD 
highlighted the importance of the host genetic susceptibility, the innate and adaptive 
immunity, and the commensal bacteria (or their products) (Xavier and Podolsky, 2007). These 
three important contributing factors (i.e. genetic predisposition, immunity, and bacteria) are 
also identified in dogs. Some specific forms of canine IBD have been described to be breed 
specific, such as immune-proliferative enteropathy in Basenjis (MacLachlan et al., 1988; 
Ochoa et al., 1984), protein-losing enteropathy and associated protein-losing nephropathy in 
Soft-Coated Wheaten Terriers (Littman et al., 2000), and histiocytic UC in Boxer dogs (Hall 
et al., 1994). With regard to immunity, nucleotide oligomerisation domain two (Nod2) gene 
polymorphisms has been found to be associated with IBD in German Shepherd dogs 
(Kathrani et al., 2014). 
Increasing evidence in humans and animals suggests that the dynamic balance 
between microbes, particularly commensal bacteria, and the host defensive responses at the 
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mucosal frontier has a critical role in initiation and pathogenesis of IBD (Xavier and 
Podolsky, 2007). Studies using transgenetic animals provide more direct evidence on the 
importance of the microbiota in the development of IBD. Spontaneous colitis animal models 
did not develop intestinal inflammation when animals were raised under germ-free conditions 
(Contractor et al., 1998; Dianda et al., 1997; Kuhn et al., 1993; Rath et al., 1996). In addition, 
antibiotic treatment has been shown to alleviate subsequent intestinal inflammation in 
Crohn’s disease (CD) and probiotic treatment can ameliorate UC in human patients 
(Gionchetti et al., 2003; Sutherland et al., 1991). 
1.3.1.1 Changes in microbial composition in IBD 
Microbiota present in intestinal biopsies in IBD patients differ from those found in 
healthy human subjects. In humans, the number of total bacteria, Bacteroidetes and 
Lachnospiraceae were decreased in both UC and CD colonic samples (Frank et al., 2007). 
Consistent reports of decreased members of the butyrate-producing clostridial clusters IV and 
XIVa, and Faecalibacterium prausnitzii, in the gut of human IBD patients have been 
published (Wang et al., 2014; Machiels et al., 2013; Sokol et al., 2008). Butyrate-producing 
bacteria are of great importance for the host health due to the beneficial properties as 
mentioned before (Section 1.1.2). F. prausnitzii, which belongs to Ruminococcaceae in 
clostridial clusters IV, is a major commensal bacterium that accounts for approximately 5-
10% of total human faecal bacteria (Arumugam et al., 2011; Ramirez-Farias et al., 2009). A 
previous study found F. prausnitzii to exhibit anti-inflammatory effects on cellular and colitis 
models, partly due to secreted metabolites able to block nuclear factor-kappa B (NF-κB) 
activation and interleukin (IL)-8 production (Sokol et al., 2008). More recently, an 
extracellular polymeric matrix produced by the F. prausnitzii strain HTF-F has been found to 
exert anti-inflammatory effects in mice (Rossi et al., 2015). 
In many studies, the microbial communities in dogs with IBD are distinct from healthy 
control dogs (Minamoto et al., 2015; Suchodolski et al., 2010; Xenoulis et al., 2008) as 
summarized in Table 1.6. Faecalibacterium spp. has been consistently reported to be 
decreased in dogs with IBD (Rossi et al., 2014; Suchodolski et al., 2012b). Whether the 
decline of Faecalibacterium spp. in IBD is related to butyrate production needs to be further 
investigated. Although Faecalibacterium spp. is a major butyrate-producing strain in humans, 
its relative proportion is much lower (<1%) in dogs compared to humans (Garcia-Mazcorro et 
al., 2012; Suchodolski et al., 2012a; b). Therefore, assessing the major butyrate-producing  
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bacteria clusters and the functional gene that expresses BCoAT could be important to explore 
the role of butyrate-producing bacteria in canine IBD. 
1.3.1.2 Changes in microbial function and host metabolism in IBD 
Intestinal microbial metabolites may play a role in the pathogenesis of IBD. An in 
vitro study has shown faecal samples from human IBD patients to produce more SCFA, 
BCFA and ammonia (van Nuenen et al., 2004). A decrease in faecal concentration of acetate, 
an increase in butyrate and no changes in lactate were observed in children with IBD 
compared with controls (Treem et al., 1994). In addition, increased faecal excretions of SCFA 
and lactate were found in UC patients (Montgomery et al., 1968). Therefore, these results may 
suggest impaired utilization of SCFA and/or altered gut microbial activity. However, to our 
knowledge, no study has investigated the fermentation end products of IBD in faecal samples 
of dogs yet.  
Host metabolic differences have been reported in animal and human IBD using a 
metabolomics approach on blood samples (Schicho et al., 2012; 2010). Canine IBD has been 
shown to have several more abundant serum metabolites (e.g. 3-hydroxybutyrate, hexuronic 
acid, and gluconic acid lactone), which suggested an energy insufficiency and an increase in 
oxidative stress (Minamoto et al., 2015). In UC mice model, a strong increase in ketone 
bodies and a drop in glucose as well as decreases in several amino acids (e.g. tyrosine, 
glutamine, and alanine) were observed in serum (Schicho et al., 2010). These results may 
reflect a high demand of the body for energy and malnutrition of the sick animals. An altered 
amino acid metabolism was observed in both UC and CD patients, for instance, increased 
levels of isoleucine and decreased valine in serum (Schicho et al., 2012). Futhermore, 
metabolic changes in human IBD patients have also been demonstrated using plasma 
acylcarnitine profiles (Bene et al., 2007; 2006). Several short-chain acylcarnitines (i.e. 
propionylcarnitine, butyrylcarnitine and isovalerylcarnitine) levels were decreased in UC 
(Bene et al., 2006), suggesting decreased SCFA production by gut microbiota. Altogether, 
IBD is characterised by significant host metabolic changes in humans but data are still lacking 
for canine IBD. 
1.3.2 OBESITY  
Obesity is defined as an accumulation of excessive amounts of adipose tissue in the 
body, and is the most common nutritional disorder in companion animals (German, 2006). 
The prevalence of obesity has been reported to range from 8-34% in dogs (Lund et al., 1998; 
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McGreevy et al., 2005; Robertson, 2003). A complicated network of factors contribute to this 
highly prevalent disorder, including host genetics, environmental factors, energy expenditure, 
energy intake, among others (Kopelman, 2000).  
1.3.2.1 Changes in microbial composition in obesity 
In the last decade, the link between obesity and gut microbiota has been established in 
both animals and humans. The first evidence was from the study of leptin-deficient mice, 
where a greater representation of Firmicutes and a fewer of Bacteroidetes were described in 
obese compared to lean mice (Ley et al., 2005). However, the concept of these classical 
bacterial changes has been challenged by other studies in humans (Schwiertz et al., 2010; 
Duncan et al., 2008). A study conducted in obese and lean twins showed a lower proportion 
of Bacteroidetes and a higher proportion of Actinobacteria in obese vs. lean individuals but no 
differences in the proportion of Firmicutes (Turnbaugh et al., 2009). Interestingly, the 
functional diversity in each microbiome was positively associated with the relative abundance 
of the Bacteroidetes; whereas microbiome enriched by Firmicutes/Actinobacteria had a lower 
functional diversity (Turnbaugh et al., 2009). Another study reported a decreased proportion 
of Firmicutes and an increased proportion of Bacteroidetes in obese compared to lean human 
individuals (Schwiertz et al., 2010). Meanwhile, the obese group exhibited a lower faecal 
concentration of Clostridium leptum group and Ruminococcus flavefaciens subgroup than the 
lean group (Schwiertz et al., 2010). More recently, lean and obese human subjects were found 
to belong to either a high or low gut bacterial richness group (Le Chatelier et al., 2013). 
Further, in the same study, Bacteroidetes were more prevalent in individuals with low 
bacterial richness, whereas F. prausnitzii was more frequent in individuals with high bacterial 
richness (Le Chatelier et al., 2013). It seems that it is not only the presence or absence of 
particular groups that needs to be assessed in obesity, but the relationship between bacterial 
richness and the abundance of particular bacterial groups that needs to be further explored. 
The relationship between obesity and gut microbial community in dogs is less well 
understood than in humans. Two studies have been conducted to investigate whether 
alterations in the intestinal microbiota associate with canine obesity. In the first study, the 
phylum Actinobacteria and the genus Roseburia were found to be more abundant in the obese 
pet dogs (Handl et al., 2013). In addition, an increase in the order Clostridiales was observed 
in diet-induced obese compared to lean dog (Handl et al., 2013). In the second study, a 
decrease in the proportion of Firmicutes and an increase in the proportion of Proteobacteria 
has been reported in obese compared to lean Beagles (Park et al., 2015). Moreover, the 
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diversity of the microbial community was lower in obese vs. lean dogs (Park et al., 2015). The 
discrepancy between these two studies might be due to the different animals included in each 
study, pet dogs vs. research dogs, as age, breed and diet can impact the composition of the 
intestinal microbiota, as well as other environmental factors (Simpson et al., 2002). 
1.3.2.2 Changes in microbial functional and host metabolism in animal/ human obesity 
The metagenomic analyses of microbial communities revealed the obese mice 
microbiome to have an enriched capacity to harvest energy from the diet (Turnbaugh et al., 
2006). An increased caecal concentration of acetate and butyrate was observed in obese mice 
(Murphy et al., 2010; Turnbaugh et al., 2006). Moreover, using proteomic and metabolomic 
approaches, a wide range of changes including amino acids (i.e. increased serum glycine and 
glutamine) were identified in obese humans (Oberbach et al., 2011). In high fat induced obese 
mice, the profile of lipid metabolites and amino acids was distinct from lean mice (Kim et al., 
2011). Therefore, these results urge for the research of gut microbial activity and host 
metabolism in canine obesity. 
 
1.4 COMMON FEATURES AMONG IBD AND OBESITY 
Obesity and IBD are both common and complex diseases that have increased 
incidence worldwide over the last decades in humans (Cosnes et al., 2011; Ogden et al., 
2007). The reasons for the rise in the incidence of IBD remains unclear, but changes in 
environmental factors including diet are likely to be important (Chapman-Kiddell et al., 
2010). Modern Western diets are often linked with the development of obesity (Cordain et al., 
2005). Studies have found the weight of patients with CD to increase over time and disease 
activity is positively correlated to body weight (Long et al., 2011; Moran et al., 2013). It is 
possible that increased incidence in obesity and IBD could be pathogenically linked (Khalili 
et al., 2013; Mendall et al., 2011). Obesity is characterized by excess adipocyte hypertrophy 
that leads to a low grade pro-inflammatory state through the secretion of inflammatory 
cytokines and chemokines, including IL-6 and tumor necrosis factor-α (TNF-α) (Kern et al., 
2001; Hotamisligil et al., 1995). These cytokines are also elevated in human IBD patients 
(Reimund et al., 1996). In addition, excess adiposity is associated with increased intestinal 
permeability, a hallmark of IBD (Lam et al., 2012; de La Serre et al., 2010). Furthermore, 
both diseases have been proven to be associated with oxidative stress in human and animal 
studies (Rezaie et al., 2007; Furukawa et al., 2004). Regardless of whether there is an 
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association between obesity and IBD, both diseases share some common features such as the 
above mentioned microbial dybiosis (Section 1.2). In this section, we will scrutinise the 
scientific literature on the effects of IBD and obesity on oxidative stress and inflammation in 
both humans and animals. 
1.4.1 OXIDATIVE STRESS 
Oxidative stress is generally described as an imbalance between the amount of 
oxidants (free radicals or reactive oxygen species, ROS) and antioxidants normally present in 
the body. Biomarkers or end products of free radical mediated oxidative processes are 
commonly used to estimate oxidative stress because direct measurements of oxidants are 
difficult and expensive. For example, malondialdehyde (MDA), thiobarbituric reactive acid 
substances (TBARS) and F2-isoprostanes are lipid oxidation products and widely used as 
biomarkers of lipid peroxidation damage (Vincent and Taylor, 2006). The mammalian 
antioxidant system includes a complex interplay between non-enzymatic and enzymatic 
antioxidants. Non-enzymatic antioxidants include dietary antioxidants and thiol-containing 
compounds. The major dietary antioxidants are vitamins A, C, E and selenium (Machlin and 
Bendich, 1987), and the major antioxidant enzymes include superoxide dismutase (SOD), 
glutathione peroxidase (GPx) and catalase (CAT) (Pigeolet et al., 1990).  
Accumulating evidence has demonstrated the relationship between obesity and 
oxidative stress in humans over the past decade (Furukawa et al., 2004). Indices of obesity, 
such as body mass index (BMI) and waist/hip ratio, are positively associated with biomarkers 
of oxidative stress (Keaney et al., 2003). A decrease in oxidative stress after dietary restriction 
and weight loss has been reported in obese individuals (Yesilbursa et al., 2005; Dandona et 
al., 2001). Moreover, oxidative stress has been considered as one of the underlying 
mechanisms by which dysfunctional metabolism occurs in human obese subjects (Furukawa 
et al., 2004). In contrast, only limited studies have demonstrated oxidative stress in obese 
canines (Pasquini et al., 2013; Grant et al., 2011). Moderately overweight German Shepherds 
dogs were reported to have oxidative stress based on the presence of increased derivatives of 
reactive oxygen metabolites (d-ROMs), and decreased biological antioxidant potential (BAP) 
and retinol (Pasquini et al., 2013). However, other studies demonstrated increased oxidation–
reduction and antioxidant enzymes in obese dogs (Cline et al., 2009; Grant et al., 2013; 2011). 
Nevertheless, there are also studies that did not observe any changes in oxidative stress in 
obese dogs (Van de Velde et al., 2012). These inconsistent results might be due to many 
factors including the degree of obesity, age, and diet, among others.  
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Oxidative stress is also a potential etiological and/or triggering factor for IBD. 
Transgenic mice deficient in gene expression of GPx had symptoms and pathology consistent 
with IBD (Esworthy et al., 2001). A systemically decreased antioxidant capacity has been 
found in an experimental colitis model (Bregano et al., 2009). In addition, antioxidant 
supplementation (glutathione, vitamin E + selenium) reduced colonic damage and pro-
oxidants concentration, and improved antioxidant capacity in the animal colitis model 
(Ademoglu et al., 2004; Loguercio et al., 2003). In humans, IBD patients are characterized by 
elevated lipid peroxidation and decreased concentration of antioxidants compared with 
healthy control subjects (Rezaie et al., 2007). However, to the best of our knowledge, there is 
no study reporting oxidative stress in dogs with IBD to date. 
1.4.2 INFLAMMATION 
To understand the role of inflammation in the evolution of IBD and obesity, it is 
important to understand what inflammation is and how it contributes to these physiological 
and pathological processes. Gut inflammation is characterized by a thickened and hypoechoic 
inflamed intestinal wall which is caused by perturbations in immune or epithelial homeostasis 
(Macdonald and Monteleone, 2005). Mounting evidence points to the commensal bacteria as 
the antigenic stimulus for gut inflammation (Danese and Fiocchi, 2006). In normal conditions, 
bacterial stimuli can act on intestinal epithelial cells (IEC) and on antigen-presenting cells in 
the lamina propria, lymphoid follicles, and Peyer’s patches. Pattern recognition receptors 
(PRRs) from the Toll-like receptors (TLR) and nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLR) families are present in IEC, allowing them to respond to 
commensal bacteria upon ligation of bacterial components or metabolites. Commensals are 
capable of down-regulating TLR-expression and signalling cascades in the epithelium, 
resulting in decreased translocation of NF-κB (Artis, 2008). When gut inflammation occurs, 
the commensal bacteria appear to act as a surrogate bacterial pathogen, and the host response 
is incapable of eliminating the bacteria (Macdonald and Monteleone, 2005). 
Obesity is associated with a low-grade inflammation of white adipose tissue (WAT) 
resulting from chronic activation of the innate immune system (Bastard et al., 2006). In the 
state of obesity, WAT is characterized by an increased production and secretion of a wide 
range of inflammatory molecules including TNF-α and IL-6, which not only have local effects 
on WAT physiology but also have systemic effects on other organs (Trayhurn and Wood, 
2004). Obese WAT is infiltrated by macrophages, which may be a major source of locally 
produced pro-inflammatory cytokines (Wellen and Hotamisligil, 2003). Furthermore, high fat 
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diet induced obesity is associated with increased gut inflammation and consequently 
increased gut permeability in mice (Lam et al., 2012; de La Serre et al., 2010). 
1.4.2.1 Systemic fatty acid profile 
Besides the pro-inflammatory cytokines and adipokines, systemic fatty acid (FA) 
profile is also closely related to the inflammatory status. N-6 polyunsaturated fatty acid 
(PUFA) arachidonic acid (AA; 20:4n-6) is the precursor of inflammatory eicosanoids which 
include prostaglandins and leukotrienes (Kuehl and Egan, 1980). In addition, n-3 PUFA 
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) decrease the 
production of inflammatory eicosanoids and inhibit the expression of inflammatory genes 
thus possess anti-inflammatory properties (Calder, 2006). Several studies have reported an 
abnormal fatty acid profile in human IBD patients (Jeppesen et al., 1999; Fernandez-Banares 
et al., 1997; Esteve-Comas et al., 1992). Plasma C22:6n-3 was elevated in both active and 
inactive human IBD patients, and C20:3n-6 was decreased in active IBD patients (Esteve-
Comas et al., 1993; Esteve-Comas et al., 1992). Furthermore, human obesity has been 
associated with high plasma concentration of saturated FA (SFA) and low concentration of 
PUFA, especially n-3 PUFA (Klein-Platat et al., 2005). However, to our knowledge, the 
systemic fatty acids profile in obese dogs without dietary manipulation (i.e. n-3 PUFA 
supplementation) remains unknown. 
1.4.2.2 Anti-inflammatory dietary components: n-3 PUFA and sPLA2 inhibitor 
The effects of dietary components with anti-inflammatory properties have been 
investigated in many studies to prevent the potential negative effects of inflammation. The 
working mechanism of most anti-inflammatory agents is through direct or indirect inhibition 
of the formation or of the effects of the C20:4 n-6 metabolites (eicosanoids). In humans, n-3 
PUFA are one of the most studied dietary components in down-regulation of inflammation 
(Calder, 2006). The well-established underlying mechanism is through decreased activation of 
NF-κB and increased activation of peroxisome proliferator-activated receptor-γ (PPAR- γ) 
(Sampath and Ntambi, 2005). In addition, a mixture of n-3 PUFA prevented high fat diet-
induced adipose tissue inflammation in obese diabetic mice (Huber et al., 2007; Todoric et al., 
2006). Different outcomes were observed on the use of n-3 PUFA in the treatment of human 
IBD, possibly due to differences in dose, source, and type of n−3 PUFA used and different 
baseline dietary consumption (MacLean et al., 2005). Fish oil supplementation increased 
circulating concentration of adiponectin in healthy dogs (Mazaki-Tovi et al., 2014). In 
addition, serum DPA was associated with increased concentrations of adiponectin and leptin 
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and a decreased triglyceride concentration (Mazaki-Tovi et al., 2012). The n-3 PUFA 
enriched diets might be beneficial to the dog suffering from chronic enteropathies through 
suppressing intestinal inflammatory activity and altering gene expression in cholesterol 
homeostasis (Ontsouka et al., 2012; Ontsouka et al., 2010). These results warrant future 
research to evaluate the effects of n-3 PUFA supplementation on gut and systemic 
inflammatory status in obese dogs, and dogs with IBD. 
Additionally, phospholipasesA2 (PLA2s) are esterases that hydrolyze the sn-2 ester of 
glycerol-phospholipids and it has been recognized that inhibition of PLA2-catalyzed AA 
release could potentially block the synthesis of the eicosanoids. The PLA2 enzyme family is 
composed of secreted PLA2s (sPLA2) and intracellular PLAs. sPLA2s consist of more than 
10 sPLA2 enzymes (IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA, XIIB and otoconin-90). 
Interestingly, a study found group IB sPLA2 (also known as pancreatic sPLA2) deficient mice 
to be resistant to diet-induced obesity compared to conventional mice (Huggins et al., 2002). 
Thus, the inhibition of group IB sPLA2 might have a potential role in protecting against diet-
induced obesity. Furthermore, an sPLA2 inhibitor (1H-indole-3-glyoxyamide compounds) has 
been registered as a patent for treating human IBD (US Patent, No US6340699B1). In 
animals, egg yolk antibody against the sPLA2 has been produced, and its administration 
(orally) has been evaluated in rainbow trout, chicken, and pigs (Barry and Yang, 2008; 
Corrigan et al., 2007; Cook, 2004). In these studies, the growth of the animals has been 
improved and the proposed mechanism was through down regulation of gut inflammation 
(Cook, 2011). However, to our knowledge, no studies have investigated the effect of sPLA2 
inhibitor in obese dogs. 
 
1.5 CONCLUSION 
The gut microbiota can be considered as a major contributor of host homeostasis. With 
the rapid development of high-throughput sequencing techniques, the composition of 
commensal bacteria in the canine GI tract started to be unravelled a few years ago. The 
metabolic function of gut microbiota involves the fermentation of non-digestible dietary 
residue (mainly carbohydrates and protein). The production of the fermentation metabolites 
contribute to the host phenotype and hence to disease risk. However, further insights into the 
mechanisms involved in the interaction between the microbiota and their host need to be 
investigated.  
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Obesity and IBD are both associated with gut microbial dysbiosis. Compared to 
human studies, limited knowledge on the composition and functionality of gut microbiota in 
these diseases is available, especially for the butyrate-producing bacteria, which have been 
suggested to play an important role in the GI tract. Dietary manipulation of the microbiota and 
their fermentation capacity may provide new solutions for managing obesity and IBD. In 
addition, gut or low-grade systemic inflammation is related to IBD and obesity, respectively. 
Blocking the inflammation could be an alternative target to alleviate these diseases. 
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Gut microbiota plays a key role in canine health and disease. Changes in gut 
microbiota has been found in dogs with IBD (Xenoulis et al., 2008) and dogs with 
obesity (Park et al., 2015). In addition to the composition, gut microbiota activity also 
contributes to host health in humans and animals (Nicholson et al., 2012). However, no 
studies are available on both the composition and functionality of gut microbiota in 
canine IBD and obesity. Furthermore, limited studies have investigated the host 
metabolism in canine IBD and obesity (Minamoto et al., 2015; Liu et al., 2014).  
Therefore, the first aim of this PhD thesis was to explore faecal microbial and 
host metabolic changes in IBD and obesity, and thus contribute to the science of 
current diseases. 
 
Diet is the easiest way to manipulate gut microbiota. Dietary protein is of great 
interest, as its high intake has been associated with relapse of human IBD (Jantchou et 
al., 2010). In addition, high protein intake in obese humans subjects can shift gut 
microbiota into a more unfavorable composition (Duncan et al., 2007). Dogs have a 
higher protein requirement compared to humans, and thus might have adapted to cope 
with the negative effects of high protein intake. Therefore, understanding the impact of 
dietary protein impact on gut microbiota in healthy dogs might point the way to 
nutritional interventions and disease prevention strategies.  
Low-grade inflammation occurring in obese humans and animals is another focus 
of nutritional intervention. Suppressing inflammation through diet or dietary 
supplements is a potential aproach to counteract the inflammatory co-morbidities of 
obesity. The sPLA2 has been suggested as a novel target to block the inflammatory 
process.  
A second aim of this PhD was to evaluate the effect of various dietary 
interventions on faecal microbiota, host metabolism and/or inflammation in obese 
dogs to provide deeper knowlegde about nutritional strategies for the treatment of 
obesity and related disorders.  
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To achieve these goals, three studies were designed: 
1. To characterize the composition and activity of faecal microbiota and host 
metabolism in dogs with IBD. 
2. To evaluate the impact of dietary protein on the composition and activity of 
faecal microbiota, and host metabolism in lean and obese dogs.  
3. To evaluate the effect of sPLA2 inhibitor on inflammation, oxidative stress and 
fatty acid profile in lean and obese dogs. 
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Can gut microbial profile affect host metabolism in 
canine inflammatory bowel disease? 
 
 
 
 
 
 
 
 
 
J. Xu 
a
, A. Verbrugghe 
a,b
, M. Lourenço 
a
, G. Janssens
 a
, D. Liu 
a
, T. Van de 
Wiele 
c
,
 
I. Van de Maele 
d
, V. Eeckhaut 
e
, F. Van Immerseel 
e
, Y.F. Niu 
f
, G. 
Bosch 
g
, G. Junius 
h
, B. Wuyts 
i
, M. Hesta 
a
 
 
a 
Department of Nutrition, Genetics and Ethology, Faculty of Veterinary Medicine, Ghent University, 
Heidestraat 19, 9820 Merelbeke, Belgium.  
b 
Present address: Department of Clinical Studies, Ontario Veterinary College, University of Guelph, 50 Stone 
Road East, Guelph, N1G 2W1 ON, Canada.  
c 
Laboratory of Microbial Ecology and Technology (LabMET), Faculty of Bioscience Engineering, Ghent 
University, Coupure Links 653, 9000 Ghent, Belgium 
d 
Department of Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent 
University, Salisburylaan 133, 9820 Merelbeke, Belgium.  
e 
Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, 
Salisburylaan 133, 9820 Merelbeke, Belgium 
f 
Laboratory of Aquaculture & Artemia Reference Center, Ghent University, Rozier 44, 9000 Ghent, Belgium 
g 
Animal Nutrition Group, Department of Animal Sciences, Wageningen University, De Elst 1, 6708 WD 
Wageningen, The Netherlands 
h Private Small Animal Clinic ‘Dierenartsencentrum Hond en Kat’, Emiel Clauslaan 134, 9800 Astene, Belgium 
I 
Laboratory of Metabolic Disorders, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium 
 
 
Under review in BMC Veterinary Research 
  
Chapter 3 
Microbial and metabolic changes in canine IBD 
69 
 
 
3.1 ABSTRACT 
Inflammatory bowel disease (IBD) refers to a diverse group of chronic gastrointestinal 
diseases, and gut microbial dysbiosis has been proposed as a modulating factor in its 
pathogenesis. The aim of the present study was to characterize the faecal bacterial profile and 
functionality and to determine changes in host metabolism of potential gut-derived 
fermentation end products in IBD dogs. Twenty-three dogs diagnosed with IBD and ten 
healthy control dogs were included. Dogs with IBD were given a clinical score using the 
canine chronic enteropathy clinical activity index (CCECAI). Faecal short-chain fatty acids 
(SCFA) and ammonia were measured and quantitative PCR were performed on 25 faecal 
samples. Plasma amino acids, acylcarnitines, serum folate, cobalamin, indoxyl sulphate were 
measured.  
No significant differences in the abundance of a selection of bacterial groups and 
fermentation metabolites were observed between the IBD and control groups. However, a 
significant negative correlation was found between CCECAI and the faecal abundance of 
Lactobacillus. Serum folate and plasma citrulline were decreased and plasma valine was 
increased in IBD compared to control dogs. Increased plasma free carnitine and total 
acylcarnitines were observed in IBD compared with control dogs, whereas short-chain 
acylcarnitines (butyrylcarnitine + isobutyrylcarnitine and, methylmalonylcarnitine) to free 
carnitine ratios decreased. Dogs with IBD had a higher ratio of leucine catabolites (3-
hydroxyisovalerylcarnitine + isovalerylcarnitine) to leucine compared to control dogs. These 
results suggest canine IBD induced a wide range of changes in metabolic profile which could 
evolve from tissue damage and alteration in host metabolism.  
 
Keywords: Butyrate-producing bacteria; Dog; Fatty acid; Fermentation; Lactobacillus, 
Metabolism; Microbiota   
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3.2 INTRODUCTION 
Canine idiopathic inflammatory bowel disease (IBD) is a group of disorders 
characterized by persistent or recurrent clinical signs of gastro-intestinal disease of 
undetermined cause associated with histological evidence of inflammation in the small or 
large intestinal mucosa (German et al., 2003). It has been considered to be the most common 
cause of chronic diarrhoea and vomiting in dogs (Washabau et al., 2010). Gut microbiota 
play a critical role in host-microbial interactions and gut health. Gut dysbiosis, an unbalanced 
microbiota composition, is often seen in IBD dogs and may contribute to the pathogenesis of 
canine IBD (Minamoto et al., 2015; Rossi et al., 2014; Suchodolski et al., 2012a; Xenoulis et 
al., 2008).  
A major function of gut microbiota is degradation of non-digestible dietary residues, 
yielding fermentation end products which can be beneficial or harmful to the host. Butyrate, 
one of the short-chain fatty acids (SCFA), is mainly used as an energy source by colonocytes 
(Roediger, 1980). Decreased butyrate concentrations and impaired butyrate metabolism have 
been found in human IBD patients (Thibault et al., 2010). Additionally, a lower abundance of 
butyrate-producing bacteria has been found in both human and canine IBD patients (Frank et 
al., 2007; Minamoto et al., 2015; Sokol et al., 2008). In contrast, protein fermentation end 
products such as ammonia, branched-chain fatty acids and phenolic compounds may be 
involved in the onset of human IBD (van Nuenen et al., 2004). However, whether protein 
fermentation contributes to canine IBD remains unclear.  
Gut-derived SCFA are absorbed and transported into the bloodstream to the liver to 
enter the citric acid cycle (den Besten et al., 2013). Acetylcarnitine, propionylcarnitine and 
butyrylcarnitines are representative of the corresponding mitochondrial co-enzyme A (CoA) 
and consequently reflect metabolites available for the citric acid cycle (Ash and Baird, 1973). 
In addition to plasma amino acids, some of the plasma acylcarnitines (isobutyrylCoA, 
isovalerylCoA, etc) also represent metabolites of the protein catabolic pathways (Michal and 
Schomburg, 2013). Therefore, the assessment of plasma amino acids and acylcarnitine profile 
could be a tool to evaluate host metabolism that is potentially derived from gut fermentation 
end products (Rochus et al., 2013; Verbrugghe et al., 2010; Bene et al., 2007).  
Several studies focused on the microbial ecology of IBD dogs, but it is yet unclear if 
this microbial profile can alter the nutrient metabolism of the host. The aim of the present 
study was to identify changes in canine host metabolism that are associated with an IBD-
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associated shift of the faecal microbial profile and functionality especially focusing butyrate-
producing bacteria and the concomitant fermentation profile.  
3.3 MATERIALS AND METHODS 
Animals 
The European Directive 2010/63/EU and institutional guidelines of Belgian Council 
for Laboratory Animal Science for the care and use of animals were followed. Informed 
written consent was obtained from the owners of all IBD dogs participating in the study. 
Twenty-three dogs, 15 admitted at the Small Animal Clinic of Ghent University 
(Belgium) and eight at a local private small animal clinic ‘Dierenartsencentrum Hond en 
Kat’, Astene (Belgium), diagnosed with IBD were included in the IBD group. The minimum 
diagnostic evaluation performed in all IBD dogs included complete blood counts, serum 
biochemistry, urinalysis, faecal parasitology, abdominal ultrasound, and histopathologic 
review of mucosal biopsy specimens. The inclusion criteria for the IBD group were adapted 
from World Small Animal Veterinary Association (Washabau et al., 2010): (1) chronic (> 3 
weeks) persistent or recurrent gastrointestinal signs such as but not limited to vomiting and 
diarrhoea; (2) histopathologic evidence of mucosal inflammation; (3) inability to document 
other causes of gastrointestinal inflammation; (4) inadequate response to dietary, antibiotic 
and anthelmintic therapies alone. The requirement of the clinical response to anti-
inflammatory or immunosuppressive agents was not included because anti-inflammatory 
drugs may influence gut microbiota (Makivuokko et al., 2010). Additionally, no dogs 
received antibiotics for at least 3 weeks before sampling.  
Dogs with IBD were allocated a clinical score using the canine chronic enteropathy 
clinical activity index (CCECAI) (Allenspach et al., 2007). Briefly, the CCECAI score is 
based on nine criteria, each scored on a scale from 0-3: attitude/activity, appetite, vomiting, 
stool consistency, stool frequency, weight loss, albumin levels, ascites and peripheral edema, 
pruritus. After summation, the total score is determined to be clinically insignificant (0-3), 
mild (4-5), moderate (6-8), severe (9-11), or very severe (≥12) IBD.  
Ten healthy dogs, four from the Department of Medical Physiology, University 
Medical Centre Utrecht (The Netherlands) and six from an animal shelter (Wase 
Dierenbescherming, Sint-Niklaas, Belgium) were included in the control group. The control 
dogs were euthanized for research purposes unrelated to the present study and for behavioural 
problems. All dogs were deemed healthy based on physical exams, complete blood counts, 
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and serum biochemistry. All dogs did not receive antibiotic for at least 3 weeks before 
sampling.  
Sample collection  
At presentation in the clinic of IBD dogs, and immediately after euthanasia of control 
dogs, blood samples (5 mL, normally taken for general health check-up) were drawn from the 
jugular vein of all dogs. Plasma and serum were obtained from all dogs, except for one IBD 
dog (due to improper sample storage) by centrifugation at 1620 g for 15 min at 4
o
C and 
stored at – 20°C until analysis. Fifteen naturally defecated faeces and rectal swabs were 
collected in the IBD group upon diagnosis. In the control group, faecal samples were 
obtained from the rectum immediately after euthanasia. All faecal samples were frozen in dry 
ice and stored at – 80 °C until analysis.  
Analytical methods 
Serum cobalamin and folate concentrations were analyzed by a commercial laboratory 
(Algemeen Medisch Laboratorium, Antwerp, Belgium) using commercially available 
ARCHITECT B12 and ARCHITECT Folate assays on ARCHITECT i System (Abbott 
Diagnostics). Plasma amino acids and acylcarnitine profile was determined according to 
Vreken et al (1999). Faecal SCFA concentrations on fresh basis were determined via gas 
chromatography after extraction with diethyl ether (Greenberg et al., 1992). Ammonia was 
analyzed by steam distillation and titration according to Bremner and Keeney (1965).  
Bacterial DNA extraction 
Bacterial DNA extraction of the faecal samples was performed according to 
Vanhoutte et al. (2004). DNA concentration was measured in triplicate using the Nanodrop 
ND 1000 spectrophotometer (NanoDrop Technologies).  
DGGE 
Isolated DNA was subsequently used as a template to amplify the 16S rDNA for all 
members of the Bacteria with forward primer P338F-GC and the reverse primer P518r, and a 
GC-clamp of 40 bp was incorporated into the forward primer. DGGE based on the protocol 
of Muyzer et al. (1993) was performed on the Bio-Rad D gene system (Bio-Rad, Hercules, 
CA, USA). The obtained DGGE patterns were normalized and analyzed using BioNumerics 
2.0 (Applied Maths, Kortrijk, Belgium). The number of bands in the DGGE profile was used 
to calculate the richness in the present study. A matrix of similarities for the densiometric 
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curves of the band patterns was calculated based on the Pearson product-moment correlation 
coefficient, and dendrograms were created by using Ward linkage (Ward Jr, 1963). 
Quantitative PCR  
DNA quantification by qPCR was performed using the C1000 Thermal Cycler (Bio-
Rad, Hercules CA, USA). The amplification and detection were carried out in 96-well plates 
using SensiMixTM SYBR No-ROX Kit (Bioline Reagents Ltd, UK). Each reaction was done 
in triplicate in 12 μL total reaction mixture using 2 µL of 50 ng of the DNA sample. The 
primer sets used in this study are listed in Table 3.1. A melting curve analysis was done after 
amplification to confirm specificity of the reaction. The quantification was done using 
standard curves made from known concentrations of plasmid DNA containing the respective 
amplicon for each set of primers.  
Table 3.1 Primer set used in the present study 
Target Primers (5’3’) References 
Bacteria V3 region PRBA338f ACTCCTACGGGAGGCAGCAG 
PRUN518r ATTACCGCGGCTGCTGG 
(Ovreas et al., 1997) 
Total Bacteria fwd CGGYCCAGACTCCTACGGG 
rev TTACCGCGGCTGCTGGCA 
(Lee et al., 1996) 
Firmicutes 
 
fwd GGAGYATGTGGTTTAATTCGAAGCA 
rev AGCTGACGACAACCATGCAC 
(Guo et al., 2008) 
Enterobacteriaceae 
 
fwd CATTGACGTTACCCGCAGAAGAAGC 
rev CTCTACGAGACTCAAGCTTGC 
(Bartosch et al., 2004) 
Bacteriodetes 
 
fwd GGARCATGTGGTTTAATTCGATGAT 
rev AGCTGACGACAACCATGCAG 
(Guo et al., 2008) 
Lactobacillus fwd GGAATCTTCCACAATGGACG 
rev CGCTTTACGCCCAATAAATCCGG 
(Bakar et al., 2010) 
Clostridial cluster I  fwd TACCHRAGGAGGAAGCCAC 
rev GTTCTTCCTAATCTCTACGCAT 
(Song et al., 2004) 
Clostridial cluster IV  fwd ATGCAAGTCGAGCGA(G/T)G 
rev TATGCGGTATTAATCT(C/T)CCTTT 
(Matsuki et al., 2004) 
Clostridial cluster 
XIVa 
fwd CGGTACCTGACTAAGAAG 
rev AGTTT(C/T)ATTCTTGCGAAC 
(Malinen et al., 2005) 
Butyryl-CoA acetate-
CoA transferase  
fwd AAGGATCTCGGIRTICAYWSIGARATG) 
rev GAGGTCGTCICKRAAITYIGGRTGNGC 
(Charrier et al., 2006) 
Dissimilative sulphate-
reducing bacteria gene 
fwd AACAACATHGARTTYATG  
rev TAGCAGTTACCRCARTACAT 
(Possemiers et al., 2007) 
 
Calculations 
Total acylcarnitines were calculated as the sum of plasma concentration of 
acetylcarnitine (C2), propionylcarnitine (C3), butyrylcarnitine and isobutyrylcarnitine (C4), 
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isovalerylcarnitine and methylbutyrylcarnitine (C5), 3-hydroxybutyrylcarnitine (3OH-C4), 3-
hydroxyisovalerylcarnitine and 2-methyl-3-hydroxybutyrylcarnitine (3OH-C5), 
methylmalonylcarnitine (C4DC), tiglylcarnitine, hexanoylcarnitine, octanoylcarnitine, 
malonylcarnitine, decenoylcarnitine, decanoylcarnitine, glutaryl- and 3OH-decanoylcarnitine, 
dodecanoylcarnitine, methylglutarylcarnitine, 3OH-dodecanoylcarnitine, 
tetradecadienoylcarnitine, tetradecenoylcarnitine, tetradecanoylcarnitine, suberylcarnitine, 
3OH-tetradecenoylcarnitine, 3OH-tetradecanoylcarnitine, hexadecenoylcarnitine , 
palmitoylcarnitine , sebacylcarnitine , 3OH-hexadecenoylcarnitine , 3OH-palmitoylcarnitine , 
octadienoylcarnitine, octadecenoylcarnitine, octadecanoylcarnitine, 3OH-
octadecenoylcarnitine and 3OH-octadecanoylcarnitine.  
As individual plasma acylcarnitines/C0 ratios resemble intramitochondrial acyl-
CoA/CoA ratios, the ratios were calculated to determine the host metabolic changes. Two 
specific ratios representing leucine catabolism and urea cycle metabolism were calculated: 
(C5 + 3OHC5)/leucine and citrulline/ornithine, respectively.  
Normalization of qPCR data was expressed by all qPCR data relative to the amount of 
total bacterial measured. 
Total SCFA were calculated as the sum of acetate, propionate, butyrate, valerate, 
isobutyrate and isovalerate. The proportions of individual SCFA were expressed relative to 
total SCFA. 
Statistical analyses  
Data were analysed using the Wilcoxon-Mann-Whitney test, for which the assumption 
of normality is not necessary. For this, four data sets were built: one with all parameters 
measured in faeces, one with all the ratios calculated from the faecal parameters, one with all 
metabolites assessed in the blood, and one with all the ratios calculated from the blood. For 
each data set, the Wilcoxon-Mann-Whitney test was run separately. To correct for false 
discovery rates, P values were adjusted (q value) using the Benjamini-Hochberg test. 
Valerate was only detected in two faecal samples in IBD dogs hence this parameter was not 
taken into consideration in the statistical analysis. These analyses were done in R (The R 
Foundation for Statistical Computing, version 3.1.0) using the Coin package (version1.0-23).  
Spearman correlations coefficients were calculated between CCECAI and the 
abundance of different bacterial groups, faecal fermentation end products, plasma amino 
acids and acylcarnitine profile. The CCECAI score assigned to control dogs was zero (0).  
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Correlations and PCA analysis were performed using Superior Performing Software 
Systems (SPSS) version 20 (SPSS Inc., Chicago, Illinois, USA).  
For all parameters, statistical significance was accepted at P < 0.05 and q < 0.05  
 
3.4 RESULTS 
Study population and CCECAI scores  
The IBD group consisted of seven intact females, four spayed females, nine intact 
males and three neutered males (0.8-12.3 years, median age: 3.8 years). Breeds included 
Dogue de Bordeaux, Spanish Water Dog, Galgo Español, Golden Retriever, Sheltie, Jack 
Russell Terrier, Miniature Pinscher, Foxhound, Eurasier, Alaskan Malamute, Bouvier des 
Flandres, Husky, Great Swiss Mountain Dog, Whippet, Standard Poodle, Lapphund, German 
Shepherd, Rottweiler, Bichon Frise, Beagle, French Bulldog and Mongrel dogs (×2). Five 
dogs had insignificant IBD (median CCECAI=2.0), five dogs had mild IBD (median 
CCECAI=5.0), six dogs had moderate IBD (CCECAI=8.0) and seven dogs had severe IBD 
(median CCECAI =10).  
The control group consisted of five intact females and five intact males (0.5-8.0 years, 
median age: 2.3 years). Breeds included American Staffordshire Terrier, Staffordshire Bull 
Terrier, German Shepherd, Scottish Collie, Labrador Retriever, Jack Russell Terrier, Beagle, 
and Mongrel dogs (×3). 
Faecal microbiota 
Based on the cluster analysis of DGGE profile of faecal samples of IBD and control 
dogs (Figure 3.1), there was no clear distinction of the faecal microbial community of IBD 
and control dogs. The similarity index between the samples ranged from 23.6 to 96.0%, with 
an average of 59.8 and 63.0% for IBD and control groups, respectively. The microbial 
richness of IBD dogs (28.0) was not different from that of control (29.7) dogs (P=0.476, 
Figure 3.2). 
No differences were found between IBD and control dogs for the faecal abundance of 
Firmicutes, Bacteroidetes, Enterobacteriaceae, Lactobacillus, clostridial cluster I, IV, XIVa , 
and the number of gene copies of butyryl-CoA acetate-CoA transferase (BCoAT) and 
dissimilative sulphate-reducing bacteria gene (dSRB) (q>0.05) in terms of absolute numbers 
(Table 3.2).  
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Figure 3.1 Cluster analysis of DGGE profile of faecal samples of dogs with IBD and healthy 
control dogs. Dogs with IBD: D1-D15; control dogs: C1-C11 (C6 was removed from the 
study because of potential enteritis). Metric scale indicates degree of similarity in percent (the 
shorter the lines of the dendrogram, the more similar the two samples are regarding the 
richness and the intensity)  
 
 
Figure 3.2 Bacterial richness of inflammatory bowel disease (IBD) and control dogs. 
Richness was calculated according to the number of bands on DGGE profile. Dogs with IBD: 
D1-D15; control dogs: C1-C11 (C6 was removed from the study because of potential enteritis) 
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No differences were found between IBD and control dogs for the faecal abundance of 
Firmicutes, Bacteroidetes, Enterobacteriaceae, Lactobacillus, clostridial cluster I, IV, XIVa , 
and the number of gene copies of butyryl-CoA acetate-CoA transferase (BCoAT) and 
dissimilative sulphate-reducing bacteria gene (dSRB) (q>0.05) in terms of absolute numbers 
(Table 3.2).  
Table 3.2 Abundance of different bacterial groups and functional gene in faeces of dogs with 
inflammatory bowel disease (IBD) and healthy control dogs (IBD: n=15, Control: n=10)
1
  
 
Control  IBD 
q value 
Mean SD  Mean SD 
Absolute value 
1
 
  
 
   
Total bacteria 10.49 0.74  10.48 0.59 0.860 
Relative value (%) 
2
 
  
 
   
Firmicutes 110.6 30.8  127.2 42.1 0.790 
Bacteroidetes 35.5 44.6  52.2 51.9 0.823 
Enterobacteriaceae 0.6 1.0  3.1 5.5 0.937 
Lactobacillus 8.7 10.4  1.1 3.5 0.145 
Clostridial cluster I 13.1 23.9  13.0 16.3 0.790 
Clostridial cluster IV 9.4 9.7  8.5 12.5 0.937 
Clostridial cluster XIVa 6.1 5.3  8.4 8.6 0.790 
BCoAT 0.090 0.083  0.061 0.071 0.823 
dSRB  0.002 0.001  0.001 0.002 0.608 
BCoAT: butyryl-CoA acetate-CoA transferase gene; dSRB: dissimilative sulphate-reducing bacteria 
gene
 
1
 Results of bacterial groups are expressed as log1016S rRNA gene copies /g fresh weight and results 
of functional genes are expressed as log10 total DNA gene copies /g fresh weight. 
2
 The relative values are expressed as the ratio of the abundance of bacteria to the abundance of total 
bacteria. 
Correlations between CCECAI and bacterial groups revealed a significant negative 
correlation with relative faecal abundance of Lactobacillus (r= -0.504, P=0.010) but not for 
BCoAT gene and butyrate producing clusters IV and XIVa (Figure 3.3). 
Faecal fermentation metabolites  
No significant differences were observed between IBD and control dogs for faecal 
ammonia and SCFA concentrations (q>0.05; Table 3.3).  
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Figure 3.3 Correlations between relative faecal abundance of bacterial groups and canine 
chronic enteropathy clinical activity index (CCECAI) in IBD and control dogs (n=25). (a) 
Lactobacillus; (b) butyryl-CoA acetate-CoA transferase gene; (c) clostridial cluster IV; and 
(d) clostridial cluster XIVa.  
 
Table 3.3 Faecal concentrations of fermentation end products of dogs with inflammatory 
bowel disease (IBD) and healthy control dogs
 
(IBD: n=15, Control: n=10) 
 
Control  IBD 
q value 
Mean SD  Mean SD 
Acetate (%) 63.0 11.6  61.9 11.8 0.937 
Propionate (%) 26.6 10.5  24.8 12.0 0.937 
Butyrate (%) 7.0 3.7  10.1 4.4 0.726 
Isobutyrate (%) 1.5 1.4  0.8 1.0 0.608 
Isovalerate (%) 1.8 2.4  1.5 1.7 0.937 
Ammonia (µmol/g) 324 195  238 86 0.843 
Total SCFA (µmol/g) 123.9 36.9  80.1 39.7 0.145 
SCFA: short-chain fatty acids 
1
 The relative values are expressed as the ratio of individual SCFA to total SCFA 
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Spearman’s correlation showed only a significant negative correlation between faecal 
total SCFA and CCECAI (r= -0.489, P=0.013) (Figure 3.4).  
 
Figure 3.4 Correlations between faecal SCFA and canine chronic enteropathy clinical 
activity index (CCECAI) in dogs (n=25). 
 
Blood parameters  
Serum cobalamin concentration did not differ between two groups, while serum folate 
concentration was lower in the IBD compared to the control group (q=0.023) (Table 3.5). The 
IBD group also showed increased plasma valine concentrations (q = 0.003), whereas plasma 
citrulline concentrations (q = 0.016) and citrulline/ornithine ratios (q = 0.014) were decreased 
in IBD compared to control dogs (Table 3.5). Also plasma C0 (q = 0.003) and total 
acylcarnitine (q = 0.003) concentrations were increased in IBD compared to control dogs 
(Table 3.5). As for the ratios of individual plasma acylcarnitines to C0, C4/C0 (q = 0.008) 
and C4DC/C0 (q = 0.006) were decreased, while (C5+3OHC5)/leucine (q = 0.006) were 
increased in IBD compared to control group (Table 3.5). For C3/C0 and 3OHC4/C0 no 
significant difference was observed between groups (Table 3.5).  
A significant negative correlation between CCECAI and C4/C0 (r= -0.496, P=0.004), 
and positive correlations between CCECAI and valine (r= 0.613, P<0.001) and CCECAI and 
alanine (r= 0.374, P=0.035) were observed (Figure 3.5). In contrast, negative correlations 
between CCECAI and citrulline were observed (r= -0.578, P=0.001) (Figure 3.5). 
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Table 3.4 Blood parameters of dogs with inflammatory bowel disease (IBD) and healthy 
control dogs (IBD: n=22, Control: n=10)
1 
 
Control  IBD 
q value 
Mean SD  Mean SD 
Cobalamin (pmol/L) 285 68.1  301 213 0.651 
Folate (pmol/L) 34.5 6.75  24.0 11.5 0.023 
Indoxyl sulphate (mg/dL) 1.56 1.05  1.57 1.65 0.681 
Plasma amino acids 
  
 
   
Valine (μmol/L) 213 43.1  287 53.8 0.003 
Leucine (μmol/L) 257 58.3  274 61.0 0.536 
Ornitine (μmol/L) 32.6 7.42  37.7 8.41 0.187 
Citruline (μmol/L) 112 48.1  71.3 39.0 0.016 
Citruline/Ornitine 3.53 1.77  2.00 1.07 0.014 
Plasma acylcarnitine profile 
  
 
   
C0
 
(μmol/l) 16.2 13.7  36.1 21.9 0.003 
Total acylcarnitines (μmol/L) 2.16 1.03  4.00 1.84 0.003 
Total acylcarnitines/C0 (%) 16.4 6.9  12.4 4.7 0.113 
C2/C0 (%) 11.0 4.8  7.6 3.6 0.096 
C3/C0 (%) 0.587 0.483  0.749 0.796 0.643 
C4/C0 (%) 0.606 0.248  0.316 0.149 0.008 
C4DC/C0 (%) 0.374 0.172  0.179 0.103 0.006 
3OHC4/C0 (%) 0.111 0.083  0.119 0.078 0.874 
(C5+3OHC5)/Leucine (%) 0.034 0.028  0.060 0.024 0.006 
C0: free carnitine, C2: acetylcarnitine, C3: propionylcarnitine, C4: butyrylcarnitine + 
isobutyrylcarnitine, C4DC: methylmalonylcarnitine, 3OHC4: 3-hydroxybutyrylcarnitine, C5: 
isovalerylcarnitine + methylbutyrylcarnitine, 3OHC5: 3-hydroxyisovalerylcarnitine + 2-methyl-3-
hydroxybutyrylcarnitine 
1
Reference range of cobalamin: 73-485 pmol/L. One dog in IBD group is out of reference range.  
2
Reference range of folate: 9.0-36.0 nmol/L. Five dogs in IBD group and 4 dogs in control group are 
out of reference range. All dogs were included in the statistical analysis. 
3.5 DISCUSSION 
This study aimed to provide new insights into the relationship between faecal 
microbiota profile and their functionality, and host metabolic changes in canine IBD. The fact 
that no significant differences were observed in faecal microbiota between IBD and control 
dogs could be due to the intrinsic variance among dogs (e.g. age, breed, disease activity, diet) 
and/or the methodology that was used (e.g. DNA extraction, DGGE). Nevertheless, the 
relative abundance of Lactobacillus gradually decreased with increased severity of IBD in 
dogs (Figure 3.3). A reduction in faecal Lactobacillus has been previously reported in human 
IBD patients (Ott et al., 2004). Several Lactobacillus strains have been proven to effectively 
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protect against IBD in murine models through down-regulation of pro-inflammatory 
cytokines (Lin et al., 2008; Matsumoto et al., 2005). Although no difference in abundance of 
Lactobacillus has been observed previously in IBD dogs (Minamoto et al., 2015), the 
probiotic VSL#3 containing several strains of Lactobacillus, and other bacterial strains 
showed a potential protective effect in IBD dogs (Rossi et al., 2014). Therefore, more in-
depth studies should be performed to identify the Lactobacillus strains that are altered in 
canine IBD. 
  
 
Figure 3.5 Correlations between plasma amino acids and acylcarnitines and canine chronic 
enteropathy clinical activity index (CCECAI) in dogs (n=32). 
 
Studies have shown the majority of butyrate-producing bacteria found in clostridial 
clusters IV and XIVa were decreased in the intestine of human IBD patients (Wang et al., 
2014; Machiels et al., 2014; Sokol et al., 2008; Frank et al., 2007). However, clostridial 
clusters IV and XIVa still harbour a diverse collection of butyrate and non-butyrate producers 
(Louis and Flint, 2009). Faecalibacterium spp., which belongs to clostridial cluster IV, has 
been repeatedly reported to be decreased in IBD dogs (Minamoto et al., 2015; Suchodolski et 
al., 2012b). But the proportion of the Faecalibacterium is lower in dogs (1%) compared to 
y = -0,0313x + 0,5411 
0,0 
0,2 
0,4 
0,6 
0,8 
1,0 
0 2 4 6 8 10 12 
C
4
/C
0
 (
%
) 
CCECAI 
P =0.004 
r= -0.496 
y = 9,2343x + 223,67 
0 
100 
200 
300 
400 
500 
0 2 4 6 8 10 12 
V
a
li
n
e 
(μ
m
o
l/
L
) 
CCECAI 
P <0.001 
r= 0.613 
y = -5,6632x + 108,35 
0 
50 
100 
150 
200 
250 
0 2 4 6 8 10 12 
C
it
ru
ll
in
e 
(μ
m
o
l/
L
) 
CCECAI 
P=0.001 
r= -0.578 
y = 30,928x + 829,89 
0 
500 
1000 
1500 
2000 
2500 
0 2 4 6 8 10 12 
A
la
n
in
e 
(μ
m
o
l/
L
) 
CCECAI 
P=0.035 
r=0.374 
 82 Chapter 3 
Microbial and metabolic changes in canine IBD 
 
humans (5-10%) (Garcia-Mazcorro et al., 2012; Suchodolski et al., 2012b; Arumugam et al., 
2011; Ramirez-Farias et al., 2009). Therefore, the concentration of BCoAT genes was 
quantified in faecal samples, yet no correlation with severity of IBD was revealed (Figure 
3.3b). However, the BCoAT pathway is one of the two main pathways known for butyrate 
production in bacteria. The other one is butyrate kinase pathway which has been reported 
only for a few strains whereas the BCoAT pathway is the dominant pathway in human 
colonic isolates (Louis and Flint, 2009). A recent study found BCoAT pathway was enriched 
in omnivores and herbivores whereas butyrate kinase pathway was more abundant in 
carnivores (Vital et al., 2015). Importantly, that study also included two dogs as carnivores, 
while BCoAT pathway was dominant for one dog and the other one seemed to have both 
pathways equally distributed (Vital et al., 2015). Therefore, further studies are warranted to 
evaluate the diversity and metabolism of butyrate-producing bacteria from canine species.  
Similarly, although the faecal proportions of individual SCFA did not reveal any 
difference between IBD and control dogs, the total faecal SCFA concentrations were 
decreased with increased severity of IBD. . In humans, a study found total SCFA excretion to 
be elevated with increased severity of ulcerative colitis (UC) (Montgomery et al., 1968). In 
contrast, another study found decreased total SCFA concentration in active but not inactive 
UC patients (Treem et al., 1994). However, it should be noted that episodes of diarrhoea are 
not uncommon in IBD patients. In the present study, 17 out of 23 dogs had soft faeces to 
watery diarrhoea (Figure 3.6). When diarrhoea occurs, more water is present in the faeces 
leading to a dilution of fermentation metabolites.  
Folate absorption occurs in jejunum and abnormalities of the proximal small intestinal 
mucosa might lead to reduced level of serum folate (Batt and Morgan, 1982), as seen in this 
study for IBD dogs. In addition, gut commensals including Bifidobacteria and Lactobacillus 
can produce folate (LeBlanc et al., 2013). Therefore, decreased serum folate concentrations 
might be a consequence of impaired intestinal function and/or altered gut microbial 
community (e.g. the observed decreased in the abundance of Lactobacillus). 
In this study, IBD dogs were characterised by higher plasma concentrations of C0 and 
total acylcarnitines. A previous study found increased carnitine in fasted dogs (Rodriguez et 
al., 1986). In this study, 18 out of 23 IBD dogs experienced different degrees of weight loss 
(Figure 3.6), which suggested the occurrence of tissue loss, e.g. the adipose tissue and lean 
mass. Extreme weight loss with muscle wasting (known as “cachexia”) may occur in dogs 
with severe IBD (Burrows, 2010). In addition, intestinal mass might be reduced as citrulline 
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mainly originates from duodenum and jejunum, and its blood level is highly dependent on 
small bowel enterocytes mass in humans (Gong et al., 2005). However, inter-species 
difference on citrulline conversion may exist (Curis et al., 2007). Free carnitine and 
acylcarnitine concentrations in tissues (muscle, intestine, etc) are higher than in the blood 
(Flores et al., 1996; Davis, 1990; Sachan and Ruark, 1985). Thus, tissue loss might lead to an 
increase in plasma C0 and total acylcarnitine concentrations in IBD dogs.  
 
 
Figure 3.6 The total canine chronic entreropathy clinical activity index (CCECAI) and the 
individual score of each criterion. 
In this study, IBD dogs were characterised by higher plasma concentrations of C0 and 
total acylcarnitines. A previous study found increased carnitine in fasted dogs (Rodriguez et 
al., 1986). In this study, 18 out of 23 IBD dogs experienced different degrees of weight loss 
(Figure 3.6), which suggested the occurrence of tissue loss, e.g. the adipose tissue and lean 
mass. Extreme weight loss with muscle wasting (known as “cachexia”) may occur in dogs 
with severe IBD (Burrows, 2010). In addition, intestinal mass might be reduced as citrulline 
mainly originates from duodenum and jejunum, and its blood level is highly dependent on 
small bowel enterocytes mass in humans (Gong et al., 2005). However, inter-species 
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difference on citrulline conversion may exist (Curis et al., 2007). Free carnitine and 
acylcarnitine concentrations in tissues (muscle, intestine, etc) are higher than in the blood 
(Flores et al., 1996; Davis, 1990; Sachan and Ruark, 1985). Thus, tissue loss might lead to an 
increase in plasma C0 and total acylcarnitine concentrations in IBD dogs.  
On the other hand, IBD dogs showed reduced plasma C4/C0 and this decrease was 
associated with the severity of IBD. This could indicate a drop in butyrate and/or isobutyrate 
metabolism in liver (Michal and Schomburg, 2013; Aas and Bremer, 1968). Additionally, 
C4DC which originate from valine and propionate (Michal and Schomburg, 2013), its ratio to 
C0 was also declined in IBD dogs. The drop of C4DC was more likely due to a lack of 
propionate because plasma valine was significantly increased. The decreases of these short-
chain acylcarnitines are supported by decreased faecal SCFA in more severe IBD dogs. 
Although faecal SCFA did not differ between IBD and control dogs, this could be due to 
rapid absorption of SCFA leaving only a small detectable amount in faeces. It is not known if 
the SCFA derived from intestinal fermentation are a substantial source of energy in dogs, but 
the shifts at least point to a change in nutrient metabolism that is associated with the events in 
the intestinal lumen. 
Inflammatory conditions are known to stimulate protein catabolism and release amino 
acids from muscle tissue to provide substrate for proteins of the immune system (Schicho et 
al., 2010). Alanine is an important transport metabolite for amino groups in animals, 
therefore, a increased concentration of alanine might indicate a higher amino acid turnover 
(Michal, 1999; Rochus et al., 2013). In addition, increased plasma valine concentrations and 
(C5+3OHC5)/leucine ratio might be associated with an increase in branched-chain amino 
acids (BCAA) catabolism in the host (Michal and Schomburg, 2013). However, these could 
also be involved with increased mobilisation from lean tissues. In contrast, a decrease in 
plasma citrulline/ornitine ratio suggested decreased protein catabolism. This contradicted 
with the previous suggestion of increased degradation. As mentioned previously, citrulline is 
an amino acid released exclusively from small bowel enterocytes, a disease condition 
involving the upper intestine could reduce its production (Diamanti et al., 2012). Notably, an 
increased citrulline level was observed in dogs with IBD that received probiotic treatment 
compared to untreated dogs (Rossi et al., 2014). Citrulline has also been proposed as a 
surrogate marker of intestinal inflammation in human patients with Crohn’s disease 
(Diamanti et al., 2011). Therefore, future studies are warranted to evaluate if plasma citrulline 
could be a putative marker of intestinal function in canine IBD. 
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3.6 CONCLUSIONS 
Dogs with increased severity of IBD were characterised by decreased faecal 
proportions of Lactobacillus and faecal concentrations of total SCFA. Neither the butyrate-
producing clostridial clusters IV and XIVa, nor BCoAT gene changed in IBD compared to 
healthy dogs. This urges for a further exploration of the pathways of butyrate production in 
dogs. Importantly, IBD induced changes in the nutritional metabolic profile. However, it 
should be take into account this may have been a result of tissue damage and/or changes in 
host metabolism.   
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4.1 ABSTRACT 
High dietary protein promotes colonic protein fermentation and modifies faecal 
microbiota in healthy dogs. In obese humans, high protein diets shift the gut microbiota into a 
more unfavourable composition. However, in obese dogs this has not yet been investigated. 
The aim of this study was to investigate gut microbial changes in lean and obese dogs in 
response to differing levels of dietary protein. Six healthy lean and six obese Beagles were 
fed a high protein diet (HP) and low protein diet (LP) for 28 days each in a crossover design. 
Denaturing gradient gel electrophoresis (DGGE) and quantitative real-time polymerase chain 
reaction (qPCR) were performed on faecal samples for profiling of microbiota. Fermentation 
metabolites were measured.  
Dogs fed HP showed higher concentrations of protein fermentation metabolites 
including faecal ammonia, isovalerate, isobutyrate, phenol, indole, serum indoxyl sulphate 
and plasma 3-OH isovalerylcarnitine compared to dogs fed LP. The abundances of clostridial 
clusters IV and XIVa, covering the majority of butyrate-producing bacteria, and of butyrate 
kinase gene, one of the terminal genes of the butyrate synthesis pathway were higher in dogs 
on HP compared to LP. Significant interactions between diet and body condition were found 
for the abundance of Firmicutes, Lactobacillus and clostridial cluster I. Interestingly, the 
similarity coefficient of faecal microbiota between the two diets was smaller in obese dogs 
than in lean dogs. In conclusion, high dietary protein content stimulated colonic protein 
fermentation and increased the abundance of butyrate-producing bacteria. Changing dietary 
protein content had a greater impact on faecal microbiota of obese compared to lean dogs. 
 
Keywords: Acylcarnitine profile; Butyrate-producing bacteria; Canine; Obesity, Protein 
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4.2 INTRODUCTION 
The gastrointestinal microbiota plays a critical role in host health and disease. 
Alterations in the gut microbial community have not only been occurred with gastrointestinal 
diseases (Minamoto et al., 2015) but also with obesity in dogs, with a higher faecal 
abundance of Actinobaccteria and Roseburia compared to lean dogs (Handl et al., 2013). 
Human obesity has been reported to be associated with changes within two dominant phyla, 
Firmicutes and Bacteroidetes (Zhang et al., 2009; Ley et al., 2006). The relationship between 
canine obesity and gut microbial community is less well understood compared to that of 
humans and need be further investigated (Park et al., 2015; Handl et al., 2013). Also, gut 
microbiota are mainly influenced by undigested carbohydrates and protein. Understanding 
how the composition and activity of gut microbiota are altered by these nutrients will point 
the way to nutritional interventions and disease prevention strategies. 
In dogs, there has been an accumulating interest in feeding high protein diets, e.g. raw 
meat-based diets and weight management diets (Freeman et al., 2013; Diez et al., 2002). In 
obese human subjects, high protein diets result in decreased concentration of butyrate and 
numbers of butyrate-producing bacteria, mainly belonging to clostridial clusters IV and XIVa 
(Duncan et al., 2007). Several studies carried out in lean dogs reported negative effects of 
colonic protein fermentation including increased intestinal pH and elevated production of 
putrefactive substances (Hesta et al., 2003). In addition, a high protein diet was shown to 
promote the growth of Clostridium perfringens and to reduce the abundance of clostridial 
cluster XIVa in dogs (Zentek et al., 2003). However, the impact of high protein diets on the 
composition and activity of gut microbiota in obese dogs has not been studied yet.  
The interactions between bacteria and host metabolism are of great importance but 
have only recently received increased attention (Nicholson et al., 2012). After being absorbed 
in the large intestine, SCFA can serve as energy source, after conversion into glucose and 
fatty acids through the citric acid cycle in the liver (den Besten et al., 2013). Acetylcarnitine, 
propionylcarnitine, and butyrylcarnitines are representative of the respective mitochondrial 
CoA and consequently reflect metabolites available for the citric acid cycle (Bremer, 1983). 
In addition, the protein fermentation product indole can be metabolized to indoxyl sulphate 
by the liver (Wikoff et al., 2009). Therefore, the assessment of these metabolites might be a 
useful approach to evaluate host metabolism of the gut fermentation end products (Rochus et 
al., 2013; Verbrugghe et al., 2010).  
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The aim of the present study was (1) to investigate the impact of dietary protein on 
faecal microbiota and host metabolism; and (2) to compare the response of lean and obese 
dogs to different levels of dietary protein. The diversity and composition of faecal microbiota 
were measured through DGGE and qPCR. The functionality of faecal microbiota was 
assessed by quantifying faecal fermentation metabolites, serum folate (vitamin B9) and 
cobalamin (vitamin B12). The effect on the host metabolism was evaluated through the levels 
of plasma acylcarnitines and serum indoxyl sulphate. 
 
4.3 MATERIALS AND METHODS 
Animals and diets  
Twelve healthy Beagles (Marshall Farms, USA and Domaine des Souches, France) 
with a mean age of 6.0 years (range 3.8-8.3 y) were included in this study. Six Beagles (one 
spayed and three intact females; two intact males) were lean with a body condition score 
(BCS) of 4-5/9 and six Beagles (three intact females, one castrated and two intact males) 
were obese with a BCS of 8-9/9 (Laflamme, 1997). Obesity was induced approximately one 
year prior to the present study by feeding the dogs a high fat commercial diet as described by 
Van de Velde et al., (2013). Prior to the study, dogs were deemed healthy, apart from obesity 
in six dogs, based on physical exams, complete blood counts, and serum biochemistry.  
Two isocaloric experimental diets (Table 4.1), a high protein diet (HP) and a low 
protein diet (LP) were formulated with the same ingredients (NV Versele-Laga, Deinze, 
Belgium). The HP contained 50.0% crude protein (CP) and 32.2% nitrogen-free extract while 
the LP contained 17.8% CP and 62.3% nitrogen-free extract, on a DM basis (Table 4.1). Both 
diets met the Minimal Requirement for adult dogs according to the National Research 
Council (NRC) (2006). The initial amount of food offered was calculated based on individual 
maintenance energy requirements according to population history and adjusted to maintain a 
stable body weight throughout the study. Dogs were fed twice daily and had free access to 
water.  
Animal experimental procedures 
A cross-over design consisting of two 28-day test periods with collections in the last 
week of each period was used. Three lean and three obese dogs were randomly selected and 
assigned to LP first and the other three lean and obese dogs first received HP. After this first 
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period, diets were switched. The study design was approved by the Ethical Committee of the 
Faculty of Veterinary Medicine, Ghent University, Belgium (EC 2011/056) and was in 
accordance with institutional and national guidelines for the Care and Use of Laboratory 
Animals. 
Table 4.1 Ingredient composition and nutrient analysis of the experimental diets 
Items LP HP 
 Ingredients 
 As-is basis (g/100g) 
Pork greaves  11.0 53.3 
Brewers rice 50.9 20.0 
Lard 11.0 8.50 
Rice meal 15.0 6.00 
Beet pulp 3.70 5.00 
CaHPO4 3.00 2.10 
Yeast 1.00 1.00 
Salmon Oil 1.00 1.00 
Digest 0.89 0.89 
CaCO3 0.40 0.50 
Bentonite clay 0.50 0.50 
Salt 0.81 0.42 
Vitamin mix 0.26 0.23 
Mineral mix 0.22 0.22 
Chorine chloride 0.14 0.14 
Lecithine  0.10 0.10 
 Nutrient Analysis 
DM (g/100g) 92.7 96.2 
 g/100g DM 
Ash 5.35 4.75 
CP 17.8 50.0 
EE 13.6 12.2 
CF 1.05 0.91 
NFE
1
 62.3 32.2 
TDF 4.79 8.56 
ME, kJ/100gDM 
2
 1850 1833 
LP: low protein diet; HP: high protein diet; CaHPO4: dicalcium phosphate; CaCO3: calcium carbonate; 
CP: crude protein; DM: dry matter; EE: ether extract; CF: crude fibre; ME: metabolizable energy; 
NFE: nitrogen-free extract; TDF: total dietary fibre.  
1 
Calculated %NFE = % DM – (% EE+ % CP + % ash + % CF) 
2 
Calculated ME = 16.7 × g CP + 37.7 × g Fat + 16.7 × g NFE (NRC, 2006) 
Chapter 4 
High protein diet in lean and obese dogs 
97 
 
 
Sampling procedure 
Leftover food was collected and weighed after each feeding. Body weight and BCS 
were measured weekly. After overnight fasting, blood samples were drawn from the jugular 
vein on day 27 of each period. Heparinized plasma and serum were obtained by 
centrifugation at 1620 g for 15 min at 4
o
C and stored at -20°C until assayed. On the same 
days, fresh faecal samples (± 10 g) were collected within 10 minutes after voiding. An aliquot 
of ± 2 g was put into a sterile plastic tube, frozen immediately on dry ice and stored at -80°C 
for microbial analyses, and the rest were stored at -20°C for chemical analyses.  
Chemical analyses 
For diets and faecal samples, dry matter (DM) was analyzed by drying to a constant 
weight at 103°C (ISO 1442, 1997), and crude ash determined by combustion at 550°C (ISO 
936, 1998). Crude protein was calculated from Kjeldahl nitrogen (6.25 × N, ISO 5983-1, 
2005), while ether extract was analyzed by the Soxhlet method (ISO 1443, 1973) and crude 
fibre by acid-alkali digestion (ISO 5498, 1981). Nitrogen-free extract was calculated by 
subtracting crude ash, crude protein, crude fat, and crude fibre of the DM content. Total 
dietary fibre (TDF) was measured with a Total Dietary Fibre Assay Kit (Sigma–Aldrich Co., 
St. Louis, MO, USA), using procedures based on a combination of enzymatic and gravimetric 
methods (Prosky et al., 1988).  
Faecal pH was measured with a portable pH meter (Hanna Instruments, Belgium). 
Faecal ammonia was analysed by steam distillation and titration (Bremner and Keeney, 1965). 
Faecal SCFA concentrations were determined via gas chromatography after extraction with 
diethyl ether (Greenberg et al., 1992). Faecal phenol, indole and p-cresol concentrations were 
measured as described by Depauw et al. (2011). 
Serum cobalamin and folate concentrations were measured using commercially 
available ARCHITECT B12 and ARCHITECT Folate assays, respectively, on ARCHITECT 
i System (Abbott Diagnostics, USA). Plasma acylcarnitine profile was determined according 
to Zytkovicz et al. (2001). Serum indoxyl sulphate concentrations were measured according 
to Depauw et al. (2011).  
Microbial analyses 
Total bacterial DNA extractions from 500 mg faeces were performed according to 
Boon et al. (2003). Isolated DNA was subsequently used as a template to amplify the 16S 
rDNA for all members of the Bacteria with forward primer P338F-GC and the reverse primer 
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P518r, and a GC-clamp of 40 bp was incorporated into the forward primer. DGGE based on 
the protocol of Muyzer et al. (1993) was performed on the Bio-Rad D gene system (Bio-Rad, 
Hercules, CA, USA). The obtained DGGE patterns were normalized and analyzed using 
BioNumerics 2.0 (Applied Maths, Kortrijk, Belgium). The number of bands in the DGGE 
profile was used to calculate the richness in the present study. A matrix of similarities for the 
densiometric curves of the band patterns was calculated based on the Pearson product-
moment correlation coefficient, and dendrograms were created by using Ward linkage (Ward 
Jr, 1963). 
The quantification of DNA by real-time PCR was performed with a C1000 Thermal 
Cycler (Bio-Rad, Hercules CA, USA). The amplification and detection were carried out in 
96-well plates using SensiMixTM SYBR No-ROX Kit (Bioline Reagents Ltd, UK). Each 
reaction was done in triplicate in 12 μl total reaction mixture using 2 µL of 50 ng of the DNA 
sample except for butyrate kinase (BK) where 2 µL of undiluted DNA was used. All qPCR 
results were expressed on gene copies per g of fresh faeces. The primer sets used in this study 
are listed in Table 3.1 except for BK (fwd: TGCTGTWGTTGGWAGAGGYGGA; rev: 
GCAACIGCYTTTTGATTTAATGCATGG) (Vital et al., 2013). A melting curve analysis 
was done after amplification to confirm specificity of the reaction. Quantisation was done by 
using standard curves made from known concentrations of plasmid DNA containing the 
respective amplicon for each set of primers. 
Statistical analyses  
All analysis were done in R (The R Foundation for Statistical Computing, version 
3.1.0) using the non-parametric gamm4 package for R (version 0.2-2).  
To test the effect of dietary protein levels on composition and functionality of 
microbiota in lean and obese dogs and its effect on host metabolism, a general additive mixed 
model was used: Y = µ + Dog + Diet + BC + Group + Diet*BC + ε, where µ is the overall 
mean, Dog a random effect, Diet refers to HP or LP; BC is the body condition of the dogs 
(lean versus obese), Group is the order by which the lean or obese dogs received the diets 
(Group 1: lean dogs received LP first; Group 2 lean dogs received HP first; Group 3 obese 
dogs received LP first; Group 4 obese dogs received HP first) and refers to the carry-over 
effect, Diet*BC is the interaction between diet and body condition (4 levels: HP-lean, LP-
lean, HP-obese, LP-obese) and refers to the direction or size of the effect of dietary protein on 
lean and obese animals; and ε is the error term.  
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Faecal concentration of valerate and p-cresol were only detected in three and one 
samples, respectively, and hence these parameters were not taken into consideration when 
performing the statistical analysis. 
For the interaction Diet*BC, the nparcomp package of R was used (version 2.0) for 
post-hoc testing by creating dummy variables and an own contrast matrix. 
Statistical significance was accepted at P < 0.05.  
 
4.4 RESULTS 
Food, energy and protein intake  
One obese dog from group 3 and one from group 4 were excluded from the study due 
to injuries not associated with the present study. As expected, BCS was higher in obese than 
in lean dogs (P<0.001) (Table 4.2). Both lean and obese dogs maintained a stable BW during 
the study. No differences were observed in BW either between diets or between lean and 
obese dogs. Food intake (P=0.041) and energy intake (P=0.046) were lower for dogs fed HP 
compared to LP, whereas protein intake was higher in dogs on HP than LP (P<0.001) (Table 
4.2). No differences were observed in food intake, energy intake and protein intake between 
lean and obese dogs.  
Faecal metabolites 
As shown in Table 4.2, faecal concentrations of ammonia (P<0.001), isovalerate 
(P<0.001), isobutyrate (P<0.001), phenol (P=0.004) and indole (P=0.002) were significantly 
higher from dogs on HP compared to LP. In addition, faecal isovalerate (P=0.010) and 
isobutyrate (P=0.009) concentrations were higher in obese than lean dogs. A significant 
interaction of Diet and BC was observed on faecal propionate (P=0.017). Faecal propionate 
concentration was significantly higher in lean dogs fed HP compared to LP, whereas no 
difference was observed in obese dogs. However, a significant carry-over effect was observed 
for faecal propionate. No differences in faecal concentrations of acetate, butyrate, and total 
SCFA were observed between diets or between lean and obese (Table 4.2).  
Blood parameters  
Serum indoxyl sulphate concentration was higher in dogs fed HP than LP (P=0.027) 
(Table 4.3). Within the plasma acylcarnitine profile, only 3-OH isovalerylcarnitine (3OH-C5) 
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was significantly higher (P=0.012) for dogs fed HP compared to LP (Table 4.3). Serum 
cobalamin and folate concentrations were not affected by Diet or by BC (Table 4.3).  
Table 4.2 Body weight, body condition score, food intake, protein intake, energy intake and 
faecal metabolites of lean (n=6) and obese (n=4) dogs fed low protein diet and high protein 
diet in a crossover design. 
Item 
LP  HP  P 
Lean  Obese  Lean  Obese  
Diet BC D*B 
Mean SD  Mean SD  Mean SD  Mean SD  
BW (kg) 10.5 1.6  14.8 1.8  10.6 1.4  14.5 1.7  0.410 0.499 0.149 
BCS 4.7 0.5  8.5 0.6  4.7 0.5  8.0 1.2  1.000 <0.001 0.045 
FI(g/d
.
kg
-1.
BW
0.75
) 37.4 10.1  40.5 7.4  31.0 5.9  30.1 9.1  0.041 0.131 0.392 
PI (g/d
.
kg
-1.
BW
0.75
) 6.2 1.7  6.7 1.2  14.9 2.8  14.5 4.4  0.046 0.115 0.354 
EI (kJ/d
.
kg
-1.
BW
0.75
) 624 171  678 124  515 98  493 156  <0.001 0.238 0.616 
pH 6.8 0.2  6.6 0.3  6.8 0.5  6.6 0.2  0.731 0.061 0.846 
Faecal metabolites  
  
 
  
 
  
 
  
 
   Ammonia (μmol/g) 1 181 45  194 45  330 57  327 107  <0.001 0.066 0.779 
Acetate (μmol/g)
 
87.4 12.1  86.7 12.1  101.4 18.9  86.2 32.3  0.230 0.403 0.423 
Propionate (μmol/g) 26.8a 8.8  35.5ab 21.0  40.0b 6.9  30.5ab 15.1  0.008 0.027 0.017 
Butyrate (μmol/g) 27.9 13.8  23.0 2.1  24.2 2.8  21.0 6.8  0.454 0.824 0.821 
Isovalerate (μmol/g) 3.2 0.9  4.8 1.0  8.3 1.8  8.7 3.7  <0.001 0.010 0.443 
Isobutyrate (μmol/g) 2.0 0.5  2.8 0.9  4.8 1.4  4.9 1.9  <0.001 0.009 0.435 
Total SCFA
 (μmol/g) 2 151 31  153 12  179 28  151 57  0.164 0.098 0.373 
Phenol (μmol/kg)  199 105  208 73  478 142  563 273  0.004 0.097 0.565 
Indole (μmol/kg) 585 227  480 108  1233 110  1193 603  0.002 0.260 0.787 
BC: body condition; BCS: body condition score; BW: body weight; D*B: interaction 
between diet and body condition; FI: food intake, PI: protein intake, EI: energy intake; SCFA: 
short-chain fatty acids 
1
 μmol/g and μmol/kg is expressed as the concentration to 1g and 1kg faecal samples, 
respectively.  
2 
Total SCFA= acetate + propionate + butyrate + isobutyrate + isovalerate + valerate 
 
Microbial ecology and populations  
Neither the type of diets nor the individual played an important role in the clustering 
of the microbial community (Figure 4.1). No statistical difference was observed in the 
richness of faecal microbiota between diets and between lean and obese dogs with an average 
value of 17.0 (Data not shown). The order of the diet (effects of group) did not significantly 
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affect the similarity coefficient of gut microbiota (Figure 4.2a). However, faecal microbiota 
of obese dogs was less stable when the diets switched as compared to lean dogs as shown in 
Figure 4.2b by the lower similarity value (52% versus 76%) (P=0.050).  
Table 4.3 Blood parameters of lean (n=6) and obese (n=4) dogs fed low protein diet (LP) and 
high protein diet (HP) in a crossover design. 
Item 
LP  HP  P 
Lean  Obese  Lean  Obese  
Diet BC D*B 
Mean SD  Mean SD  Mean SD  Mean SD  
Cobalamin 
(pmol/L) 416 78  357 112  400 57  406 70  0.635 0.139 0.262 
Folate (nmol/L) 26.2 6.3  29.7 5.1  28.2 6.7  20.0 6.7  0.588 0.817 0.061 
Indoxyl sulphate 
(mg/dL) 154 106  118 74  362 351  223 128  0.027 0.841 0.454 
SCAC (μmol/L) 
  
 
  
 
  
 
  
 
   C0 19.2 6.9  19.3 10.8  21.5 8.7  21.6 12.8  0.242 0.998 0.996 
C2 3.04 0.94  3.64 1.62  4.18 2.40  4.33 2.95  0.198 0.742 0.742 
C3 0.138 0.047  0.165 0.070  0.147 0.038  0.203 0.103  0.690 0.918 0.382 
C4 0.080 0.030  0.085 0.052  0.100 0.016  0.085 0.029  0.114 0.531 0.305 
C5 0.075 0.023  0.143 0.118  0.100 0.036  0.150 0.114  0.060 0.908 0.381 
3OH-C4 0.023 0.005  0.028 0.017  0.035 0.026  0.038 0.029  0.191 0.948 0.903 
3OH-C5 0.030 0.006  0.040 0.022  0.047 0.008  0.055 0.021  0.012 0.356 0.859 
C3DC 0.023 0.008  0.025 0.013  0.020 0.009  0.023 0.005  0.429 0.761 0.900 
BC: body condition; D*B: interaction between diet and body condition; SCAC: short-chain 
acylcarnitines; C0: free carnitine; C2: acetylcarnitine; C3: propionylcarnitine; C4: butyryl- and 
isobutyrylcarnitine; C5: isovalerylcarnitine, 3OH-C4: 3-OH butyrylcarnitine; 3OH-C5: 3-OH 
isovalerylcarnitine; C3DC: malonylcarnitine 
 
Higher faecal abundances of clostridial clusters IV (P=0.025), XIVa (P=0.001) and of 
the BK gene (P = 0.019) were observed when dogs were fed HP compared to LP. In addition, 
a significant interaction between Diet and BC was observed for Firmicutes (P=0.007), 
Lactobacillus (P=0.017) and clostridial cluster I (P=0.022). Compared to LP, HP increased 
the abundance of Firmicutes in lean dogs (P<0.05), while no changes were observed in obese 
dogs. clostridial cluster I was more abundant in lean dogs when fed HP than when consuming 
LP (P<0.05), whereas, post-hoc testing did not reveal any differences between the four 
groups for Lactobacillus. No effects of Diet or BC were found for faecal concentrations of 
total bacteria, Bacteroidetes, Enterobacteriaceae and gene express butyryl-CoA acetate-CoA 
transferase (BCoAT) and dissimilative sulphate reducing bacteria gene (dSRB).  
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Figure 4.2 Similarity coefficients of DGGE band patterns from comparison of microbial 
communities of (a) dogs consuming low protein diet (LP) then high protein diet (HP) versus 
dogs consuming HP then LP; (b) obese dogs versus lean dogs. DGGE: denaturing gradient 
gel electrophoresis. 
 
4.5 DISCUSSION 
The present study has demonstrated an impact of dietary protein content on both 
composition and activity of gut microbiota in dogs. In particular, the major butyrate-
producing bacterial groups, clostridial clusters IV and XIVa, and one of the terminal genes 
for butyrate synthesis, the BK gene, were increased in dogs fed HP. In addition, the present 
study has also shown a different response between lean and obese dogs to dietary protein, 
which has not been reported to date.  
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Table 4.4 The abundance of different bacterial groups and functional genes in lean (n=6) and 
obese (n=4) dogs fed low protein diet (LP) and high protein diet (HP) in a crossover design
1
.  
Item 
LP  HP  P 
Lean  Obese  Lean  Obese  
Diet BC D*B 
Mean SD  Mean SD  Mean SD  Mean SD  
Total bacteria 10.76 0.15  10.64 0.35  11.01 0.08  10.61 0.23  0.126 0.557 0.285 
Firmicutes 9.49a 0.26  9.60ab 0.37  9.88c 0.08  9.61b 0.17  0.006 0.976 0.007 
Bacteroidetes 10.66 0.41  9.54 1.50  11.07 0.43  10.22 0.43  0.287 0.795 0.648 
Enterobacteriaceae 7.58 0.95  8.23 0.36  7.30 1.03  8.36 0.74  0.488 0.597 0.526 
Lactobacillus 7.48a 1.00  8.00a 1.43  7.84a 1.31  6.92a 1.22  0.306 0.402 0.017 
Clostridial cluster I 8.76a 0.13  9.33ab 0.72  9.29b 0.29  9.01ab 0.17  0.025 0.954 0.022 
Clostridial cluster IV 7.65 0.28  7.61 0.39  8.17 0.19  7.86 0.44  0.025 0.354 0.432 
Clostridial cluster XIVa 8.80 0.20  9.20 0.30  9.60 0.30  9.40 0.20  0.001 0.160 0.095 
Butyryl-CoA acetate-
CoA transferase 6.82 0.72  6.59 0.73  7.16 0.50  6.74 0.20  0.139 0.988 0.426 
Butyrate kinase 5.79 0.24  6.81 0.25  6.34 0.77  6.67 0.24  0.019 0.877 0.334 
dSRB 5.83 0.37  5.44 0.71  5.66 0.28  5.39 0.30  0.381 0.720 0.704 
BC: body condition; D*B: interaction between diet and body condition; dSRB: dissimilative sulphate-
reducing bacteria gene;  
1
The abundance of bacterial groups was expressed as log10 16S rRNA gene copies / g of fresh faeces 
and of functional gene was expressed as log10 gene copies of total DNA / g of fresh faeces 
 
The accumulation of butyrate-producing bacteria is often associated with intake of 
fibre rich diets, and the reduction of these bacteria has been reported in human obesity and 
Crohn’s disease (Machiels et al., 2014; Wang et al., 2014; Schwiertz et al., 2010; Sokol et al., 
2008). In this study, increased abundance of clostridial clusters IV and XIVa were observed 
for dog fed HP vs. LP. This could be due to the two-fold higher TDF in HP compared to LP. 
Generally, TDF is comprised of plant fibre which in this study was provided by brewer’s rice, 
rice meal, and beet pulp (Table 4.1), with TDF ranging from 1.6-16.4% (Carciofi et al., 2008; 
de-Oliveira et al., 2008), 2.4-4.6% (NRC, 2006), and 60-80% (Middelbos et al., 2007), 
respectively. However, TDF does not clearly differ from HP to LP in terms of plant fibre 
content. Therefore, the higher TDF content in HP vs. LP could be of animal origin (Codex, 
2009), where the content of pork greaves was clearly higher in HP vs LP. TDF in the pork 
greaves was thus analyzed and observed to be 7.0% on DM basis. The increased numbers of 
clostridial clusters IV and XIVa could also be explained by the fact that butyrate can be 
formed by fermentation of amino acids, such as glutamate and leucine (Michal and 
Schomburg, 2013). Opposite to the results of this study, high greaves meal inclusion to the 
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diet was reported to decrease the abundance of clostridial cluster XIVa in dogs (Hang et al., 
2012). This contradiction might be due to the different quality/components in the greaves 
meal, and/or different level of greaves meal included in the diet, 80.0% in that study versus 
53.4% in our study. 
It is worth mentioning that clostridial clusters IV and XIVa still harbour non-butyrate-
producing bacteria and some butyrate producing strains within these clusters (eg. 
Coprococcus catus and Roseburia inulinivorans) can switch from butyrate to propionate 
production (Reichardt et al., 2014; Pryde et al., 2002). Therefore, the terminal genes of the 
two butyrate production pathways, BCoAT and BK were determined. The BCoAT pathway 
has been found to be the dominant pathway for butyrate formation in human colonic isolates. 
However, the BCoAT remained unchanged while the BK gene was increased when dogs fed 
HP compared to LP. Therefore, although the abundance of both genes seemed to be equally 
distributed (Table 4), the BK pathway could be more important in butyrate production in 
dogs compared to humans. This is supported by the recent finding that the BK gene was more 
abundant in carnivorous animals and BCoAT gene was enriched in omnivores and herbivores 
(Vital et al., 2015). However, faecal butyrate concentrations and plasma C4 concentrations 
did not differ between the two diets. This could be due to the fact that faecal concentrations 
may not necessarily reflect SCFA production in the proximal colon because more than 95% 
of SCFA are absorbed there (Pryde et al., 2002). Moreover, the technique used to measure 
acylcarnitines could not separate butyrylcarnitine and isobutyrylcarnitine. Therefore, the 
accurate estimation of the in vivo butyrate production is not feasible in dogs yet.  
As expected, colonic protein fermentation was increased in dogs fed HP as indicated 
by higher faecal concentrations of putrefactive compounds (ammonia, indole and phenol) and 
branched-chain fatty acids (isovalerate and isobutyrate) compared to dogs consuming LP. 
These results are in agreement with previous studies in dogs fed high protein diets (Nery et 
al., 2012; Hesta et al., 2003). In addition, higher serum concentrations of indoxyl sulphate 
and 3-OH isovalerylcarnitine in dogs fed HP were observed, supporting colonic production 
and absorption of protein fermentation metabolites (Michal and Schomburg, 2013). To date, a 
link between protein fermentation and increased risk for gut diseases has not yet been shown 
in dogs the way it has been implicated in humans (Windey et al., 2012). No toxicity or 
tolerance tests have been performed on the effects of protein fermentation metabolites on 
canine gut health, and the only studies available concerning the link between protein 
fermentation and canine gut health have evaluated the effects of prebiotics, probiotics and 
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synbiotics (Flickinger et al., 2003; Swanson et al., 2002). Therefore, whether the increased 
protein fermentation metabolites are harmful for dogs needs to be further investigated, 
especially the beneficial effects of indole that have been proposed by in vitro studies, such as 
increase the expression of anti-inflammatory genes and strengthen epithelial cell barrier 
properties (Bansal et al., 2010). 
Generally, a more hospitable environment can host a broader variety of 
microorganisms and hence give a higher richness (Marzorati et al., 2008). In this study, 7 out 
of 10 dogs had greater richness when fed HP compared to LP irrespective of body condition 
(Fig 1b). Unfortunately, cluster analysis of the complex microbiota pool did not allow clear 
conclusions to be made due to highly diverse faecal microbiota and considerable inter-
individual variation among diets and body condition. It is noteworthy that the similarity 
coefficient of faecal microbiota between the two diets was lower in obese dogs (52%) than in 
lean dogs (76%) (Figure 4.2b). Therefore, gut microbiota in lean dogs seemed to be more 
resilient to dietary protein changes than in obese dogs. This finding warrants further 
validation and investigation on overall changes of faecal microbiota upon high dietary protein 
with a larger number of obese dogs.  
Lean dogs consuming HP had higher abundances of Firmicutes and clostridial cluster 
I compared to LP while such effects were not observed in obese dogs. Firmicutes is one of 
the most predominant bacterial phyla in dogs and consists of 30%-50% total faecal 
microbiota (Swanson et al., 2011; Xenoulis et al., 2008). A previous study has shown 
Clostridium perfringens, which belongs to clostridial cluster I, to be increased in dogs fed a 
high protein diet (Zentek et al., 2003). However, clostridial cluster I also contains other 
species which are beneficial for the host, e.g. C. butyricum and therefore requires caution in 
the interpretation of the results. Within selected bacterial groups obese dogs did not respond 
to dietary protein changes, which seems to be contradictory to the lower similarity coefficient 
observed in obese dogs when switch diets. This contradiction could however be due to the 
bacterial groups that were amplified by qPCR only represented a very small percent of total 
bacteria that were present in the gut. 
 
4.6 CONCLUSIONS 
Increased dietary protein intake leads to a shift towards protein fermentation. 
However, faecal microbiota in obese dogs tended to be more vulnerable to dietary protein 
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changes according to the DGGE profile. Within the quantified bacterial groups, a high 
protein diet promoted bacterial growth in lean dogs as opposed to obese dogs. Surprisingly, 
the high protein diet promoted the growth of butyrate-producing bacteria including clostridial 
clusters IV and XIVa, and increased the abundance the BK gene, which might be beneficial 
for the dogs. However, further studies are needed to evaluate the overall effect of high protein 
diets on canine health, since increased faecal concentration of putrefactive compounds rise 
health concerns in humans.  
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5.1 ABSTRACT 
Secreted phospholipase A2 inhibitor (sPLA2i) has been reported to have an anti-
inflammatory function by blocking the production of inflammatory mediators. Obesity is 
characterized by low-grade inflammation and oxidative stress. The aim of this study was to 
investigate the effects of dietary supplementation of sPLA2i on inflammation and oxidative 
stress in dogs. Seven obese and seven lean Beagle dogs were used in a 28-day double blind 
cross-over design. Dogs were fed a control diet without supplemental sPLA2i or a sPLA2i 
supplemented diet.  
The sPLA2i diet decreased plasma fibrinogen levels and increased the 
protein:fibrinogen ratio in obese dogs to levels similar to those of lean dogs fed the same diet. 
Obese dogs had a higher plasma concentration of the lipophilic vitamin A with potential 
antioxidative capacity and a lower ratio of retinol binding protein 4: vitamin A compared to 
lean dogs, independent of the diets. A higher proportion of myristic acid and a lower 
proportion of linoleic acid were observed in the dogs fed sPLA2i diet compared to dogs fed 
the control diet. Furthermore, a higher ratio of n-6 to n-3, a lower proportion of n-3 
polyunsaturated fatty acids and lower omega-3 index were observed in obese compared to 
lean dogs. The results indicate that obese dogs are characterized by a more ‘proinflammatory’ 
serum fatty acid profile and that diet inclusion of sPLA2i may reduce inflammation and alter 
fatty acid profile.  
 
Keywords: Dog; Inflammation; Obesity; Oxidative stress; sPLA2 inhibitor. 
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5.2 INTRODUCTION 
Secreted phospholipases A2 (sPLA2), consisting of more than 10 sPLA2 enzymes 
(IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA, XIIB and otoconin-90), are one of the largest 
families of lipolytic enzymes that hydrolyse the sn-2 ester of glycerophospholipids to yield 
lysophospholipids and non-esterified fatty acids, such as arachidonic acid (Murakami and 
Lambeau, 2013; Lambeau and Gelb, 2008). Arachidonic acid can be converted into 
eicosanoids, including prostaglandins and leukotrienes which are pro-inflammatory 
mediators. In addition, lysophopholipids can serve as precursors for lipid mediators such as 
platelet-activating factor (PAF), which is particularly involved in inflammatory processes 
(Nevalainen, 1993). By producing these non-esterified fatty acids, sPLA2 can induce 
inflammation and is an attractive target to block in order to modulate the inflammatory 
process (Murakami and Kudo, 2002). However, sPLA2s have been shown to release n-3 
polyunsaturated fatty acids (PUFA) in vitro and these have been reported to have a potential 
anti-inflammatory role (Murakami et al., 2011; Curfs et al., 2008). Despite the diverse 
biological functions attributed to sPLA2s, their definitive role in vivo is still unclear.  
Several approaches can be used to help define the physiological role of sPLA2s in 
vivo, including using sPLA2 inhibitors (sPLA2i). sPLA2is can be either produced by 
chemical synthesis or in vivo from egg yolk antibody against sPLA2 (Cook, 2004). In 
previous studies, animals fed a sPLA2i diet showed improved growth and feed efficiency, 
and the proposed mechanism was thought to involve down-regulation of gut inflammation 
(Cook, 2011). Gut inflammation is associated with a number of diseases in humans, not only 
on-site diseases such as inflammatory bowel disease (IBD), but also obesity through 
increased gut permeability (Cani et al., 2007).  
Obesity is highly prevalent in dogs, and is characterized by oxidative stress and 
altered inflammatory markers (Tvarijonaviciute et al., 2012). Obesity can lead to many health 
problems A lower omega-3 index has been suggested to be associated with a higher risk of 
coronary heart disease mortality (Harris and Von Schacky, 2004), and reduced insulin 
sensitivity in obese humans (Albert et al., 2014). Therefore, the assessment of omega-3 index 
could give indications on the health condition of obese humans but to date no studies have 
measured the omega-3 index in obese dogs. Although obesity in both animals and humans are 
highly studied, it remains a particularly challenging medical condition to treat and prevent. 
Interestingly, a study found group IB sPLA2 (also known as pancreatic sPLA2) deficient 
mice to be resistant to diet-induced obesity compared to conventional mice (Huggins et al., 
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2002). This suggests a potential novel role of sPLA2i in protection against diet-induced 
obesity.  
The present study aimed to test a sPLA2 inhibitor as a candidate treatment for diet 
induced-obesity related inflammation and co-morbidities in dogs. For this purpose, the 
sPLA2 was inhibited by supplementation of egg yolk that contained an antibody against 
group IB sPLA2 in the diet. The effects on gut permeability and systemic inflammation, 
oxidative stress status and fatty acid (FA) composition were assessed in obese vs. lean Beagle 
dogs. 
 
5.3 MATERIALS AND METHODS 
Study design 
The study was designed as a double-blind placebo controlled crossover with two 4-
week periods. Dogs were randomly assigned to one of the two experimental diets (sPLA2i 
diet or control diet) in the first period, and subsequently received the second diet in the 
second period.  
The first 3 weeks were an adaptation period and samples were taken in the fourth 
week. Dogs were fed twice daily and the amounts of feed given to the animals were adapted 
to maintain their bodyweight (BW). The nutrients in the diets met adequate intake of NRC 
(2006). At each feeding, leftovers from the previous feeding were removed and weighed. 
Body condition score (BCS) (Laflamme, 1997) and BW were measured weekly. This study 
was approved by the Ethical Committee of the Faculty of Veterinary Medicine, Ghent 
University, Belgium (EC 2012_044). 
Animals and diets 
Fourteen adult Beagle dogs with an average age of 7.9 years (range 4.7-10.6 years) 
were included in the study. Seven obese dogs (BCS, 7/9; three males; two castrated males; 
one female and one spayed female) and seven dogs had an ideal body condition (BCS, 5/9; 
one male; one castrated male and five females). Obesity was induced approximately one year 
prior to the present study by feeding the dogs a high fat commercial diet as described by Van 
de Velde et al., (2013). Dogs could interact with each other (housed two by two) except 
during feeding and sample collection periods when they were housed individually. 
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The experimental diets were produced by Diana Pet food (Table 5.1). The ingredient 
and nutrient composition was exactly the same except for the addition of sPLAi. The sPLAi 
and control diets contained 2% dried egg powder with or without 0.5% pig pancreatic sPLA2 
antibody, respectively. On day 16 to day 25 of each experimental period, 1.5% celite was 
added homogeneously on top of the diets as an external marker for determination of apparent 
digestibility of the nutrients (Hesta et al., 2001). 
Table 5.1 Chemical composition of the experimental diets 
1,2
.  
 
Item sPLA2i Control 
Dry matter
 
(g/kg as fed) 938 940 
 g/kg dry matter 
Ash 62 62 
Crude protein (CP) 278 273 
Ether extract (EE) 140 146 
Nitrogen-free extract (NFE) 
3
 498 498 
Crude fibre (CF) 22 21 
Metabolizable energy
 
(ME, kJ/g) 
4
 12.6 12.6 
1
Ingredients list: brewers rice, chicken by-product meal, wheat, corn gluten meal, oat groats, chicken 
fat, natural flavours, beet pulp, fish oil, calcium carbonate, yeast, vegetable oil, potassium chloride, 
monocalcium phosphate, salt, L-lysine, choline chloride, vitamins mix, minerals mix, rosemary 
extract 
2
 Instead of using a fat coating, a 2% dried egg powder was added, with or without 0.5% pig 
pancreatic sPLA2 antibody for sPLA2i or control diet, respectively. 
3
 Calculated %NFE = % DM – (% fat + % CP + % ash + % CF) 
4 
Data of metabolizable energy were provided by the Diana Pet Food.
 
 
Gut permeability test  
On day 28 of each period, intestinal permeability (IP) was estimated by oral ingestion 
of a test solution of the 51-chromium-labeled ethylenediaminetetraacetic acid (
51
Cr-EDTA) 
dissolved in water, and by subsequently quantifying the recovery of the radioisotope in the 
blood as described by Frias et al. (2010).  
Sampling procedure 
Chapter 5 
Diet with sPLA2 inhibitor in lean and obese dogs 
119 
 
 
On day 26 of each period, after an overnight fast, a pre-prandial blood sample (10 mL) 
was taken from the jugular vein. Heparinized plasma and serum were obtained by 
centrifugation at 1620 g, 15 min and 4 ºC. From day 21 to day 25 of each experimental period, 
all dogs were housed individually and faeces were collected to determine apparent 
digestibility of dry matter (DM), crude protein (CP), ether extract (EE), and crude fibre (CF). 
Stool consistency was scored for from day 21 to day 23 according to a scale of 1 (hard) to 7 
(watery) (Purina Faecal Scoring System for Dogs, Nestlé Purina PetCare). 
Analytical methods 
For diets and faecal samples, DM was analyzed by drying to a constant weight at 
103 °C (ISO 1442, 1997), and crude ash by combustion at 550 °C (ISO 936, 1998). CP was 
calculated from Kjeldahl nitrogen (6.25 × N, ISO 5983-1, 2005), EE was analyzed by the 
Soxhlet method (ISO 1443, 1973) and CF by acid-alkali digestion (ISO 5498, 1981). 
Nitrogen-free extract was calculated by subtracting crude ash, CP, crude EE, and CF on a 
DM basis from 100.  
Plasma vitamins A (retinol), C (ascorbic acid) and E (alpha-tocopherol) were 
analyzed by a commercial laboratory (Algemeen Medisch Laboratorium, Antwerp, Belgium). 
Briefly, lipid was extracted from plasma with n-hexane and the solvent was separated by 
reverse-phase high-performance liquid chromatography (HPLC). Vitamins A and E were 
detected by an ultraviolet (UV) detector monitoring 325 and 295 nm, respectively. Plasma 
vitamin C was extracted from trichloroacetic acid-treated plasma with metaphosphoric acid 
(3%), separated on a C18 reverse-phase column and quantified by HPLC with fluorescence 
(excitation measured at 355 nm, emission measured at 425 nm) after precolumn 
derivatisation (with o-phenylenediamine).  
Glutathion peroxidase (GPx) was measured according to the method of Paglia and 
Valentine (1967) on a Daytona Analyzer with Ransel Glutathion Peroxidase kit (Randox). 
Total plasma malondialdehyde (MDA) was assayed according to the HPLC method of 
Chromsystems. MDA was separated by HPLC and quantified by fluorescence detection 
(excitation measured at 515 nm and emission measured at 553 nm).  
Plasma fibrinogen was determined according to the method of Clauss (1957). C-
reactive protein (CRP) was determined by a canine CRP enzyme-linked immunosorbent 
assay (ELISA) kit (BD Bioscience). Serum retinol binding protein 4 (RBP4) was measured 
using a human RBP ELISA kit shown adequate for canine RBP detection (Immunology 
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Consultants Laboratory) (Maddens et al., 2010). For CRP and RBP4, the manufacturer’s 
instructions were followed. 
Omega-3 index and serum fatty acids 
Two drops of blood were collected on a filter paper. The filter paper was dried at 
room temperature for 2-4 h and thereafter put into a sealed aluminium bag containing 
desiccant and stored at -80 °C until shipment for omega-3 index measurements (Vitas AS, 
Oslo, Norway) (de la Fuente et al., 2013). Serum FA was analyzed according to Tanghe et al. 
(2013).  
Calculations 
Digestibility of DM, CP, EE and CF were calculated as digestibility of nutrients (%) = 
100 × (1- (nutrients in faeces × celite in diet) / (nutrients in diet × celite in faeces)) with all 
nutrients and celite expressed as g/kg DM. 
The red blood cell (RBC) omega-3 index is given as the proportion of 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) 
to the total FA content in RBC. 
The data of FA profile in the present study were expressed as the proportion of FA to 
total FA. Total n-6 PUFA was the sum of linoleic (C18: 2n-6), γ-linolenic (C18: 3n-6), 
eicosadienoic (C20: 2n-6), dihomo-γ-linolenic (C20: 3n-6), arachidonic (AA, C20: 4n-6), 
adrenic (C22: 4n-6) and docosatetraenoic (C22: 5n-6) acid proportions. Total n-3 PUFA was 
the sum of α-linolenic acid (C18: 3n-3), eicosatrienoic acid (C20: 3n-3), eicosatetraenoic 
(C20: 4n-3), EPA (C20: 5n-3), EPA (C22: 5n-3) and DHA (C22: 6n-3) proportions. The n-6/ 
n-3 ratio was calculated by dividing the total proportion of n-6 PUFA by the total proportion 
of n-3 PUFA. The serum omega-3 index was calculated as the proportion of the sum of EPA, 
DHA and DPA in the total amount of FA.  
Statistical analyses 
Statistical analyses were performed using Superior Performing Software Systems 
(SPSS) v.20. Data were statistically analyzed by repeated measurements with diet as within 
subject factor and body condition (BC) as between subject factor. The interaction between 
BC and diet was evaluated from the within-subject contrasts. Average BW and BCS from 
each feeding period were used for statistical analysis. Duncan’s test was used as post-hoc test 
when the interaction between diet and BC was significant. Partial Pearson correlations 
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coefficients were calculated between RBC omega-3 index and serum omega-3 index. 
Statistical significance was accepted at P < 0.05 and P < 0.1 was considered as a trend.  
 
5.4 RESULTS 
The BW (P=0.001) and BCS (P=0.001) of obese dogs were higher compared to lean 
dogs irrespective of the diet (Table 5.2). There was no statistical difference in feed intake 
between lean and obese dogs fed the diet with either the sPLA2i or control diet (P >0.05). 
Faecal consistency scores were normal for all dogs irrespective of the BC and diet (P >0.05). 
There were no significant differences in the apparent digestibility of DM, CP, CF, and EE 
between both diets (P >0.05) (Table 5.2). The apparent digestibility of EE was significantly 
lower in obese dogs compared with lean dogs (P=0.040). The recovery rate of 
51
Cr-EDTA at 
3 h and 5 h did not differ among diets and BC (Figure 5. 1). 
 
Table 5.2 General parameters and apparent nutrients digestibility of lean (n = 7) and obese (n 
= 7) dogs fed either the control or the sPLA2i diet. 
Item 
sPLA2i  Control  P 
Lean  Obese  Lean  Obese  
Diet BC D*B 
Mean SD  Mean SD  Mean SD  Mean SD  
BW (kg) 9.8 1.7  12.4 1.8  9.9 1.8  12.4 2.0  0.978 0.001 0.895 
BCS (1-9) 5.1 0.6  7.4 1.7  5.1 0.6  7.3 1.7  0.974 0.001 0.895 
Food intake (g/d) 177 38  185 52  175 64  187 37  0.960 0.678 0.874 
Energy intake 
(kJ/d) 
2962 638  3098 866  2921 1070  3119 615  0.960 0.678 0.874 
Faecal score (1-7) 2.4 0.5  2.5 0.9  2.4 0.3  2.5 0.9  0.998 0.689 0.988 
Apparent digestibility (%) 
DM 94.1 0.5  94.1 0.4  94.5 0.5  94.1 0.5  0.150 0.305 0.080 
CP 83.7 1.8  82.7 1.2  84.3 2.1  83.4 1.2  0.150 0.240 0.940 
EE 97.2 0.3  96.9 0.6  97.5 0.5  97.1 0.3  0.310 0.040 0.640 
NFE 90.7 0.8  90.5 0.7  91.3 1.4  90.1 1.8  0.820 0.330 0.140 
BW, bodyweight; BC, body condition; BCS: body condition score; D*B, interaction between diet and 
body condition; CP: crude protein; DM: dry matter; EE: ether extract, NFE: Nitrogen-free extract; 
sPLA2i: secreted phospholipase A2 inhibitor 
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CRP serum levels were not different between obese and lean dogs fed either of both 
diets (P >0.05) (Table 5.3). However, a significant interaction between diet and BC was 
observed for fibrinogen (P=0.017) and for the ratio of protein to fibrinogen (P=0.045). 
Fibrinogen plasma levels were significantly higher in obese than lean dogs when fed the 
control diet, whereas no difference was observed between obese and lean dogs when fed the 
sPLA2i diet. The plasma protein:fibrinogen ratio was lower in obese compared to lean dogs 
when fed the control diet, but no difference in this inflammatory parameter was observed 
between lean and obese dogs when fed the sPLA2i diet. 
 
Figure 5.1 Recovery rate of 
51
Cr-EDTA 3 h and 5 h after oral administration in obese 
compared to lean dogs. At 3 h: P (Diet) =0.396, P (BC) =0.320, P (D*B) =0.630; At 5 h: P 
(Diet) =0.650, P (BC) =0.410, P (D*B) =0.630. 
 
Both lipophilic (A, E) and hydrophilic (C) vitamins and GPx with antioxidative 
capacity and the oxidative stress marker MDA were assessed (Table 5.3). There were no 
differences in the concentration of antioxidants and MDA between dogs fed sPLA2i or 
control diet (Table 5.3). A significant interaction between diet and BC was observed for 
vitamin A plasma concentration (P=0.020). A lower vitamin A was found in obese compared 
to lean dogs when fed both the control and sPLA2i diets. Serum concentrations of RBP4 were 
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not significantly different between both groups of dogs independent of diet or BC (P >0.05). 
However, the ratio of RBP4: vitamin A was highly significantly lower in obese dogs 
compared to lean dogs (P=0.003). 
Table 5.3 Inflammatory and oxidative stress markers in lean (n = 7) and obese (n = 7) dogs 
fed either the control or the sPLA2i diet 
1
 
Item 
sPLA2i   Control   P 
Lean  Obese  Lean  Obese  
Diet BC D*B 
Mean SD   Mean SD   Mean SD   Mean SD   
CRP (mg/dL) 0.22 0.14  0.12 0.09  0.21 0.24  0.11 0.08  0.334 0.700 0.324 
Fibrinogen (g/L) 1.76
b 0.47  2.01ab 0.33  1.67b 0.32  2.53a 0.67  0.150 0.030 0.017 
Protein/Fibrinogen 34
ab 9  30ab 6  34a 7  25b 7  0.175 0.114 0.045 
GPx (U/g Hb) 250 21.3  299 104  305 97.3  265 95.5  0.374 0.870 0.220 
Vitamin A (μmol/L) 6.40
b 1.54  11.12a 2.91  7.12b 2.40  10.27a 2.29  0.854 0.007 0.020 
Vitamin C (μmol/L) 23 5  27 6  25 7  25 6  0.917 0.513 0.317 
Vitamin E (μmol/L) 117 11  131 28  120 23  130 30  0.793 0.347 0.698 
MDA (μmol/L) 0.15 0.05  0.18 0.07  0.17 0.04  0.16 0.04  0.937 0.249 0.521 
RBP4 (mg/L) 17.5 1.13  18.2 0.64  18.2 2.38  18.0 0.62  0.459 0.711 0.122 
RBP4/Vitamin A 9.92 2.12    6.00  1.28    9.54  2.36    6.37  1.49    0.990 0.003 0.180 
BC, body condition; D*B, interaction between diet and body condition; CRP, C-reactive protein; GPx, 
glutathione peroxidase; Hb, haemoglobin; MDA, malondialdehyde; RBP4, retinol binding protein 4;
 
sPLA2i: secreted phospholipase A2 inhibitor
 
1 
Values within a row not sharing a common superscript are significantly different (P <0.05) 
 
The RBC omega-3 index was not different between both diets (Figure. 5.2). However, 
the RBC omega-3 index was significantly lower in obese dogs compared with lean dogs, 3.92% 
and 4.59%, respectively (P=0.023, data not shown). To further confirm these results, the 
serum FA profile was assessed. The serum omega-3 index was also significantly lower in 
obese dogs compared to lean dogs, 6.19% and 9.73% (P=0.020, data not shown) and again 
did not differ between both diets (P=0.998, data not shown). In addition, the calculated 
serum omega-3 index was positively correlated with the RBC omega-3 index (P <0.001, 
r=0.72). 
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Figure.5.2 Serum omega-3 index and RBC omega-3 index of obese and lean dogs fed with 
sPLA2i and control diet (y = 0.9328x + 1.3814; r= 0.718; ○ =lean dogs fed with control diet; 
● =obese dogs fed with control diet; ∆ =lean dogs fed with sPLA2i diet; ▲ =obese dogs fed 
with sPLA2i diet) 
 
Obese dogs had significantly lower proportions of capric acid (C10:0), pentadecanoic 
acid (C15:0), arachidic acid (C20:0), lignoceric acid (C24:0), DPA (C22:5n-6), DHA 
(C22:6n-3) and n-3 PUFA compared to lean dogs (P <0.05; Table 5.4). The same dogs also 
had higher proportions of stearic acid (C18:0), dihomo-gamma-linolenic acid (C20:3n-6, 
DGLA), a higher ratio of n-6 to n-3 PUFA, AA to DPA (P=0.015), AA to DHA (P=0.012) 
and AA to (EPA+DPA+DHA) (P=0.031) compared to lean dogs (Table 5.4). There was a 
trend for obese dogs to have higher levels of total FA, saturated fatty acid (SFA), 
monounsaturated fatty acid (MUFA) and n-6 PUFA compared to lean dogs (data not shown). 
In addition, dogs fed the sPLAi diet had a significantly higher proportion of myristic acid 
(C14:0) (P=0.037) and a lower proportion of linoleic acid (C18:2n-6, LA) (P=0.007). 
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Table 5.4 Fatty acid profile of lean (n = 7) and obese dogs (n = 7) fed either the control or the 
sPLA2i diet  
Fatty acid 
profile 
(%)
1 
sPLA2i   Control   P 
Lean  Obese  Lean  Obese  
Diet BC D*B 
Mean SD   Mean SD   Mean SD   Mean SD   
C10:0 0.348 0.284  0.275 0.087  0.442 0.151  0.238 0.130  0.710 0.039 0.388 
C14:0 0.267 0.054  0.224 0.052  0.243 0.054  0.196 0.041  0.037 0.089 0.893 
C15:0 0.110 0.013  0.097 0.017  0.109 0.011  0.090 0.012  0.292 0.006 0.788 
C18:0 17.3 0.6  17.9 0.6  17.0 1.3  18.1 0.8  0.841 0.042 0.434 
C20:0 0.050 0.012  0.038 0.007  0.044 0.008  0.038 0.008  0.064 0.046 0.690 
SFA 30.6 1.0  30.8 0.6  30.5 0.6  30.5 0.6  0.316 0.830 0.570 
MUFA 15.9 1.7  17.1 1.9  15.5 1.5  16.4 1.5  0.292 0.189 0.755 
C18:2n-6 26.0 1.9  25.7 2.6  27.1 2.2  26.0 2.6  0.007 0.600 0.122 
C20:3n-6 1.15 0.35  1.46 0.23  1.13 0.28  1.47 0.23  0.844 0.045 0.680 
C22:5n-6 0.075 0.021  0.055 0.015  0.071 0.021  0.049 0.013  0.179 0.039 0.643 
n-6 PUFA 41.7 1.7  42.5 1.9  42.3 1.3  43.1 1.5  0.271 0.316 0.952 
C22:6n-3 2.05 0.36  1.63 0.27  1.97 0.35  1.67 0.29  0.825 0.028 0.511 
n-3 PUFA 6.15 0.84   5.12 0.68   6.08 0.81   5.20 0.93   0.988 0.023 0.748 
n-6/ n-3 6.89 0.97  8.42 1.00  7.08 1.08  8.49 1.38  0.652 0.016 0.823 
AA/(EPA+ 
DHA+DPA) 2.48 0.57  3.26 0.59  2.46 0.65  3.29 0.80  0.957 0.031 0.849 
AA/ EPA 11.37 5.84  13.55 4.92  10.37 4.20  13.74 7.17  0.676 0.351 0.542 
AA/ DPA 6.35 1.03  8.61 1.92  6.38 1.63  8.89 1.87  0.570 0.015 0.636 
AA/ DHA 6.79 1.45  9.07 1.24  6.87 1.76  9.06 1.63  0.910 0.012 0.891 
BC, body condition; D*B, interaction between diet and BC; SFA, saturated fatty acids; MUFA, 
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; sPLA2i: secreted phospholipase A2 
inhibitor; AA, arachidonic acid (20:4n-6); EPA, eicosapentaenoic acid (20:5n-3); DHA, 
docosahexaenoic acid (22: 6n-3); DPA, docosapentaenoic acid (22: 5n-3) 
1
 %= the proportion of a specific type of FA to total fatty acids 
 
5.5 DISCUSSION 
To our knowledge, this is the first study that tests the effect of sPLA2i supplementation 
in dogs by monitoring the gut permeability, inflammation and oxidative stress. In addition, 
the effects of this diet were compared between obese and lean dogs. The FA pattern in obese 
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dogs was characterized by higher circulating levels of stearic acid and of DGLA. Of 
relevance, the former saturated long-chain FA has been shown in human diabetes to induce 
inflammation through Toll-like receptor (TLR) 4 signalling (Tsukumo et al., 2007), while 
DGLA has been demonstrated to be positively associated with obesity in women (Warensjo 
et al., 2006).  
Additionally, in the current study, obesity in dogs was associated with a lower serum 
proportion of n-3 PUFA and a higher ratio of serum n-6/n-3. A low ratio of dietary n-6/n-3 is 
preferable in reducing the risk of chronic inflammatory conditions, such as diabetes, obesity 
and cardiovascular disease (Simopoulos, 2002). In addition, higher ratios of specific FA (AA/ 
(EPA+DHA+DPA), AA/DPA, AA/DHA) that have a direct effect on host inflammation 
again supported our hypothesis. Thus, our results suggest that the altered serum FA profile in 
obese compared to lean dogs makes them more prone to inflammation. It is noteworthy that 
gender may have biased our results, as the obese group contained less female dogs than the 
lean group.  
The omega-3 index has been developed as a novel biomarker of cardiovascular 
disease in humans (Harris and Von Schacky, 2004). A lower omega-3 index was associated 
with a higher risk of coronary heart disease mortality. In dogs, the RBC omega-3 index was 
positively correlated with cardiac tissue n-3 PUFA content (Billman et al., 2010). In the 
present study, the RBC omega-3 index was much lower in obese dogs compared to lean dogs, 
which was consistent with the decreased serum omega-3 index. The RBC omega-3 index 
might also be a reliable biomarker in dogs. Dogs with obesity are prone to cardiovascular 
complaints (Montoya et al., 2006) and future studies are needed to evaluate if the RBC 
omega-3 index could be used as a biomarker for cardiovascular disease risk in obese dogs. 
Supplementing sPLA2i increased the serum proportion of myristic acid and decreased 
the proportion of LA. Myristic acid is the 14-carbon SFA which is usually associated with 
negative effects on human health, although it has also been recently reported to activate many 
physiological pathways, including the activity of the mammalian desaturases and N-terminal 
myristoylation (Rioux et al., 2011). Linoleic acid is the most abundant n-6 PUFA in the diet, 
therefore, a decreased proportion of LA to total FA might contribute to a decreased n-6/n-3 
ratio. In the current study, the sPLA2i diet did not change n-6 proportion and n-6/n-3 ratio in 
obese and lean dogs. 
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Elevated CRP levels have been well documented in obese human subjects (Yudkin et 
al., 1999; Bastard et al., 2006). However, in the present study CRP concentrations were not 
changed in obese Beagle dogs. This corroborates the results of other weight management 
studies in dogs (Tvarijonaviciute et al., 2012; 2011). Nevertheless, it shows for the first time 
that plasma fibrinogen, another putative inflammatory marker, was increased in obese dogs. 
In humans, fibrinogen is positively associated with weight gain and body fat (Festa et al., 
2001; Duncan et al., 2000). Therefore, our initial results warrant future studies to evaluate if 
plasma fibrinogen could be used as a novel biomarker for low-grade inflammation in dogs.  
Interestingly, the sPLA2i diet reduced this presumed inflammation in obese dogs by 
lowering the fibrinogen concentration while increasing the plasma protein:fibrinogen ratio. 
One study showed that the plasma protein:fibrinogen ratio was decreased in cats with 
inflammation (Schalm, 1970). The results indirectly suggest that group IB sPLA2 plays a role 
in inflammation in dogs. However, compared to other groups of sPLA2, IB sPLA2 produced 
less inflammatory mediators in in vitro studies (Murakami et al., 2011). Consequently, the 
role of group IB sPLA2 in inflammation has probably been underestimated during the past 
few years. Indeed, because of the high levels of group IB sPLA2 present in pancreatic juice, 
it can still play a major role in stimulating the inflammatory process in vivo.  
Persistent low-grade inflammation in obese mice caused impairment of the intestinal 
barrier function by increasing IP (Brun et al., 2007), while decreased inflammation has shown 
to lower IP in mice (Cani et al., 2009). However, in the present study, IP was not different 
between obese and lean dogs. It is possible that our dogs were either not obese enough 
compared to human subjects to have differences in IP or, alternatively, the analytical method 
we used may not have been sensitive enough to determine subtle changes, if any, among lean 
and obese dogs.  
Obesity has been shown to induce systemic oxidative stress in humans based on the 
induction of oxidative stress markers, such as MDA, and the suppression of antioxidants 
(Vincent and Taylor, 2006; Keaney et al., 2003). The mammalian antioxidant system includes 
a complex interplay between enzymatic antioxidants, such as superoxide dismutase and GPx 
and both lipophilic and hydrophilic free radical scavengers such as vitamins A, E and C 
(Finkel and Holbrook, 2000). Studies on oxidative stress in obese dogs are rare and have not 
reported increased oxidative stress after either a 13-week or a 24- week weight gain program 
(Van de Velde et al., 2012; Grant et al., 2011). Similarly, concentrations of MDA and 
antioxidants were not altered in obese vs. lean dogs in our study. 
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Plasma vitamin A concentration was higher in obese compared to lean dogs regardless 
of the diets. In obese human subjects, both increased and decreased plasma vitamin A levels 
have been observed (Gunanti et al., 2014). The active vitamin A metabolite retinoic acid has 
been shown to inhibit adipogenesis and adipocyte differentiation (Bonet et al., 2003). In 
addition, retinoic acid can inhibit proinflammatory T-helper 17 cell and promote anti-
inflammatory regulatory T-cell differentiation (Mucida et al., 2007). However, retinoic acid 
was not measured in this study. It is noteworthy that contradictory findings of increased 
systemic vitamin A concentration may be due to the diverse biological roles of the different 
types of vitamin A derivatives as well as their lipophilic properties (Gunanti et al., 2014). 
This suggests sPLA2i could improve the oxidative-antioxidative balance in obese dogs.  
Complementary to its ligand, serum RBP4 was measured, since its increased ratio to 
serum retinol has been associated with obesity, metabolic syndrome and insulin resistance in 
humans (Aeberli et al., 2007; Yang et al., 2005). RBP4 is a specific protein carrier for retinol 
in plasma and functions as a positive acute phase protein secreted by adipocytes which 
increases in insulin-resistant states (Aeberli et al., 2007). In our study, serum concentration of 
RBP4 did not change and the RBP4: retinol ratio was thus decreased in obese vs. lean dogs. 
In vitamin A sufficient animals, minimal or no changes of plasma RBP have been observed 
after vitamin A administration (Muto et al., 1972). Therefore, unchanged RBP4 and hence 
reduced RBP4: retinol ratio could be due to abundant vitamin A present in these dogs 
probably indicating an increased fat mobilization.  
 
5.6 CONCLUSIONS 
An sPLA2i diet can reduce plasma fibrinogen, a putative novel inflammatory marker, 
in obese Beagle dogs to levels similar to those of lean dogs fed the same diet. Obese dogs 
appear to be already at risk for inflammation related comorbidities because they display an 
undesired serum FA profile, characterized by a lower omega-3 index and serum n-3 PUFA 
and a higher ratio of serum n-6/n-3, which makes them more prone to inflammation. 
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The gut microbiota is a remarkable asset for animal health. Gut dysbiosis has been 
proposed as one of the most important pathophysiological mechanisms in both IBD and 
obesity (Zhao, 2013; Sartor, 2008). The incidences of IBD and obesity have been increasing 
not only in humans but also in dogs (German, 2006; Jergens, 1999). In this research, the 
microbial changes in dogs with IBD and obese dogs were evaluated in Chapter 3 and 4, 
respectively.  
Diet can modulate gut microbiota (David et al., 2014). High levels of protein in the 
diet lead to increased protein fermentation and herewith production of putrefactive substances 
that are considered detrimental to human health (Windey et al., 2012). However, dietary 
protein requirement is lower in humans compared to dogs, thus dogs might have adapted to 
the negative effects of increased protein fermentation. In Chapter 4, the impact of dietary 
protein on faecal microbiota in lean and obese dogs was investigated.  
Inflammation and oxidative stress are important factors in the pathogenesis of IBD 
and obesity (Rezaie et al., 2007; Furukawa et al., 2004). Obese dogs were found to be 
characterized by a more pro-inflammatory serum fatty acid profile compared to lean dogs 
(Chapter 5). Reducing inflammation and oxidative stress through dietary intervention might 
be an alternative to alleviate the comorbidities associated with these diseases. Therefore, a 
potential anti-inflammatory modulator, sPLA2i, has been tested for its impact on 
inflammation and oxidative stress in lean and obese dogs (Chapter 5). 
Taken together, this PhD thesis attempted to elucidate the gut microbial related 
changes in both dogs with IBD and obese dogs and evaluated the impact of different dietary 
interventions on gut microbiota, on inflammatory status and on oxidative stress in dogs.  
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6.1 THE IMPACT OF IBD, OBESITY, AND DIET ON FAECAL MICROBIOTA AND 
RELATED CHANGES IN DOGS 
6.1.1 CHANGES IN FAECAL MICROBIOTA PROFILE IN DOGS WITH IBD AND OBESE 
DOGS 
Within this PhD research, no distinct differences of composition of faecal microbiota 
and their fermentation end products were observed between dogs with IBD and healthy dogs 
or between obese and lean dogs (Chapter 3 and 4). This is in line with other studies which 
also reported no differences in faecal microbial diversity in canine IBD (Suchodoski et al., 
2012b) and canine obesity (Handl et al., 2013). However, some authors noted reduced 
bacterial diversity and distinct bacterial communities in canine IBD (Minamoto et al., 2015; 
Suchodoski et al 2012a; Xenoulis et al., 2008) and obesity (Park et al., 2015).  
Several possible reasons could explain the previously mentioned contradictory results: 
1) The severity of the disease/disorder. Indeed, in this PhD thesis gradual changes in faecal 
bacterial groups have been observed as the severity of canine IBD and obesity increased 
(discussed latter in this section). Thus, differences in faecal microbial profile might be easier 
to detect between animals with more extreme conditions, e.g. healthy controls vs. very severe 
IBD. In this research, CCECAI score was used as a measure for the severity of IBD but many 
other studies used CIBDAI score as a measure of IBD severity (Table 1.6). The difference of 
these two indices is shown in Figure 6.1. The CCECAI was developed based on CIBDAI 
with addition of three parameters, namely albumin levels, ascites and peripheral edema, and 
pruritus. Although the median severity index from different canine studies are similar, the 
range for the index is different (Table 1.6); 2) Sample type: faeces vs. biopsies. Most studies 
using duodenum biopsies have observed distinct differences in gut microbial community 
between IBD and healthy dogs (Suchodoski et al 2012a; Xenoulis et al., 2008). Although 
faecal samples are non-invasive to obtain, whether faecal microbiota can provide accurate 
information on changes of gut microbiota remains a debate (Eckburg et al., 2005; Mentula et 
al., 2005); 3) Different techniques were used to determine the microbial composition. 
Compared to next-generation sequencing, DGGE alone cannot obtain phylogenetic 
identification. However, a combination of DGGE and sequence analysis could give the same 
results as 16S rRNA sequencing (Van Praet et al., 2015); 4) A large inter-individual 
variability among dogs may exist and has been observed in other canine studies (Handl et al., 
2013; 2011). The sources of the variation may include gender, age, breed, living conditions 
(e.g. exposure to pathogens, people, or other animals) and diet (e.g. macronutrients 
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composition or form). In addition, no histopathological examination was performed on the 
intestinal biopsies in control dogs as compared to IBD dogs (Chapter 3). This could be one of 
the drawbacks of the study. However, the inter-individual variability was not always possible 
to control as good as desired (Chapter 3 vs. Chapter 4). As a result, inter-individual 
variability did not allow for clear differences between groups to be identified. This was 
particularly remarkable in Chapter 3, where indications for differences were noted but 
statistically almost no differences could be demonstrated for gut microbiota composition and 
functionality. 
As mentioned in the general introduction (Chapter 1, Section 1.3) of this PhD thesis, a 
number of changes in important gut microbial groups have been reported in humans and 
animals with obesity and IBD, such as 1) changes in Firmicutes and Bacteroidetes in human 
obesity research (Schwiertz et al., 2010; Ley et al., 2006); 2) changes in butyrate-producing 
bacteria in human obesity and IBD research; 3) an increase in the family Enterobacteriaceae 
(belonging to γ-Proteobacteria), an important producer of inflammatory lipopolysaccharide, 
in dogs (Xenoulis et al., 2008), cats (Janeczko et al., 2008) and humans with IBD (Martinez-
Medina et al., 2006) as well as in human obesity (Santacruz et al., 2010). A decrease in 
numbers of Lactobacillus was found in human IBD patients with active but not inactive IBD 
(Fabia et al., 1993); and 5) increased numbers of SRB has been reported in UC patients 
(Pitcher et al., 2000). SRB utilize a process termed “dissimilatory sulphate reduction” to 
reduce sulphite and sulphate to sulphide and consequently produce potentially toxic hydrogen 
sulphide (Hawrelak and Myers, 2004). Therefore, these bacterial groups and functional genes 
(BK, BCoAT and dSRB) were scrutinized by qPCR in this PhD research. 
In the IBD study (Chapter 3), Lactobacillus was decreased with increased severity of 
IBD (Figure 3.1). As far as the scientific community is concerned, the relationship between 
bacterial groups and the degree of obesity is not yet well studied and data is lacking. Hence in 
this PhD thesis, to begin to comprehend this relationship, Spearman correlations between 
BCS and different bacterial groups were performed to evaluate the impact of degree of 
obesity on the profile of faecal microbiota (Figure 6.3), of which lean and obese dogs of both 
diets (Chapter 4) were included (n=20). Interestingly, the faecal abundance of total bacteria 
(P=0.032), Bacteroidetes (P=0.025) and the gene expression of BCoAT (P=0.035) were 
negatively associated with BCS, but no significant correlations were observed for clostridial 
clusters IV and XIVa and the gene expression of BK (Figure 6.2). It should be noted that for  
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Figure 6.1. Scoring sheet for measuring severity of canine inflammatory bowel disease: A) 
canine chronic enteropathy activity index (Allenspach et al., 2007); B) canine inflammatory 
bowel disease activity index (Jergens et al., 2003).  
A. Canine Chronic Enteropathy Activity Index (CCECAI) Scoring Sheet for Measuring Severity of 
Canine Inflammatory Bowel Disease 
CCECAI Criteria: 
A. Attitude/Activity: 0=normal 1=slightly decreased 2=moderately decreased 3=severely decreased 
B. Appetite: 0=normal 1=slightly decreased 2=moderately decreased 3=severely decreased 
C. Vomiting: 0=normal 1=slightly increased 2=moderately increased 3=severely increased 
D. Stool consistency: 0=normal 1=soft feces blood/mucus 2=very soft feces 3=watery diarrhea 
  (3 X/day) (3-5 X/day) (>5 X/day) 
E. Stool frequency: 0=normal 1=slightly increased 2=moderately increased 3=severely increased 
F. Weight Loss: 0=none 1=mild (<5% loss) 2=moderate (5%-10% loss) 3=severe (>10% loss) 
G. Albumin levels 0= >20g/L 1= 15-19.9g/L 2= 12-14.9g/L 3= <12g/L 
H. Ascites and 
peripheral edema 
0=none 1=mild ascites or 
peripheral edema 
2=moderate ascites or 
peripheral edema 
3=severe ascites or 
peripheral edema 
I. Pruritus 0=no 
pruritus 
1= occasional episodes of 
itching 
2= regular episodes of 
itching, but stop when sleep 
2= regular wakes up 
because of itching 
CCECAI Score: 
 
Insignificant 
Total score of 0-3 
Mild IBD 
Total score of 4-5 
Moderate IBD 
Total Score of 6-8 
Severe IBD 
Total Score 9-11 
Very Severe IBD 
Total Score >12 
     
 
 
B. Canine Inflammatory Bowel Disease Activity Index (CIBDAI) Scoring Sheet for Measuring 
Severity of Canine Inflammatory Bowel Disease 
CIBDAI Criteria: 
A. Attitude/Activity: 0=normal 1=slightly decreased 2=moderately decreased 3=severely decreased 
B. Appetite: 0=normal 1=slightly decreased 2=moderately decreased 3=severely decreased 
C. Vomiting: 0=normal 1=slightly increased 2=moderately increased 3=severely increased 
D. Stool consistency: 0=normal 1=soft feces blood/mucus 2=very soft feces 3=watery diarrhea 
  (3 X/day) (3-5 X/day) (>5 X/day) 
E. Stool frequency: 0=normal 1=slightly increased 2=moderately increased 3=severely increased 
F. Weight Loss: 0=none 1=mild (<5% loss) 2=moderate (5%-10% loss) 3=severe (>10% loss) 
CIBDAI Score: 
Clinically Insignificant 
Total score of 0-3 
Mild IBD 
Total score of 4-5 
Moderate IBD 
Total Score of 6-8 
Severe IBD 
Total Score >9 
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Spearman correlations from both studies (Chapters 3 and 4) of this PhD research, the r values 
were low, although correlations were significant. This could be explained by the low number 
of dogs used in the correlations. Still some interesting and valid findings were observed and 
confirmed by indications from the literature. It is interesting to note that gene expression of 
BCoAT seems to be more sensitive to changes in BCS than that of BK (discussed later in 
Section 6.1.3). 
 
m 
  
  
Figure 6.2 Spearman correlations between body condition score (BCS) and bacterial groups 
(a) total bacteria, (b) Bacteroidetes, (c) butyryl-CoA acetate-CoA transferase gene (n=20), (d) 
butyrate kinase gene, (e) clostridial cluster IV and (f) clostridial cluster XIVa. The abundance 
was expressed as log10 16S rRNA gene copies/g or as log10 gene copies of total DNA / g of 
fresh faeces for bacteria groups and functional gene, respectively. 
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Similar to our results, several studies reported the abundances of total bacteria and 
Bacteroidetes to be positively correlated with the percentage loss of BW in humans 
(Santacruz et al., 2009; Ley et al., 2006). In human subjects, increased Firmicutes and 
decreased Bacteroidetes were associated with an increased energy harvest (Jumpertz et al., 
2011). In addition, gut microbiota in mice was shown to have increased numbers of 
Bacteroidetes and lower numbers of Firmicutes in response to reduced caloric intake 
(Crawford et al., 2009). Therefore, the negative correlation of Bacteroidetes with increased 
BCS might suggest dogs with greater degree of obesity to have higher capability to capture 
energy by their gut microbes. However, the underlying mechanism of how the dynamics 
between the abundances of Bacteroidetes and Firmicutes influence energy harvest should be 
further investigated. It should be kept in mind that the function of microbes within one 
phylum can be highly diverse. Future studies need to identify the key role player within 
Bacteroidetes and Firmicutes in canine obesity. Further, to fully elucidate the relationship 
between microbiota and disease activity/severity, larger scale studies are warranted. 
6.1.2 HIGH PROTEIN DIET AFFECTS FAECAL MICROBIOTA AND RELATED CHANGES 
DIFFERENTLY IN LEAN AND OBESE DOGS 
Understanding the impact of high protein diets on gut microbiota profile is essential 
for companion animal nutrition. High protein diets are used for weight reduction in obese 
dogs, however, while these diets have a higher protein concentration, the total protein intake 
may still be lower due to energy restriction. Further, there is an increasing interest in feeding 
raw meat-based diets to companion animals (dogs and cats). The latter often include higher 
amounts of protein and fat, with relatively low starch and plant fibre amounts than those are 
typically found in commercial dry extruded and moist foods (Freeman et al., 2013). 
Interestingly, this PhD research (Chapter 4) found HP to lead to an increase in the faecal 
abundance of clostridial clusters IV and XIVa and of butyrate kinase gene independent of 
phenotypes (i.e. obese and lean) (discussed later in 6.1.3). Moreover, other bacterial changes 
induced by HP were phenotype dependent, including Firmicutes, Lactobacillus and clostridial 
cluster I, where faecal microbiota in obese dogs seemed to be less stable compared to lean 
dogs.  
Although several studies have shown that high protein diets can shift gut microbiota 
to a more detrimental profile in obese human subjects (Duncan et al., 2007), whether the diet 
independent of the obese phenotype is responsible for the changes remains unknown. 
Previous research found large alterations associated with switching to a high fat diet, 
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including a decrease in Bacteroidetes and an increase in both Firmicutes and Proteobacteria 
(Hildebrandt et al., 2009). This was seen for mice in the presence and absence of obesity, 
indicating that the high fat diet itself, and not the obese state, mainly accounted for the 
observed changes in the gut microbiota (Hildebrandt et al., 2009). Another study showed a 
decrease in total bacterial density and an increase in the relative proportion of Bacteroidales 
and Clostridiales orders in high fat fed rats regardless of phenotype (de La Serre et al., 2010). 
In the same study, an increase in Enterobacteriales was seen in the microbiota of obese rats 
only (de La Serre et al., 2010). Together, these results suggest that diet composition per se 
had an important effect on the gut microbiota, however, phenotype also affects microbiota 
composition, which cannot be neglected in dogs 
In addition to the composition of faecal microbiota, the effect of diets (HP vs. LP) on 
serum folate was also different in obese and lean dogs (Figure 6.5). A decrease in the 
concentration of serum folate was observed in IBD vs. healthy dogs and obese dogs with HP 
vs. LP diet in this thesis. However, the reason for the observed drop of folate might be 
different in IBD vs. obese dogs. Folate is absorbed only in the proximal small intestine. A 
study using metagenomics has shown that the biosynthesis of folate is enriched in human gut 
with Prevotella enterotype (Arumugam et al., 2011), and this enterotype seems to be 
associated with a carbohydrate-based diet (Wu et al., 2011). Changes in small intestinal 
microbiota composition and especially impaired proximal small intestine function could be 
the reason for the drop in folate in IBD dogs. In contrast, impaired small intestinal function 
cannot be the reason for reduced folate in obese dogs because obese dogs fed the LP diet did 
not show a drop in folate. Hence, one could suggest that HP might reduce the abundance of 
bacteria that produce folate in the small intestine of obese dogs. Compared to humans (<10
4 
CFU/mL), the number of bacteria in the duodenum is much higher in dogs (10
4
-10
5
 CFU/mL) 
(Bures et al., 2010; Mentula et al., 2005), thus contribution of folate production in the small 
intestine might be bigger in dogs than humans. However, lean dogs fed HP did not show a 
decrease in folate. This could be explained by the fact that the homeostasis of gut microbial 
ecosystem in obese dogs is less stable than in lean dogs. In agreement with our study, a 
decrease in folate was also observed in overweight and obese human subjects (Tungtrongchitr 
et al., 2003). Furthermore, the folate content in HP and LP diets formulated for our study was 
57 and 63 μg/1000 kJ ME, respectively. These are above the FEDIAF (2013) Minimum 
Recommended (16.1 μg/1000 kJ ME), AAFCO (2014) Adult Maintenance Minimum (12.9 
μg/1000 kJ ME), and the NRC (2006) Adequate Intake (54 μg/1000 kJ ME), thus dietary 
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folate deficiency should not be a cause for the drop in obese dogs. Therefore, these results 
suggest HP decreased numbers of bacteria that synthesize folate in the small intestine of 
obese dogs. However, it is unknown whether the decreased folate is of clinical relevance or 
not.  
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Figure 6.3 Serum concentration of folate in three different studies. Healthy: healthy control 
dogs; IBD: dogs with inflammatory bowel disease; L: lean; LP: low protein diet; HP: high 
protein diet; O: obese; sPLA2i: diet with secreted phospholipase A2 inhibitor; control: 
control diet without sPLA2i. (P values are from individual studies). Error bars represent the 
standard deviation. 
6.1.3 CHANGES OF BUTYRATE-PRODUCING BACTERIA UPON IBD, OBESITY, AND DIET 
Instead of digging into specific butyrate-producing bacteria strains (Faecalibacterium, 
Blautia, Roseburia, etc.), in this PhD thesis it was chosen to get a bigger picture of butyrate-
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producing bacteria by evaluating the abundance of the major butyrate producers (ie. 
clostridial clusters I, IV and XIVa) and the terminal genes of two butyrate-producing 
pathways: BCoAT pathway and BK pathway. The BCoAT pathway is utilized by the 
majority of known butyrate-producing in the human gut strains, whereas much less bacteria 
use the butyrate kinase pathway (Vital et al., 2015; Duncan et al., 2004). Many studies have 
proven that amplifying the BCoAT gene is a valuable approach to specifically target the 
activity of the butyrate-producing bacterial community (Vermeiren et al., 2012; Wang et al., 
2012; Hippe et al., 2011). Up to date, only one preliminary report demonstrated the 
abundance of BCoAT not to be correlated with faecal butyrate concentration (Loman et al., 
2014). As most abundant butyrate-producing bacteria in humans have been also identified in 
the canine gut (Suchodoski et al., 2008), it was assumed that dog gut microbiota are using the 
same pathway for butyrate production. However, our research (Chapter 4) suggested BK 
pathway might have a bigger contribution to the butyrate gut pool than what has been 
established for humans. 
A recent study found BCoAT pathway significantly enriched in omnivores and 
herbivores compared with carnivores, whereas BK pathway was more abundant in many 
carnivores (Vital et al., 2015). That study also included two dogs as carnivores, while BCoAT 
pathway was dominant for one dog and the other one seemed to have both pathways equally 
distributed (Vital et al., 2015). In our research, although these two terminal genes seemed to 
be equally distrubted, the faecal abundance of BK was enriched together with the major 
butyrate producing clusters. When comparing these two butyrate producing pathways (Figure 
1.3), it is not surprising that carnivores used more BK. The BK pathway might be more 
associated with protein-rich environments, whereas BCoAT pathway is dependent on a 
consistent supply of acetate. The availability of acetate might be less in carnivores compared 
to omnivores and herbivores that consume more carbohydrate. However, it is still unclear 
from our study if the bigger contribution of the BK gene is induced by HP or in general dogs 
use more BK pathway for butyrate production. Moreover, the gene expression of BCoAT 
seems to be more sensitive to changes in BCS than that of BK, which also means BK is more 
resilient to changes in body condition. One could suggest that obesity will primarily affect 
BCoAT pathway, or due to the fact BK is more stable because of a possible longer evolution 
way compared to BCoAT. Thus, it would be interesting for future studies to investigate the 
butyrate producing bacteria in dogs and wolves to have an evolutional view for butyrate 
production.  
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As dogs may use a different pathway for butyrate synthesis, it raises the question 
whether dogs possess the same predominant butyrate producers as from humans (clostridial 
clusters IV and XIVa). The butyrate kinase gene pathway is linked to C. perfringens 
dominated in many Carnivores (e.g. ferret, tiger, African lion) and non-carnivorous 
Carnivora (e.g. red panda and giant panda) (Vital et al., 2015). In this study C. perfringen 
was not measured, but it is the major components of clostridial cluster I. The clostridial 
cluster I was increased when dogs were fed HP (Chapter 4), however, it still needs to be 
confirmed if increased clostridial cluster I abundance is due to increases in C. perfringen 
numbers. Nevertheless, other canine studies have also shown that high protein diets promoted 
the growth of C. perfringen (Zentek et al., 2003). Thus, closteridial cluster I might also be 
important for butyrate production in dogs. On the other hand, up to now C. perfringens has 
been considered to be detrimental for canine gut health due to the clinical documentation as a 
cause of diarrhoea in dogs (Weese et al., 2001). In the past, several studies considered a 
decrease of C. perfringens as a potential improvement of colonic microbial ecology 
(Flickinger et al., 2002; Swanson et al., 2002). However, the gut of healthy adult carnivores is 
significantly enriched with C.perfringens (Muegge, 2013). These facts lead to the hypothesis 
that a protein-rich diet may create a favourable environment for the growth of C. perfringens, 
but with an expressional profile that is not pathogenic or even beneficial to the dogs.  
6.1.4 DOES PLASMA ACYLCARNITINE PROFILE REPRESENT HOST-MICROBIAL 
INTERACTION? 
Insights into the microbial-host inter-relationships may provide a foundation to 
understand the relevant, functional diversity of the gut microbiota in the context of IBD and 
obesity. In this PhD research, plasma acylcarnitines profile was measured to achieve this goal. 
Detailed information of how acylcarnitines are derived from gut fermentation products and 
which acylcarnitines are of importance in host metabolism is showed in Figure 1.3 (Chapter 
1). Based on the results published from our group, gut fermentation can have significant 
impact on targeted acylcarnitines (Rochus et al., 2014; Verbrugghe et al., 2010; 2009). For 
instance, a prebiotic diet with 4% of a blend of oligofructose and inulin increased plasma 
propionylcarnitine in domestic cats (Verbrugghe et al., 2010). More directly, plasma 
propionylcarnitine rose markedly when cats received a colonic propionate infusion 
(Verbrugghe et al., 2012). A previous study using stable isotopes labelled acetate, butyrate 
and propionate, found labelled stable isotopes incorporated into plasma acetylcarnitine and 
palmitoylcarnitine, however, no information is available on propionylcarnitine and 
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butyrylcarnitine changes (den Besten et al., 2013). Taken together, these results suggested 
circulating short-chain acylcarnitines could, at least partially, reflect cellular metabolism of 
gut-derived SCFA. 
To date, limited studies have revealed the efficiency of butyrylcarnitine as an 
estimator of the large intestinal fermentation-derived butyrate (Rochus, 2013). In the IBD 
study (Chapter 3), C4/C0 had a negative correlation with severity of IBD in dogs. It should be 
noted that the technique used to analyse acylcarnitine in this research cannot separate isomers, 
meaning C4 consists of two isomers: butyrylcarnitine and isobutyrylcarnitine. Indeed, a 
significant positive correlation (n=24) was found between plasma C4/C0 and faecal 
isobutyrate (P=0.009, r=0.521) but not for butyrate (Chapter 3). Therefore, the negative 
correlation of C4/C0 with increased severity of IBD might be mainly due to the reduced 
faecal isobutyrate concentration.  
Plasma C4DC that originates mainly from propionate and less likely from valine 
metabolism was decreased in IBD compared to control dogs (Chapter 3). Two other studies 
found several short-chain acylcarnitines, including propionylcarnitine, butyrylcarnitine and 
isovalerylcarnine, to be significantly lower in CD and UC patients compared to healthy 
controls (Bene et al., 2007; 2006). These results suggest canine IBD to be associated with a 
decreased metabolism of the circulating SCFA originating from gut fermentation. 
Besides giving information on gut fermentation, acylcarnitines are also useful to infer 
on amino acid metabolism in the gut and of the host. Increased acylcarnitines that represent 
amino acid degradation (ie. isovalerylcarnitine and 3OH- isovalerylcarnitine) accompanied 
with high rate of protein fermentation was observed in dogs fed HP (Chapter 4). However, it 
is difficult to distinguish whether the elevated acylcarnitine concentrations were due to the 
absorption of higher amount of amino acids from the diet or due to increased gut protein 
fermentation. Nevertheless, serum indoxyl sulphate, which can only be formed by the liver 
from the gut protein fermentation end product indole, was increased in HP vs. LP fed dogs, 
indicating the differences in the acylcarnitines were, at least partially, due to changes in gut 
protein fermentation.  
Overall, despite the technical problems that might still exist to completely separate all 
acylcarnitines, their profile in a host, combined with the analysis of gut end fermentation 
products renders valuable information in the understanding how gut microbiota interacts with 
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the host. Additionally, the acylcarnitine profile gives insight on major gut microbiota changes 
upon severe disease or drastic diet changes. 
 
6.2 IBD AND OBESITY RELATED PROBLEMS: INFLAMMATION AND OXIDATIVE 
STRESS  
Gut microbiota have the potential to stimulate both pro- and anti-inflammatory 
responses, and the composition of the bacterial communities in the gut might be linked to the 
proper functioning of the immune system (Round and Mazmanian, 2009). Compositional 
changes of microbiota in terms of severity of IBD and obesity were found in this PhD thesis 
(Chapter 3 and 4). Further, this research also examined the inflammatory status of dogs with 
obesity, however, the causal relationship between gut microbiota and host immunity is out of 
the scope of this PhD thesis.  
Serum CRP, plasma fibrinogen and serum fatty acid profile were measured in lean 
and obese dogs as a marker for systemic inflammation (Chapter 5). Moreover, oxidative 
stress which has been implied in the underlying mechanism for inflammation, was evaluated 
in this PhD, to help explain the inflammatory status of dogs (Chapter 5).  
Although unexpectedly, no differences in serum CRP concentrations were revealed between 
obese and lean dogs, it was found that obese dogs are characterized by a more ‘pro-
inflammatory’ serum fatty acid profile with a lower omega-3 index (3.9 vs. 4.6) and a higher 
ratio of serum n-6/n-3 PUFA (8.5 vs. 7.0). In humans, a greater proportion of obese children 
(33%) had an omega-3 index of < 4.0 compared with non-obese children (17%) (Burrows et 
al., 2011). A higher omega-3 index has been shown to be associated with increased insulin 
sensitivity and a more favourable metabolic profile in middle-aged overweight men (Albert et 
al., 2014). Similarly, a significant inverse association between omega-3 index and type 2 
diabetes was also observed in overweight and obese female individuals (Garg et al., 2015). 
Interestingly, the omega-3 index was found to be inversely associated with waist 
circumference and positively associated with seafood servings in a study including 503 
French individuals (Wagner et al., 2015). However, in this PhD research, a significant 
relationship between BCS and omega-3 index was however not observed (Figure 6.4) In 
addition, significant positive correlations were found between BCS and AA: 
(EPA+DPA+DHA), BCS and AA: DPA, BCS and AA: DHA (n=28, Figure 6.4). These 
results further support other findings of this PhD research that suggest obese dogs to be 
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associated with a more ‘pro-inflammatory’ status, reflected in the serum fatty acid profile. 
Therefore, n-3 PUFA (i.e. DPA and DHA) supplementation might change the undesired pro-
inflammatory FA profile and consequently ameliorate inflammatory comorbidities in obese 
dogs. 
It will be interesting to know if the serum “pro-inflammatory” fatty acid profile has an 
effect on the gut microbiome in canine obesity. It is known that PUFA can have anti-
microbial effects in ruminants as indicated in the general introduction of this thesis (section 
1.2.3 in Chapter 1). Indeed, studies have shown dietary supplementation of PUFA could 
change the composition of gut microbiota in mice (Ghosh et al., 2013) and neonatal piglets 
(Andersen et al., 2011). Actually, SFA even have stronger effects than PUFA (n-6 and n-3) in 
shifting gut microbiota profiles toward those typical of obese human individuals (Liu et al., 
2012). In addition, it has been described that the human gut microbiome is able to 
biohydrogenate these PUFA, and hence reduce the anti-microbial effects (Devillard et al., 
2007). However, it is not yet known whether dogs’ gut microbiome has this capacity or not. 
In this PhD thesis, the amount of fish oil and plant oil were the same, hence not allowing for 
inference on the biohydrogenate capacity nor on the possible antimicrobial activity of these 
PUFA on gut microbiota. At the same time, no intestinal biopsies or faecal samples were 
taken in this study to evaluate the compositional and funtional changes on gut microbiota. It 
is therefore difficult to comment on possible changes in gut microbiota based on serum FA 
profile, as it is also known that human adipose tissue is able to desaturate FA that could have 
been hydrogenated by gut microbiota (Sjögren et al., 2008). Hence, serum FA profile is a 
reflection of both gut FA hydrogenation and tissue desaturation. 
Among all the measured markers for oxidative stress (MDA and antioxidants: GPx, 
vitamin A, C, E), a 1.6-fold higher plasma concentration of vitamin A (retinol) was observed 
in obese compared to lean dogs, but the other antioxidants remain unchanged (Chapter 5). Up 
to date, vitamin A metabolism in obese dogs is not well understood and future studies are 
warranted. Nevertheless, a negative correlation was found between serum retinol and weight, 
BMI and hip circumference in both overweight and obese human subjects (Viroonudomphol 
et al., 2003). In our study free retinol was measured as vitamin A and the latter was higher in 
obese dogs compared to lean dogs. It was then speculated that its higher levels could be due 
to: 1) increased fat mobilization in obese dogs, or 2) impaired esterification of retinol in 
obese dogs. Adipose tissue can take up circulating retinol, store it as fatty acid esters (retinyl 
esters) and convert it into retinoic acid. In this way, the host can mobilize its retinol reserves 
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to meet both local and total body demands (Bonet et al., 2003), by mobilizing adipose tissue. 
On the other hand, impaired esterification of retinol by the adipose tissue has reported in 
obese diabetics subjects (Bagdade et al., 1969). Furthermore, β-carotene has been implicated 
as an antioxidant rather than vitamin A due to its higher capacity to scavenge free radicals 
(Vrolijk et al., 2015), however, it was not measured in our study. 
  
  
 
Figure 6.4 Spearman correlations between body condition score (BCS) and several 
polyunsaturated fatty acid ratios (a) AA: (EPA+DPA+DHA), (b) AA: DPA, (c) AA: DHA, (d) 
AA:EPA, (e) n-6/ n-3, (f) RBC omega-3 index (n=28).  
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6.3 INHIBITOR OF SPLA2, A POTENTIAL ANTI-INFLAMMATORY MODULATOR 
The sPLA2s are consisting of more than 10 sPLA2 enzymes and have been implicated 
in inflammatory reactions through the generation of eicosanoids and other lipid mediators for 
signal transduction (Lambeau and Gelb, 2008). From in vitro studies, a potency order of 
eicosanoids production is X > V > III > IIF > IIA > IB > IID > IIE > XIIA (Murakami et al., 
2011). However, these in vitro studies were often performed using super-physiological 
amounts of exogenous or over-expressed sPLA2s, thus it remained unclear whether or not 
endogenous sPLA2s could play such a role in vivo.  
Several studies using mice that are transgenic, or more physiologically knocked out, 
for individual sPLA2s have revealed that they can mobilize lipid mediators in vivo. For 
example, the activation of sPLA2s (group II and group V, major PLA2 enzymes expressed in 
term placenta) is associated with the generation of placental lipid signals (TNF-α and leptin 
stimulation) and fetal obesity (Varastehpour et al., 2006). In addition, group IB sPLA2 is 
secreted from the pancreas in response to food intake, and its deficiency (PLA2
-/-
) could 
protect the mice from diet-induced obesity compared to wild-type controls (Huggins et al., 
2002). In the same study, the PLA2
-/-
 mice also displayed increased lipid content in the stool, 
thus indicating decreased fat absorption in these animals (Huggins et al., 2002). Therefore, 
sPLA2 may function as cellular links between inflammatory pathways and lipid metabolism.  
In our study (Chapter 5), dietary supplementation of egg yolk antibody against group 
IB sPLA2 attenuated the increase in plasma fibrinogen levels observed in obese dogs. Plasma 
fibrinogen was measured as a putative inflammatory marker and was increased in obese vs. 
lean dogs when fed the control diet. However, changes in apparent crude fat digestibility 
were not observed when fed the sPLA2i diet (Table 5.2). A potential beneficial role of 
sPLA2i supplementation in obese dogs through down-regulation of low-grade inflammation 
still need to be further confirmed as only changes for fibrinogen were observed. Still, it offers 
a potential novel target for treatment of canine obesity related inflammation and co-
morbidities. 
The egg yolk antibody has many advantages, including the polyclonal nature of the 
antibody, which allows one to rapidly proceed in development of an effective antibody for 
usage, as well as the efficiency in time, labour and input cost (Cook, 2004). However, 
limitations do exist such as difficulty to identify the targeted antigen and demonstrate 
efficiency. The measurement of the antibody in faeces and blood would provide more direct 
evidence of the effect of the supplementation. There are several methods to determine sPLA2 
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concentration in the blood including measuring catalytic activity of sPLA2 and 
immunoassays. Radiometric assays are the most sensitive assay among the methods for 
determining the catalytic activity of sPLA2. Immunoassays are available for humans, rodents 
and rabbits; however, there are species differences of the affinity of the sPLA2 antibodies 
(Santavuori et al., 1991). To our knowledge, sPLA2 has not yet been measured in dog blood 
and faecal samples and there are no sPLA2 antibody developed for immunoassay for dogs. 
Since, sPLA2 yolk antibody addition is the only treatment of the present study, the difference 
of the parameters was assumed to be the effect of the treatments.  
6.4 LIMITATIONS AND FUTURE PERSPECTIVE 
It is rather challenging to draw definite conclusions on the importance of various 
bacterial groups in IBD, as many other factors could had influenced the results, such as diet, 
genetic background, age and living conditions (e.g. exposure to pathogens, people, or other 
animals). To search for breed and age matched IBD and healthy dogs was the initial goal of 
the IBD study (Chapter 3). However it was impossible to put this into practice. More 
standardized requirements (e.g. diets and living condition) might help in this situation. 
Despite all odds, large individual variances in faecal microbiota were still observed in the 
research Beagles (with an assumed lower variation in genetic background compared to pet 
dogs) and with similar living conditions when fed the same diet (Chapter 4). It is utopic to 
think that it is possible to genetically manipulate gut microbiota composition as the factors 
that determine the composition are plentiful. At the most, one will be able to steer gut 
microbiota composition to a limited extent, be it through dietary changes, environmental 
changes or genetic manipulation. Therefore, future studies on gut microbiota should better 
take into account this great individual variation and have enough animals in order to reliably 
detect significant changes in gut microbiota profiles. 
In this research, DGGE and qPCR were used to have a rapid comparison of faecal 
microbial ecology and bacterial groups of interest, respectively. However, using 16S rRNA 
sequencing and metagenomic sequencing could provide a more in-depth characterisation of 
overall faecal microbiota shifts (including bacteria, archaea, fungi and viruses). The latter can 
determine the microbiome in terms of potential functions, but which genes are expressed and 
functioning remains unknown. Moreover, shotgun metaproteomics have been developed to 
directly identify microbial proteins in faecal samples, although substantial efforts are still 
required to define and characterize the massive dataset (Verberkmoes et al., 2009). In 
addition, metabolomics in serum and faecal samples could also be a useful approach to 
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identify the functionality of the gut microbiota. Thus, metabolomic profiling of gut microbes, 
metagenomic and proteomic approaches may help narrow the microbial factors central to 
disease pathogenesis in gut dysbiosis related diseases. 
As most previous studies focused on the dietary effects only in obese subjects, limited 
information is available for the difference of dietary impact between lean and obese 
individuals. Importantly, many impacts of dietary treatments on faecal microbiota and 
inflammatory markers were found in obese dogs whereas these changes did not occur in lean 
dogs. These results suggest a dietary manipulation/intervention can be useful way to regulate 
gut microbiota and inflammation in obese dogs. On the other hand, dietary change in obese 
dogs should be used with caution not to evoke unnecessary negative consequences (e.g. shift 
gut microbiota toward a detrimental composition and function). Furthermore, these results 
also imply that using healthy dogs to study how nutrients can modulate gut microbiota cannot 
be copied to unhealthy animals in which gut microbiota are not the same as the healthy 
animals. Nutritional intervention studies should be carried out on animals with targeted 
condition rather than healthy animals to get reliable results. 
Supplementing sPLA2i to the diet of obese dogs showed some encouraging results on 
plasma fibrinogen. A potential beneficial or detrimental effect on long-term dietary 
supplementation of sPLA2i should be investigated. It might also be interesting to test the 
effects of inhibitor of other groups of sPLA2s on the low-grade inflammation in obese dogs, 
such as group IIA. In addition, more bio-markers for inflammation (e.g. cytokines, 
chemokines, adipokines) and oxidative stress (ROS, F2-isoprostanes, advanced oxidation 
protein products) could be measured in the future studies to have a more complete view of the 
inflammatory status and oxidative stress status of the host.  
In light of the increased awareness of animal welfare and the reduction of animals in 
research, future studies aiming at screening dietary manipulations of gut microbiota in canine 
IBD and obesity, in vitro models should be further developed as they are a good strategy to 
rapidly identify potential dietary treatments. Currently, two in vitro models are available for 
the GI tract of the dog, the TNO Gastro-Intestinal Model (TIM) and the Simulator of the 
Human Intestinal Microbial Ecosystem (SHIME
®
) (Smeets-Peeters, 2000; Van de Wiele et 
al., 2015). In addition, the SHIME is also available as a model for human UC patients. This 
model not only provides a niche for luminal but also for surface-attached mucosal microbes 
(Van den Abbeele et al., 2013). Therefore, using these well-established gut models might 
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help to unravel a more in vivo-like microbial composition and activity compared to faecal 
samples.  
 
6.5 IMPLICATIONS 
Trying to find the reasons behind the large individual variations of the gut 
microbiome is equally important as trying to reduce the variations in research. Targeted gut 
therapy, for example, faecal microbiota transplantation (FMT), is a promising area for the 
treatment of canine IBD and obesity. FMT has been successfully applied for human IBD 
patients with C.difficile infection. However, much work remains before the accurate FMT 
manipulation can apply, e.g. the underlying mechanism of the diseases, the efficiency and 
stability of donor microbiota colonization. 
High protein diet is getting more popular in the pet food market, e.g weight 
management diet (high protein and high plant fibre), raw-meat based diet (high protein and 
low plant fibre). Based on this PhD research, high protein diet enriched faecal butyrate 
producing bacteria in lean dogs which might be beneficial for canine gut health. However, the 
shift of the whole microbial community was not investigated. In addition, future research on 
high protein diet for obese dogs is warranted as it seems to have a greater impact on the 
“obese faecal microbiome” than on the lean one, thus high protein diets in obesity 
management need to be used with caution before the complete validation on gut microbial 
homeostasis. 
From this PhD research, bacteria in canine gut may use a different pathway for 
butyrate production compared to bacteria in humans. This could be just one of many 
differences between dogs and humans regarding their gut microbiome and the interaction 
with the host. Therefore, many more in-depth comparative gut microbiome-related nutritional 
studies are needed before application of the dietary supplements, e.g. prebiotics and 
probiotics, which have been used in humans can be put forward in dogs. 
 
6.6 CONCLUSIONS 
Compared to humans, dogs used a different pathway for butyrate production, namely 
the butyrate kinase. This could be resulted from high dietary protein intake in dogs. Dietary 
protein concentrations had a different impact on faecal microbiota in lean vs. obese dogs. HP 
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raised the abundance of butyrate producing bacteria in lean dogs but not in obese dogs. In 
addition, DGGE profile showed faecal microbiota in obese dogs tended to be more vulnerable 
to dietary protein changes than lean dogs. 
Finally, IBD dogs are associated with significant changes in metabolic profile. Obese 
dogs are characterized by a more ‘pro-inflammatory’ status, with an increased level of plasma 
fibrinogen, a lower omega-3 index and a higher ratio of serum n-6/n-3. Adding sPLA2i 
attenuated the increase in plasma fibrinogen levels observed in obese dogs.  
154 Chapter 6 
General discussion 
 
References 
Albert, B.B., Derraik, J.G., Brennan, C.M., Biggs, J.B., Smith, G.C., Garg, M.L., Cameron-Smith, D., 
Hofman, P.L., Cutfield, W.S., 2014. Higher omega-3 index is associated with increased insulin 
sensitivity and more favourable metabolic profile in middle-aged overweight men. Sci Rep 4, 6697. 
Allenspach, K., Wieland, B., Grone, A., Gaschen, F., 2007, Chronic enteropathies in dogs: Evaluation 
of risk factors for negative outcome. Journal of Veterinary Internal Medicine 21, 700-708. 
Andersen, A.D., Molbak, L., Thymann, T., Michaelsen, K.F., Lauritzen, L., 2011, Dietary long-chain 
n-3 PUFA, gut microbiota and fat mass in early postnatal piglet development--exploring a potential 
interplay. Prostaglandins Leukot Essent Fatty Acids 85, 345-351. 
Anderson, J.L., Edney, R.J., Whelan, K., 2012. Systematic review: faecal microbiota transplantation 
in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36, 503-516. 
Angelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., 
Trauner, M., Loy, A., Berry, D., 2013. Temporal bacterial community dynamics vary among 
ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108, 1620-1630. 
Assies, J., Lieverse, R., Vreken, P., Wanders, R.J., Dingemans, P.M., Linszen, D.H., 2001. 
Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte 
membranes from schizophrenic patients compared with a carefully matched control group. Biol 
Psychiatry 49, 510-522. 
Bagdade, J.D., Porte, D., Jr., Bierman, E.L., 1969. The interaction of diabetes and obesity on the 
regulation of fat mobilization in man. Diabetes 18, 759-772. 
Bene, J., Komlosi, K., Magyari, L., Talian, G., Horvath, K., Gasztonyi, B., Miheller, P., Figler, M., 
Mozsik, G., Tulassay, Z. et al., 2007. Plasma carnitine ester profiles in Crohn's disease patients 
characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. Br J Nutr 98, 345-350. 
Bene, J., Komlosi, K., Havasi, V., Talian, G., Gasztonyi, B., Horvath, K., Mozsik, G., Hunyady, B., 
Melegh, B., Figler, M., 2006. Changes of plasma fasting carnitine ester profile in patients with 
ulcerative colitis. World J Gastroenterol 12, 110-113. 
Benson, A.K., Kelly, S.A., Legge, R., Ma, F., Low, S.J., Kim, J., Zhang, M., Oh, P.L., Nehrenberg, D., 
Hua, K. et al., 2010. Individuality in gut microbiota composition is a complex polygenic trait shaped 
by multiple environmental and host genetic factors. Proc Natl Acad Sci U S A 107, 18933-18938. 
Bonet, M.L., Ribot, J., Felipe, F., Palou, A., 2003. Vitamin A and the regulation of fat reserves. Cell 
Mol Life Sci. 60, 1311-1321. 
Bures, J., Cyrany, J., Kohoutova, D., Forstl, M., Rejchrt, S., Kvetina, J., Vorisek, V., Kopacova, M., 
2010, Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 16, 2978-2990. 
Burrows, T., Collins, C.E., Garg, M.L., 2011. Omega-3 index, obesity and insulin resistance in 
children. Int J Pediatr Obes 6, e532-539. 
Cook, M.E., 2004. Antibodies: Alternatives to antibiotics in improving growth and feed efficiency. J 
Appl Poult Res 13, 106-119. 
Crawford, P.A., Crowley, J.R., Sambandam, N., Muegge, B.D., Costello, E.K., Hamady, M., Knight, 
R., Gordon, J.I., 2009. Regulation of myocardial ketone body metabolism by the gut microbiota 
during nutrient deprivation. Proc Natl Acad Sci U S A 106, 11276-11281. 
Chapter 6 
General discussion  
155 
 
 
David, L.A., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., Wolfe, B.E., Ling, A.V., 
Devlin, A.S., Varma, Y., Fischbach, M.A. et al., 2014. Diet rapidly and reproducibly alters the human 
gut microbiome. Nature 505, 559-563. 
de La Serre, C.B., Ellis, C.L., Lee, J., Hartman, A.L., Rutledge, J.C., Raybould, H.E., 2010. 
Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and 
gut inflammation. Am J Physiol Gastrointest Liver Physiol 299, G440-448. 
den Besten, G., Lange, K., Havinga, R., van Dijk, T.H., Gerding, A., van Eunen, K., Muller, M., 
Groen, A.K., Hooiveld, G.J., Bakker, B.M. et al., 2013. Gut-derived short-chain fatty acids are vividly 
assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol 305, G900-
910. 
Devillard, E., McIntosh, F.M., Duncan, S.H., Wallace, R.J., 2007, Metabolism of linoleic acid by 
human gut bacteria: different routes for biosynthesis of conjugated linoleic acid. J Bacteriol 189, 
2566-2570. 
Duncan, S.H., Louis, P., Flint, H.J., 2004. Lactate-utilizing bacteria, isolated from human feces, that 
produce butyrate as a major fermentation product. Appl Environ Microbiol 70, 5810-5817. 
Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S.R., Nelson, 
K.E., Relman, D.A., 2005. Diversity of the human intestinal microbial flora. Science 308, 1635-1638. 
Fabia, R., Ar'Rajab, A., Johansson, M.L., Andersson, R., Willen, R., Jeppsson, B., Molin, G., 
Bengmark, S., 1993. Impairment of bacterial flora in human ulcerative colitis and experimental colitis 
in the rat. Digestion 54, 248-255. 
Fraher, M.H., O'Toole, P.W., Quigley, E.M., 2012. Techniques used to characterize the gut 
microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 9, 312-322. 
Freeman, L.M., Chandler, M.L., Hamper, B.A., Weeth, L.P., 2013. Current knowledge about the risks 
and benefits of raw meat-based diets for dogs and cats. J Am Vet Med Assoc 243, 1549-1558. 
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., 
Makishima, M., Matsuda, M., Shimomura, I., 2004. Increased oxidative stress in obesity and its 
impact on metabolic syndrome. J Clin Invest 114, 1752-1761. 
Garces, F., Lopez, F., Nino, C., Fernandez, A., Chacin, L., Hurt-Camejo, E., Camejo, G., Apitz-Castro, 
R., 2010. High plasma phospholipase A2 activity, inflammation markers, and LDL alterations in 
obesity with or without type 2 diabetes. Obesity (Silver Spring) 18, 2023-2029. 
Garg, M., Abbott, K., Veysey, M., Lucock, M., Niblett, S., King, K., Burrows, T., 2015. Association 
Between Omega-3 Index and Type 2 Diabetes in Older Overweight/Obese People is Sex Dependent. 
FASEB J 29, LB272. 
German, A.J., 2006. The growing problem of obesity in dogs and cats. J Nutr 136, 1940S-1946S. 
Ghosh, S., DeCoffe, D., Brown, K., Rajendiran, E., Estaki, M., Dai, C., Yip, A., Gibson, D.L., 2013, 
Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but 
impairs LPS dephosphorylation activity causing sepsis. PLoS One 8, e55468. 
Haapamaki, M.M., Gronroos, J.M., Nurmi, H., Alanen, K., Nevalainen, T.J., 1999. Gene expression 
of group II phospholipase A2 in intestine in Crohn's disease. Am J Gastroenterol 94, 713-720. 
Handl, S., Dowd, S.E., Garcia-Mazcorro, J.F., Steiner, J.M., Suchodolski, J.S., 2011. Massive parallel 
16S rRNA gene pyrosequencing reveals highly diverse fecal bacterial and fungal communities in 
healthy dogs and cats. FEMS Microbiol Ecol 76, 301-310. 
156 Chapter 6 
General discussion 
 
Handl, S., German, A.J., Holden, S.L., Dowd, S.E., Steiner, J.M., Heilmann, R.M., Grant, R.W., 
Swanson, K.S., Suchodolski, J.S., 2013. Faecal microbiota in lean and obese dogs. FEMS Microbiol 
Ecol 84, 332-343. 
Hawrelak, J.A., Myers, S.P., 2004. The causes of intestinal dysbiosis: a review. Altern Med Rev 9, 
180-197. 
Hildebrandt, M.A., Hoffmann, C., Sherrill-Mix, S.A., Keilbaugh, S.A., Hamady, M., Chen, Y.Y., 
Knight, R., Ahima, R.S., Bushman, F., Wu, G.D., 2009. High-fat diet determines the composition of 
the murine gut microbiome independently of obesity. Gastroenterology 137, 1716-1724. e2. 
Hippe, B., Zwielehner, J., Liszt, K., Lassl, C., Unger, F., Haslberger, A.G., 2011. Quantification of 
butyryl CoA:acetate CoA-transferase genes reveals different butyrate production capacity in 
individuals according to diet and age. FEMS Microbiol Lett 316, 130-135. 
Huggins, K.W., Boileau, A.C., Hui, D.Y., 2002. Protection against diet-induced obesity and obesity- 
related insulin resistance in Group 1B PLA2-deficient mice. Am J Physiol Endocrinol Metab 283, 
E994-E1001. 
Janeczko, S., Atwater, D., Bogel, E., Greiter-Wilke, A., Gerold, A., Baumgart, M., Bender, H., 
McDonough, P.L., McDonough, S.P., Goldstein, R.E. et al., 2008. The relationship of mucosal 
bacteria to duodenal histopathology, cytokine mRNA, and clinical disease activity in cats with 
inflammatory bowel disease. Vet Microbiol 128, 178-193. 
Jergens, A.E., Schreiner, C.A., Frank, D.E., Niyo, Y., Ahrens, F.E., Eckersall, P.D., Benson, T.J., 
Evans, R., 2003, A scoring index for disease activity in canine inflammatory bowel disease. J Vet 
Intern Med 17, 291-297. 
Jergens, A.E., 1999. Inflammatory bowel disease. Current perspectives. Vet Clin North Am Small 
Anim Pract 29, 501-521, vii. 
Jumpertz, R., Le, D.S., Turnbaugh, P.J., Trinidad, C., Bogardus, C., Gordon, J.I., Krakoff, J., 2011. 
Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient 
absorption in humans. Am J Clin Nutr 94, 58-65. 
Lambeau, G., Gelb, M.H., 2008. Biochemistry and physiology of mammalian secreted phospholipases 
A2. Annu Rev Biochem 77, 495-520. 
Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I., 2006. Microbial ecology: human gut microbes 
associated with obesity. Nature 444, 1022-1023. 
Liu, T., Hougen, H., Vollmer, A.C., Hiebert, S.M., 2012, Gut bacteria profiles of Mus musculus at the 
phylum and family levels are influenced by saturation of dietary fatty acids. Anaerobe 18, 331-337. 
Loman, B., Barnes, J., Tappenden, K., 2014. Butyryl-CoA transferase DNA abundance is not 
correlated with butyrate production of the intestinal microbial community in piglets with short-bowel 
syndrome (SBS)(LB370). FASEB J 28, LB370. 
Louis, P., Young, P., Holtrop, G., Flint, H.J., 2010. Diversity of human colonic butyrate-producing 
bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol 12, 
304-314. 
Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van 
Immerseel, F., Verbeke, K. et al., 2014. A decrease of the butyrate-producing species Roseburia 
hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 
1275-1283. 
Chapter 6 
General discussion  
157 
 
 
 
Martinez-Medina, M., Aldeguer, X., Gonzalez-Huix, F., Acero, D., Garcia-Gil, L.J., 2006. Abnormal 
microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by 
polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 12, 1136-1145. 
Mentula, S., Harmoinen, J., Heikkila, M., Westermarck, E., Rautio, M., Huovinen, P., Kononen, E., 
2005. Comparison between cultured small-intestinal and fecal microbiotas in beagle dogs. Appl 
Environ Microbiol 71, 4169-4175. 
Minamoto, Y., Otoni, C.C., Steelman, S.M., Buyukleblebici, O., Steiner, J.M., Jergens, A.E., 
Suchodolski, J.S., 2015. Alteration of the fecal microbiota and serum metabolite profiles in dogs with 
idiopathic inflammatory bowel disease. Gut Microbes 6, 33-47. 
Muege, B.D. 2013. The influence of diet on mammalian gut microbiome. Electronic Theses and 
dissertation, Washington University: 
Murakami, M., Taketomi, Y., Sato, H., Yamamoto, K., 2011. Secreted phospholipase A2 revisited. J 
Biochem 150, 233-255. 
Park, H.J., Lee, S.E., Kim, H.B., Isaacson, R.E., Seo, K.W., Song, K.H., 2015. Association of Obesity 
with Serum Leptin, Adiponectin, and Serotonin and Gut Microflora in Beagle Dogs. J Vet Intern Med 
29, 43-50. 
Pitcher, M.C., Beatty, E.R., Cummings, J.H., 2000. The contribution of sulphate reducing bacteria and 
5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 46, 64-72. 
Rezaie, A., Parker, R.D., Abdollahi, M., 2007. Oxidative stress and pathogenesis of inflammatory 
bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52, 2015-2021. 
Rochus, K., Cools, A., Janssens, G.P., Vanhaecke, L., Wuyts, B., Lockett, T., Clarke, J.M., Fievez, V., 
Hesta, M., 2014. Dietary supplementation of propionylated starch to domestic cats provides propionic 
acid as gluconeogenic substrate potentially sparing the amino acid valine. J Nutr Sci 3, e16. 
Rochus, K, 2013. Can fermentation-derived propionic acid spare glucogenic amino acids in domestic 
cats? PhD Thesis, Faculty of Veterinary Medicine, Merelbeke, Ghent University. Belgium: 
Rossi, G., Pengo, G., Caldin, M., Palumbo Piccionello, A., Steiner, J.M., Cohen, N.D., Jergens, A.E., 
Suchodolski, J.S., 2014. Comparison of Microbiological, Histological, and Immunomodulatory 
Parameters in Response to Treatment with Either Combination Therapy with Prednisone and 
Metronidazole or Probiotic VSL#3 Strains in Dogs with Idiopathic Inflammatory Bowel Disease. 
PLoS One 9, e94699. 
Round, J.L., Mazmanian, S.K., 2009. The gut microbiota shapes intestinal immune responses during 
health and disease. Nat Rev Immunol 9, 313-323. 
Santacruz, A., Collado, M.C., Garcia-Valdes, L., Segura, M.T., Martin-Lagos, J.A., Anjos, T., Marti-
Romero, M., Lopez, R.M., Florido, J., Campoy, C. et al., 2010. Gut microbiota composition is 
associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr 
104, 83-92. 
Santacruz, A., Marcos, A., Warnberg, J., Marti, A., Martin-Matillas, M., Campoy, C., Moreno, L.A., 
Veiga, O., Redondo-Figuero, C., Garagorri, J.M. et al., 2009. Interplay Between Weight Loss and Gut 
Microbiota Composition in Overweight Adolescents. Obesity 17, 1906-1915. 
Santavuori, S.A., Kortesuo, P.T., Eskola, J.U., Nevalainen, T.J., 1991. Application of a new 
monoclonal antibody for time-resolved fluoroimmunoassay of human pancreatic phospholipase A2. 
Eur J Clin Chem Clin Biochem 29, 819-826. 
158 Chapter 6 
General discussion 
 
Sartor, R.B., 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology 134, 577-
594. 
Schwiertz, A., Taras, D., Schafer, K., Beijer, S., Bos, N.A., Donus, C., Hardt, P.D., 2010. Microbiota 
and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 18, 190-195. 
Smeets-Peeters, M.J.E, 2000. Feeding FIDO: Development, validation and application of a dynamic 
in vitro model of the gastrointestinal tract of the dog. PhD Thesis, Wageningen University. Universal 
Press, Veenendaal, The Netherlands 
Sjogren, P., Sierra-Johnson, J., Gertow, K., Rosell, M., Vessby, B., de Faire, U., Hamsten, A., 
Hellenius, M.L., Fisher, R.M., 2008, Fatty acid desaturases in human adipose tissue: relationships 
between gene expression, desaturation indexes and insulin resistance. Diabetologia 51, 328-335. 
Strauss, R.S., 1999. Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a 
cross-sectional sample of obese and nonobese children (NHANES III). National Health and Nutrition 
Examination Survey. J Pediatr 134, 160-165 
Suchodolski, J.S., Camacho, J., Steiner, J.M., 2008. Analysis of bacterial diversity in the canine 
duodenum, jejunum, ileum, and colon by comparative 16S rRNA gene analysis. FEMS Microbiol 
Ecol 66, 567-578. 
Suchodolski, J.S., Dowd, S.E., Wilke, V., Steiner, J.M., Jergens, A.E., 2012a. 16S rRNA gene 
pyrosequencing reveals bacterial dysbiosis in the duodenum of dogs with idiopathic inflammatory 
bowel disease. PLoS One 7, e39333. 
Suchodolski, J.S., Markel, M.E., Garcia-Mazcorro, J.F., Unterer, S., Heilmann, R.M., Dowd, S.E., 
Kachroo, P., Ivanov, I., Minamoto, Y., Dillman, E.M., et al., 2012b. The fecal microbiome in dogs 
with acute diarrhea and idiopathic inflammatory bowel disease. PLoS One 7, e51907. 
Tungtrongchitr, R., Pongpaew, P., Tongboonchoo, C., Vudhivai, N., Changbumrung, S., 
Tungtrongchitr, A., Phonrat, B., Viroonudomphol, D., Pooudong, S., Schelp, F.P., 2003. Serum 
homocysteine, B12 and folic acid concentration in Thai overweight and obese subjects. Int J Vitam 
Nutr Res 73, 8-14. 
Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., Sogin, M.L., 
Jones, W.J., Roe, B.A., Affourtit, J.P. et al., 2009. A core gut microbiome in obese and lean twins. 
Nature 457, 480-484. 
Van den Abbeele, P., Belzer, C., Goossens, M., Kleerebezem, M., De Vos, W.M., Thas, O., De 
Weirdt, R., Kerckhof, F.M., Van de Wiele, T., 2013. Butyrate-producing Clostridium cluster XIVa 
species specifically colonize mucins in an in vitro gut model. ISME J 7, 949-961. 
Van de Wiele, T., Van den Abbeele, P., Ossieur, W., Possemiers, S., Marzorati, M., 2015. The 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), In: The Impact of Food 
Bioactives on Health. Springer International Publishing, pp. 305-317.Van Praet, J.T., Donovan, E., 
Vanassche, I., Drennan, M.B., Windels, F., Dendooven, A., Allais, L., Cuvelier, C.A., van de Loo, F., 
Norris, P.S. et al., 2015. Commensal microbiota influence systemic autoimmune responses. EMBO J 
34, 466-474. 
Van Praet, J.T., Donovan, E., Vanassche, I., Drennan, M.B., Windels, F., Dendooven, A., Allais, L., 
Cuvelier, C.A., van de Loo, F., Norris, P.S., Kruglov, A.A., Nedospasov, S.A., Rabot, S., Tito, R., 
Raes, J., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Van de Wiele, T., Eberl, G., Ware, C.F., 
Elewaut, D., 2015. Commensal microbiota influence systemic autoimmune responses. EMBO J 34, 
466-474. 
Chapter 6 
General discussion  
159 
 
 
Varastehpour, A., Radaelli, T., Minium, J., Ortega, H., Herrera, E., Catalano, P.,Hauguel-de Mouzon, 
S., 2006. Activation of phospholipase A2 is associated with generation of placental lipid signals and 
fetal obesity. J Clin Endocrinol Metab 91, 248-255. 
Verbrugghe, A., Hesta, M., Daminet, S., Polis, I., Holst, J.J., Buyse, J., Wuyts, B., Janssens, G.P., 
2012. Propionate absorbed from the colon acts as gluconeogenic substrate in a strict carnivore, the 
domestic cat (Felis catus). J Anim Physiol Anim Nutr (Berl) 96, 1054-1064. 
Verbrugghe, A., Hesta, M., Gommeren, K., Daminet, S., Wuyts, B., Buyse, J., Janssens, G.P., 2009. 
Oligofructose and inulin modulate glucose and amino acid metabolism through propionate production 
in normal-weight and obese cats. Br J Nutr 102, 694-702. 
Verbrugghe, A., Janssens, G.P., Meininger, E., Daminet, S., Piron, K., Vanhaecke, L., Wuyts, B., 
Buyse, J., Hesta, M., 2010. Intestinal fermentation modulates postprandial acylcarnitine profile and 
nitrogen metabolism in a true carnivore: the domestic cat ( Felis catus). Br J Nutr 104, 972-979. 
Vermeiren, J., Van den Abbeele, P., Laukens, D., Vigsnaes, L.K., De Vos, M., Boon, N., Van de 
Wiele, T., 2012. Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species 
from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS 
Microbiol Ecol 79, 685-696. 
Viroonudomphol, D., Pongpaew, P., Tungtrongchitr, R., Changbumrung, S., Tungtrongchitr, A., 
Phonrat, B., Vudhivai, N., Schelp, F.P., 2003. The relationships between anthropometric 
measurements, serum vitamin A and E concentrations and lipid profiles in overweight and obese 
subjects. Asia Pac J Clin Nutr 12, 73-79. 
Vital, M., Gao, J., Rizzo, M., Harrison, T., Tiedje, J.M., 2015. Diet is a major factor governing the 
fecal butyrate-producing community structure across Mammalia, Aves and Reptilia. ISME J 9, 832-
843. 
Vital, M., Howe, A.C., Tiedje, J.M., 2014. Revealing the bacterial butyrate synthesis pathways by 
analyzing (meta)genomic data. MBio 5, e00889. 
Vital, M., Penton, C.R., Wang, Q., Young, V.B., Antonopoulos, D.A., Sogin, M.L., Morrison, H.G., 
Raffals, L., Chang, E.B., Huffnagle, G.B. et al., 2013. A gene-targeted approach to investigate the 
intestinal butyrate-producing bacterial community. Microbiome 1, 8. 
Vrolijk, M.F., Opperhuizen, A., Jansen, E.H., Godschalk, R.W., Van Schooten, F.J., Bast, A., Haenen, 
G.R., 2015. The shifting perception on antioxidants: the case of vitamin E and beta-carotene. Redox 
Biol 4, 272-278. 
Wagner, A., Simon, C., Morio, B., Dallongeville, J., Ruidavets, J.B., Haas, B., Laillet, B., Cottel, D., 
Ferrieres, J., Arveiler, D., 2015. Omega-3 index levels and associated factors in a middle-aged French 
population: the MONA LISA-NUT Study. Eur J Clin Nutr 69, 436-441. 
Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S., Zhao, L., 2012. Structural 
segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 6, 
320-329. 
Weese, J.S., Staempfli, H.R., Prescott, J.F., Kruth, S.A., Greenwood, S.J., Weese, H.E., 2001. The 
roles of Clostridium difficile and enterotoxigenic Clostridium perfringens in diarrhea in dogs. J Vet 
Intern Med 15, 374-378. 
Windey, K., De Preter, V., Verbeke, K., 2012. Relevance of protein fermentation to gut health. Mol 
Nutr Food Res 56, 184-196. 
160 Chapter 6 
General discussion 
 
Wu, G.D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.Y., Keilbaugh, S.A., Bewtra, M., Knights, 
D., Walters, W.A., Knight, R. et al., 2011. Linking long-term dietary patterns with gut microbial 
enterotypes. Science 334, 105-108. 
Xenoulis, P.G., Palculict, B., Allenspach, K., Steiner, J.M., Van House, A.M., Suchodolski, J.S., 2008. 
Molecular-phylogenetic characterization of microbial communities imbalances in the small intestine 
of dogs with inflammatory bowel disease. FEMS Microbiol Ecol 66, 579-589. 
Zhao, L., 2013. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 11, 
639-647. 
Zentek, J., Marquart, B., Pietrzak, T., Ballevre, O., Rochat, F., 2003. Dietary effects on bifidobacteria 
and Clostridium perfringens in the canine intestinal tract. J Anim Physiol Anim Nutr (Berl) 87, 397-
407. 
 
 
Chapter 6 
General discussion  
161 
 
 
  
S
U
M
M
A
R
Y
/  S
A
M
E
N
V
A
T
T
IN
G
 
162 Summary 
 
  
Summary 163 
 
 
The gastrointestinal tract harbours diverse microbes that play a fundamental role in 
the well-being of their host. Obesity and inflammatory bowel disease (IBD) have occurred 
with an imbalance in the gut microbiota, and these disorders are characterized by low-grade 
systemic inflammation or aberrant inflammation in the gut, respectively. Diet has long been 
considered as an important modulator of gut microbiota and thus targeted nutrition may exert 
beneficial effects in restoring gut homeostasis. Moreover, dietary components with anti-
inflammatory properties might prevent the potential negative effects of inflammation that 
establish upon disease. 
The focus of this PhD research was to characterize the faecal microbiota and host 
metabolism in canine IBD and obesity, and to determine the impact of diets (with different 
levels of protein, and with anti-inflammatory supplement) on faecal microbiota profile 
changes or on host metabolic and inflammatory status. Three studies were designed to 
address these two major research objectives. Study 1 (Chapter 3) characterized the 
composition and activity of faecal microbiota and evaluated host metabolic changes in dogs 
with IBD. Study 2 (Chapter 4) evaluated the impact of dietary protein on the composition and 
activity of faecal microbiota and host metabolism in lean and obese dogs. Study 3 (Chapter 5) 
investigated the effect of an secreted phospholipase A2 inhibitor (sPLA2i) on inflammation, 
oxidative stress and fatty acid profile in lean and obese dogs. 
Distinct differences in faecal microbiota profile were neither observed between IBD 
and control dogs, nor between obese and lean dogs (Chapters 3 and 4). However, canine IBD 
was characterized by a negative correlation between IBD clinical activity index and 
Lactobacillus. In addition, negative correlations were observed between the BCS and the 
faecal abundance of total bacteria, Bacteroidetes, and butyryl-CoA acetate-CoA transferase 
(BCoAT) gene. These results suggested severity of canine IBD and obesity to be associated 
with gradually changes in bacterial profile. 
Significant changes in metabolic profile were found in dogs with IBD (Chapter 3). 
Plasma citrulline was decreased and plasma valine was increased in IBD compared to control 
dogs. Dogs with IBD had higher plasma free carnitine and total acylcarnitines and lower 
short-chain acylcarnitines (butyrylcarnitine + isobutyrylcarnitine, and 
methylmalonylcarnitine) to free carnitine ratios compared to control dogs. In addition, dogs 
with IBD had a higher leucine catabolites (3-hydroxylisovalerylcarnitine + 2-mehyl-3-
hydroxylbutyrylcarnitine (3-OHC5), and isovalerylcarnitine + mehylbutyrylcarnitine ) to 
leucine compared to control dogs. These results suggest canine IBD induced a wide range of 
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changes in metabolic profile which could have evolved from tissue damage and alteration in 
host metabolism.  
Although no significant metabolic changes with regard to plasma amino acids and 
acylcarnitines profile between lean and obese dogs, a higher n-6: n-3, a lower proportion of 
n-3 PUFA and a lower omega-3 index were observed in obese compared to lean dogs 
(Chapter 5). In addition, obese dogs had a higher plasma concentration of the lipophilic 
vitamin A with potential antioxidative capacity and a lower ratio of retinol binding protein 4: 
vitamin A compared to lean dogs. However, no changes were observed in other oxidative 
stress and antioxidant markers (i.e. glutathione peroxidase, vitamin C and E, and 
malondialdehyde). Therefore, obese dogs were characterized by a more pro-inflammatory 
fatty acid profile compared to lean dogs. Further studies are warranted on evaluating 
oxidative stress with incorporation of more bio-markers in obese dogs.  
High levels of protein in the diet promoted protein fermentation with increased faecal 
production of ammonia, BCFA, indole and phenol, serum indoxyl sulphate, and plasma 3-
OHC5 (Chapter 4). Compared to low protein diet (LP), high protein diet (HP) raised the 
abundances of clostridial clusters IV and XIVa, covering the majority of butyrate-producing 
bacteria, increased the abundance the butyrate kinase (BK) gene but not that of BCoAT gene, 
opposite to what has been reported in humans. Interestingly, HP increased faecal abundance 
of Firmicutes and clostridial cluster I in lean dogs but not in obese dogs. In addition, the 
similarity coefficient of faecal microbiota was lower in obese dogs than in lean dogs. 
Therefore, these results suggested HP had a different impact on faecal microbiota in obese 
and lean dogs, showing phenotype may be an important factor influencing the outcome of a 
dietary treatment and the effect of it on gut microbial profile. 
A potential anti-inflammatory modulator, sPLA2i, has been tested for its impact on 
inflammation and oxidative stress in lean and obese dogs (Chapter 5). The sPLA2i diet 
reduced a putative inflammatory marker, fibrinogen in obese dogs to levels similar to those of 
lean dogs fed the same diet without added sPLA2i, suggesting a reduced inflammatory status 
in obese dogs. However, no changes were observed on bio-markers of oxidative stress. 
Taken together, this PhD thesis found that not only host health/disease, diet, but also 
phenotype (lean and obese) play a role in determining the impact of dietary changes in faecal 
microbial profiles (Chapter 6). In contrast to human, the BK pathway could be more 
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important for butyrate production compared to BCoAT pathway in dogs. Moreover, diet with 
sPLA2i was able to reduce inflammation in obese dogs to levels similar to those of lean dogs. 
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Het gastrointestinaal stelsel huisvest diverse microbiota die een fundamentele rol 
spelen in het welbehagen van hun gastheer. Bij obesitas en inflammatory bowel disease (IBD) 
werd een onevewicht in de GI microbiota vastgesteld en beide aandoeningen werden 
bovendien respectievelijk gekarakteriseerd door een lage graad van systemische ontsteking en 
ernstige ontsteking van de darm. Het dieet werd reeds lang beschouwd als een belangrijke 
factor in de modulatie van de darm microbiota en bijgevolg kan aangepaste voeding 
mogelijks een belangrijke rol spelen bij het herstellen van de darm homeostasis. Meer nog, 
anti-inflammatoire componenten in de voeding kunnen mogelijks beschermen tegen de 
negatieve effecten van de ontsteking die gepaard gaat met de aandoeningen. 
De focus van dit doctoraatsonderzoek was het karakteriseren van de fecale microbiota 
en effect op het metabolisme van de gastheer bij canine IBD en obesitas. Daarnaast zal ook 
het effect van het dieet (hoeveelheid eiwit, anti-inflammatoir supplement) op het fecale 
microbiota profiel en het metabolisme en de inflammatoire status van de gastheer bepaalt 
worden. Om deze 2 belangrijke wetenschappelijke doelstellingen te onderzoeken werden 3 
studies opgezet. In studie 1 (hoofdstuk 3) werd de samenstelling en activiteit van de fecale 
microbiota bij honden met IBD gekarakteriseerd evenals het effect van de aandoening op het 
metabolisme van de gastheer. In een 2° studie (hoofdstuk 4) werd het effect van diëtair eiwit 
op samenstelling en activiteit van de fecale microbiota en gastheer metabolisme bij obese en 
normale honden onderzocht. In studie 3 (hoofdstuk 5) werd het effect van gesecreteerd 
fosfolipase A2 inhibitor (sPLA2i) op inflammatoire status, oxidatieve stress en vetzuurprofiel 
onderzocht bij obese honden en honden met een normaal lichaamsgewicht. 
Zowel bij IBD en gezonde controle honden als bij obese en normale honden, werden 
duidelijke verschillen in fecale microbiota niet aangetoond (hoofdstuk 3 en 4). Echter, er 
werd een negatieve correlatie gezien tussen de IBD klinische activiteitsindex en concentratie 
aan Lactobacilli. Bovendien werd er ook een negatieve correlatie gezien tussen de BCS en de 
fecale concentratie aan totale bacteriën, Bacteroidetes en het butyryl-CoA acetate-CoA 
transferase (BCoAT) gen. Deze resultaten suggereren dat de ernst van canine IBD en obesitas 
geassocieerd zijn met graduele veranderingen in het microbieel profiel. 
Bij honden met IBD werden bovendien ook veranderingen in het metabole profiel 
waargenomen (hoofdstuk 3). In vergelijking met de controle honden was plasma citruline 
gedaald en plasma valine gestegen bij IBD patiënten. Bovendien hadden honden met IBD een 
hoger gehalte aan plasma vrije en totale carnitine en een lagere ratio korte keten 
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acylcarnitines (butyrylcarnitine + isobutyrylcarnitine, and methylmalonylcarnitine) t.o.v. vrije 
carnitine. Er werd ook een hogere verhouding aan leucine katabolieten (3-
hydroxylisovalerylcarnitine + 2-mehyl-3-hydroxylbutyrylcarnitine (3-OHC5) en 
isovalerylcarnitine + mehylbutyrylcarnitine ) t.o.v. leucine waargenomen bij honden met IBD. 
Deze resultaten suggereren dat IBD bij de hond verschillende veranderingen in het 
metabolisme induceert die op hun beurt het gevolg kunnen zijn van zowel weefselschade als 
veranderingen in het metabolisme van de gastheer. 
Alhoewel gelijkaardige veranderingen in het plasma aminozuur en acylcarnitine 
profiel niet gezien werden bij obese honden, werd wel een hogere verhouding n-6:n-3, een 
lagere proportie n-3 PUFA en een lagere omega 3 index vast gesteld bij obese versus normale 
honden (hoofdstuk 5). Obese honden werden ook gekenmerkt door een hoger gehalte aan het 
lipofiele vitamine A met mogelijks antioxidatieve capaciteiten en een lagere verhouding van 
retinol binding proteïne 4 t.o.v. vitamine A. Echter, wijzingen in oxidatieve stress en andere 
antioxidanten (glutathione peroxidase, vitamin C and E, and malondialdehyde) werden niet 
waargenomen. Er werd besloten dat obese honden gekenmerkt worden door een meer pro-
inflammatoir vetzuurprofiel in vergelijking met normale honden. Meer studies zijn echter 
nodig om het effect op oxidatieve stress in obese honden te evalueren.  
Een hoog eiwitdieet stimuleert eiwitfermentatie met als gevolg verhoogde fecale 
gehaltes aan ammoniak, BCFA, indol en phenol, verhoogde serum gehaltes aan indoxyl 
sulfaat en plasma 3-OHC5 (hoofdstuk 4). In vergelijking met een laag eiwit dieet, gaat een 
hoog eiwit dieet gepaard met verhoogde gehaltes aan Clostridium clusters IV en XIVa die de 
meerderheid van de boterzuur producerende bacteriën bevatten, een verhoogde concentratie 
aan het butyraat kinase gen maar niet het BCoAT gen in tegenstelling tot de mens. Het hoog 
eiwitdieet verhoogde ook de fecale concentratie aan Firmicutes en Clostridium cluster 1 in 
normale maar niet bij obese honden. Ook was de similariteitsindex van fecale bacteriën lager 
bij obese t.o.v. honden met normaal gewicht. Er werd opgemerkt dat een hoog eiwit dieet een 
verschillend effect kan hebben bij obese t.o.v. normale honden en dus dat het fenotype een 
bepalende factor kan zijn bij het effect van een diëtaire behandeling en effect op het fecale 
microbiële profiel. 
Een potentiële anti-inflammatoire modulator, sPLA2i, werd getest voor zijn effect op 
ontsteking en oxidatieve stress bij zowel obese als normale honden (hoofdstuk 5). sPLA2i 
zorgde voor een gedaalde concentratie aan fibrinogeen, een krachtige inflammatoire merker, 
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in obese honden in die mate dat de waarden die van normale honden die niet met sPLA2i 
behandeld werden, benaderden. Echter, er werden geen verandering vastgesteld bij de 
biomerkers voor oxidatieve stress zelf. 
Deze doctoraatsthesis besluit dat de gezondheid/ziekte status van de gastheer, het 
dieet maar ook het fenotype (obees of normaal lichaamsgewicht) een rol spelen in het fecale 
microbiële profiel (hoofdstuk 6). In tegenstelling tot de mens, kan de BK pathway 
belangrijker zijn dan de BCoAT pathway bij honden. Bovendien is een dieet dat 
gesupplementeerd werd met sPLA2i in staat om de ontsteking bij obese honden te reduceren 
tot gehaltes die teruggevonden worden bij honden met normaal lichaamsgewicht. 
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